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 1. ABSTRACT 
 
 
The phatophysiology of muscle atrophy is a complex multifactor process, which occurs 
in response to environmental solicitations, injury, various disease states, disuse and normal 
aging. Persistent low-grade or acute activation of inflammatory/oxidative cascade, acute 
stress, altered energy intake, or reduced mechanical action, contribute to muscle decline, as 
well as to the progression of chronic and acute associated disease. Elevated concentrations of 
pro-inflammatory markers have also devastating effects on the vasculature and are implicated 
in the pathogenesis of atherosclerosis, which at peripheral level contributes to muscle 
suffering. A more understanding of the molecular relationships underpinning muscle atrophy, 
inflammation and cardiovascular risk in different human clinical models should be helpful to 
design new therapies to  the recovery of muscle. Thus, we investigated the effect of some 
effectors of inflammatory/oxidative responses on muscle atrophy, inflammation and 
cardiovascular dysfunction, in chronic, acute or healthy conditions. We explored: a) the 
interaction between energy restriction and muscle unloading in the regulation of lean body 
mass, protein kinetics or inflammatory response in healthy subjects; b) the links among 
inflammation, organ failure, cardiovascular risk and cytokine genotypes, in models of chronic 
muscle atrophy; c) the cross-interaction connecting translational machinery, proteolysis and 
apoptotic response with skeletal muscle atrophy induced by acute stress.   
We highlighted a link between inflammatory process, cardiovascular risk and muscle 
unloading, likely involving leptin hormone and the long pentraxin PTX3; the latter may 
represent a novel key of reading of some bed-rest effect on vasculature or inflammatory 
system. Cytokine genotypes (interpheron-gamma), and the extent of renal functions on 
cytokine clearence, may account of intraindividual variability and vulnerability to the process. 
Finally, we gained knowledge about a novel catabolic mechanism, involving the eukariotic 
elongation factor EEF1A1 and the stress response protein p66(ShcA) in acute muscle atrophy. 
We suggest that, a more controlled energy intake combined with various exercise 
regimes might protect from the effects of unloading and may be a reasonable approach to 
maintain muscle mass in health but also in disease conditions. 
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5. INTRODUCTION 
 
5.1 Why muscle atrophy  
 
 Muscle atrophy is a long-term process orchestrated by a cascade of multi-step events, 
which occur in response to environmental solicitations, injury, various disease states, disuse 
and normal aging. To counteract several types of solicitations, skeletal muscle enrols a 
number of adaptive responses (plasticity), by changing mass, fiber size and type, fiber 
strength and metabolism (Figure 5.1.A). The maintenance of this muscle  response depends 
by a delicate balance between mechanical, angiogenic, hormonal,  nutritional,  anabolic and 
catabolic signals, that at molecular level modulate a number of hypertrophy 
(phosphoinositide-3 kinase/Akt, mTOR, myogenin, myoD, Myf5, etc.) and atrophy pathways 
(proteolysis-inducing factor, TNF-alpha, the FOXO forkhead and nuclear factor NF-κB 
systems, myostatin, atrogin-1, muscle ring finger 1, etc.), (Gilson et al., 2007). The unbalance 
of these systems typically characterized the extent of muscle loss (Figure 5.1.A).  
 
Figure.5.1.A: Scheme visualizing the loop between physiological (mechanical action) and pahatophysiological 
(stress) solicitations underpinning muscle maintenance and its countermeasure adaptation. Broken lines represent 
the cross-interaction between exertion and activation of damaging/injury responses. 
 
MUSCLE STRESS
• Vigorous twitch
• Inflammation
• Oxidative stress
• Hypoxia
• Hormones
• Diseases
• Genotypes
• Toxicagents…
MUSCLE ADAPTATION AND 
REMODELLING
•Change in fiber type (Type I-to-Type II)
•Myogenesis and differentiation
•Metabolic adaptation
•Mass and/or cell loss (protein turnover and/or apoptosis)
MECHANICAL  ACTION
•Excitation-Contraction Coupling
•Ca++ release
•MGF
•MAPKs (ERK1/2, P38)
•eNOS/NO
•VEGF
•Myodulin
•Mitofusins
•PGC1-alpha…
Muscle behaviour
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a. The balance between anabolic and catabolic responses  
 
More simply, it is assumed that the loss of muscle mass is primary caused by an altered 
protein turnover, due to a decreased protein synthesis or by an increased in protein 
degradation. Low-protein turnover condition is usually associated with the adequate sparing 
of body proteins, whereas in high-protein turnover condition protein loss may proceed at a 
fast rate. A mosaic of different synthesis/degradation profiles orchestrates the rate of catabolic 
condition. In hypercatabolic states such as trauma or sepsis the rate of muscle proteolysis is 
greatly accelerated and not balanced by the rate of protein synthesis (Biolo et al., 2000b; 
Biolo et al., 2000a). Conversely, chronic catabolic conditions are characterized either by 
decreased or accelerated protein turnover (Biolo et al., 2003). Whilst, chronic muscle loss due 
to disuse rises mainly from a decreased rate of protein synthesis rather than degradation 
(Biolo G et.al. 2007).  The precise cascade of events conditioning these responses remained to 
be clarified; notwithstanding, protein breakdown emerges as an early key event, 
independently from the type of catabolic state (Figure 5.1.B).  
Different and multiple proteolysis systems work in synergism to the complete 
degradation of myofibrillar and non-myofibrillar proteins. The lysosomal cathepsins, Ca++ 
dependent-calpains and the ubiqutin-proteasome pathway, represent the pivotal players (Du et 
al., 2004; Lee et al., 2004; Mansoor et al., 1996). These systems contribute to atrophy 
program cross-activating both proteolysis and apoptosis machineries (Du et al., 2004; Lee et 
al., 2004).  
The activity of lysosomal cathepsins (B, D, E, H and L), has been related to the 
degradation of non-myofibrillar proteins (membrane-associated proteins and endocytosed 
proteins), (Du et al., 2004; Li and Pober, 2005). Low activated  in chronic diseases, cathepsins 
appear highly up-regulated in hypercatabolic conditions (cancer cachexia, sepsis, trauma, 
etc.),  and in disuse muscle (myopathy, denervation, etc.),  (Bosutti et al., 1999; Bosutti et al., 
2002; Mansoor et al., 1996). Despite their role in protein catabolism is limited and less 
elucidated, these proteases appear crucial to apoptotic and necrotic death cascade, mediated 
by lysosomal injury, heat shock, oxidative stress, hypoxia, and cation channel hyperactivity 
(Luke et al., 2007). In particular, the cathepsin B engages the enhancement of cytochrome c 
release from mitochondria membrane and the mitochondria membrane permeabilization in 
response to a variety of apoptotic signals, including p53 activation (Li and Pober, 2005). 
Otherwise, ubiquitously expressed the mu- and m-calpain proteases are considered key 
modulators of stress/damage response  (Demarchi et al., 2006; Demarchi and Schneider, 
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2007). Implicated in both apoptosis and survival pathways in response to different cell 
stimuli, calpains regulate macroautophagy in mammalian cells (Demarchi et al., 2006; 
Demarchi and Schneider, 2007). Recent evidences link calpains also to cytoskeleton 
remodelling (Demarchi et al., 2006; Demarchi and Schneider, 2007).  In response to oxidative 
stress and muscle unloading, these proteases critically modulate the release of sarcomeric titin 
and nebulin from contractile apparatus, without degrading myofibrillar proteins (Altznauer et 
al., 2004). An apoptotic role of calpains has been found  in the end-stage of atrophy (via 
caspase-12 and -3, BAX and JNK activation).  Whereas, their contribution to the early phase 
of the process is not fully documented (Vermaelen et al., 2007). Finally, the ubiquitin-
proteasome system  represents the heart of proteolysis machinery. It is required to maintain 
muscle metabolism, cellular architecture and the structure of  neuromuscular junction. 
Proteasome  provides also a mechanism for  the critical control of protein quality and 
abundance (Haas et al., 2007), since the uncorrected function of the system implies 
accumulation of both protein aggregates and dangerous misfolded/unfolded proteins. The  two 
novel characterized  muscle specific ubiquitin associated genes, the ligases MAFbx (atrogin-
1) and MuRF-1 (muscle ring finger 1), represent two new hallmarks of muscle atrophy in 
diseases (Bodine et al., 2001). Normally, they mediate the covalent interaction between 
ubiquitin and protein substrate and regulate sarcomeric M-line and thick filament structure. 
But, in response to  hormonal (glucocorticoid), inflammatory (TNF-alpha), or oxidative 
signals, mediate the over-activation of the proteasome system and proteolysis cascade  
(Bodine et al., 2001).  
Several investigators have pointed out the strictly cooperation between ubiquitin–
proteasomal mechanisms and caspases, in modulation of proteolysis during muscle atrophy. 
Caspases are known as the apoptotic initiators that in response to cytokines (such as TNF-
alpha), control either the intrinsic (mitochondria mediated) or extrinsic (death receptor-
triggered)  pathways of apoptosis (Saini et al., 2006). These proteases resulted activated only 
in “selected forms” of muscle atrophy. Likely, they are activated in the initial step of 
myofibrillar proteolysis, to assure the viability of myofibrillar proteins to ubiquitination (Saini 
et al., 2006). Basically, three are the major apoptotic mechanisms that lead to caspases 
activation: a receptor–ligand binding with activation of caspase-8, a mitochondria mechanism 
with activation of caspase-9 and a process involving the endoplasmic reticulum with 
activation of caspase-12 (Nakagawa et al., 2000). Briefly, about the connection between 
apoptosis and caspase, we can resume that the intrinsic apoptotic pathway begins from 
starting intracellular stress signals which induce severe perturbation in mitochondria 
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homeostasis, and culminates in the release of cytochrome c from the mitochondrial 
intermembrane space into the cytosol with the further apoptosome formation (cytochrome c 
complexes with Apaf-1 and dATP), caspase-9, -3, -6, -7  activation, DNA fragmentation and 
cell death (Figure 5.1.C). Conversely, the extrinsic pathway starts from an extracellular 
signal, (such as TNF-alpha), that binds to FADD or FAS death receptors and activates 
caspase-8, which in turn activates caspase-3, -6 and –7 cascade, the processing of some pro-
apoptotic factors (such as  Bid), followed by the induction of cytochrome c- mitochondria 
mediated apoptosis (Figure 5.1.C).  A cross talk between the two apoptotic systems is 
currently assumed (Figure 5.1.C), thus it is very difficult to dissect their role and identify the 
timing activation of their components in human striated muscle atrophy (Figure 5.1.C). Even 
so, apoptosis is a very complex and delicately regulated process, which dictates the proper 
control of development, architecture, integrity and homeostasis of tissues. Despite, in highly 
proliferating tissues it counterbalances the rapid proliferation and stabilizes stem cell 
population, its role in post-mitotic tissues (muscle) is still unclear. This because, skeletal 
muscle represents a unique tissue with respect to apoptosis because muscle cells are 
multinucleated and contain a variable mitochondrial content which is dependent on fibre type 
and the extent of training (Saini et al., 2006). Thus, taken together these factors contribute to 
the complexity of apoptotic mechanisms within skeletal muscle (Saini et al., 2006). Moreover, 
during atrophy, muscle apoptosis associates with a significant loss of myonucleus, which not 
always correspond to cell death. In other terms, apoptosis of individual nuclei and 
disassembly of their associated sarcomeric segments lead not to immediate loss of a muscle 
fiber but “contribute” to muscle depletion. Noteworthy, minor damage triggers a slow 
activation of intrinsic apoptotic cell-death, but in the presence of an higher damage  (such as 
energy depletion), fiber goes quickly to necrosis (Tews, 2002). The low or marked necrosis 
depends by the origin of stress signals, started from endoplasmic reticulum or mitochondria,  
respectively.  Believable, activation of proteolysis may be an early “self-safety” event, 
directed to counteract the stress. Furthermore, to complicate this view, genes of apoptosis or 
proteolysis appear selectively regulated in a fiber type - specific manner (Tews, 2002; Tews, 
2005). 
In opposition to protein breakdown and apoptosis, the modulation of translational 
machinery is the crucial rate-limiting step involved in control of protein anabolism and 
hypertrophy. This system is delicately regulated through phosphorylation of a number of its 
components, especially those of initiation and elongation steps. Hormones, amino acids, 
growth factors and other extracellular signals modulate the rates of  phosphorylation via the  
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activation of  specific serin/threonin kinases [such as  the mammalian target of rapamycin 
(mTOR), the ERK and p38 MAP kinase pathways, and protein kinase B (Akt)], (Wang et al., 
2006). A particular contribution  is  provided by the  two eukaryotic elongation factor EEF1A 
proteins. Following codon-anticodon recognition, they carry each aminoacyl-tRNA complex 
to the A site of ribosome (Lund A et al., 1996; Browne et al., 2002).  In mammals, the eEF1A 
proteins are encoded by the EEF1A1 and EEF1A2 genes mapped on different chromosomes. 
The coding sequence of the two genes has a 78% homology with a protein identity of 92% 
(Lund A et al., 1996; Browne et al., 2002).  In human tissues EEF1A1 is ubiquitously 
expressed, with the exception of skeletal muscle, heart and brain, where it progressively 
declines at early phases of development (Lee et al., 1993; Lund et al., 1996; Khalyfa et al., 
2001).  In adult muscle EEF1A2 takes over the EEF1A1 specific function for protein 
synthesis (Ruest et al., 2002; Khalyfa et al., 2001). In aging rats, muscle EEF1A1 increases 
reverting the ratio eEF1A1/eEF1A2 (Carlson et al., 2002). In contrast to the rat model, in 
humans there is no increase of EEF1A1 mRNA/protein in late phases of life (Welle et al., 
1997). In cultured myotubes, EEF1A1 expression was associated to increased apoptosis, 
while EEF1A2 was associated to anti-apoptotic conditions and cell proliferation (Ruest et al., 
2002). Thus changes in the expression levels of these two elongation factors related to pro and 
anti-apoptotic responses (Ruest et al., 2002; Chen et al., 2005) could be informative on the 
molecular events underlying accelerated catabolism in skeletal muscle. 
 At this point, a simply evidence arises, a sort of coordination between proteolysis, 
apoptosis and  protein synthesis may underpin in a mechanistic manner muscle suffering. The 
homeostasis of endoplasmic reticulum  (ER) can represent  a crucial figure in this view. The 
ER is a critical point for quality control of many newly synthesized proteins. Correctly folded 
proteins are packaged and delivered into transport vesicles to their final destination, whilst 
incorrectly folded proteins are retained and degraded by an ER quality control system 
(Rutkowski and Kaufman, 2004).  A number of genetic diseases result from the failure of this 
quality checkpoint. Stress, biochemical and physiological stimuli change ER homeostasis  and 
lead to the accumulation of unfolded or misfolded proteins in the ER lumen, which in turn 
amplified the stress. To alleviate this condition, ER engages an adaptive transcriptional and 
translational program, focused to cell cycle arrest, protein degradation and the reduction of 
protein synthesis. If, stress cannot  be alleviated ER pathway of apoptosis ensues (Rutkowski 
and Kaufman, 2004). Interestingly, the  eukaryotic elongation factor EEF1A1 may contribute 
to this process, mediating the ubiquitin-protein degradation of damaged nascent proteins after 
their release from the ribosome (Bosutti et al., 2007c). The eEF1A1 protein exerts its non-
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canonical functions also in apoptosis. The contribution  of actin  in this action is suggested, 
since this protein may have a critical role in ensuring translation fidelity, stimulating eEF1A1 
coupled-proteosome degradation of damaged proteins (Kandl et al., 2002). 
 
 
Figure.5.1.B: Representative model of triggers and effectors of muscle wasting in diseases.  
 
Main metabolic and catabolic triggers of muscle mass loss and their interplay in the score from low 
grade muscle atrophy to acute catabolic condition.  
Reduced muscle activity, chronic or acute inflammation, vascular adaptation, negative energy balance, 
energy restriction, organ failure, metabolic disorders (acidosis), hormone unbalance, oxidative stress, 
and apoptosis impaire muscle architecture and determine the magnitude of muscle mass loss process. 
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Figure.5.1.C: Apoptosis pathways involved in skeletal muscle atrophy.  
 
Caspase dependent and independent pathways are both involved in apoptotic loss of myonucleous during muscle 
atrophy. Both directly pilot DNA fragmentation in nucleus of muscle fiber. The intrinsic mitochondria pathway 
(caspase dependent) requires the activation of stress response genes, release of cytochrome c from mitochondria 
inner-membrane and the formation of the apoptosome (caspase-9, plus ATP and  Apaf-1), which in turn, 
activates caspase-3, 6,7, followed by DNA fragmentation. Whilst, the extrinsic pathway of apoptosis (caspase 
dependent) starts by the binding of FAS-FADD ligands (such as TNF-alpha) to the respective cellular surface 
receptors. This pathway required the activation of caspase-8, followed by the activation of mitochondria pathway 
(Bid-tBid-Bax stream). Finally, in response to high stress, such as accumulation of unfolded-damaged proteins in 
ER, the intrinsic ER pathway of apoptosis starts with the activation of caspase-12. This enrols the apaptosome 
via pro-caspase-9 activation. Broken lines represent the caspase independent pathway engaged by mitochondria 
and related to the release from the organelle of endonuclease G and AIF proteins. 
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b. The regenerative potential of skeletal muscle  
 
Satellite cells (the skeletal muscle stem cells) play a critical role in skeletal muscle 
regeneration in response to injury or exertion. These cells lie in their own niche separated 
from the muscle fiber by a basement membrane. Under normal circumstances, satellite cells 
are quiescent, but become activated upon muscle injury and contribute to tissue regeneration 
and self-renew their own population. The understanding of the basic mechanisms that regulate 
satellite cells behaviour, in muscle atrophy or in physiological condition, is still rudimentary. 
Our current knowledge is that the regenerative process consists into two distinct phases: a 
degenerative phase, in which inflammatory cells infiltrate the site of injury and play a critical 
role in the phagocytosis of necrotic myofibers, and a regenerative phase, in which quiescent 
muscle stem cells are activated, proliferate, withdraw from cell cycle, differentiate, and fuse to 
form new myofibers (Figure 5.1.D). The achievement of the terminally differentiated state 
implies a close functional cross-talk between  these two phases and between myogenic muscle 
regulatory factors, such as MyoD and Myf5 (up-regulated in the early phases of quiescent 
satellite cells proliferation), myogenin and MRF4 (up-regulated later during differentiation), 
as well as  cell cycle regulators, such as retinoblastoma pRb and the cyclin-dependent kinase 
inhibitors p27Kip1and p21Cip1 (know to modulate MyoD timing-expansion and cell cycle 
arrest), (Maione and Amati, 1997), (Figure 5.1.D). A functional link between cadherin-
cadherin interactions, p27Kip1 and terminal differentiation of myoblast, has been also relieved, 
supporting the active role of mechanical force on myogenesis and differentiation. Defects in 
spatial and temporal regulation of these systems affect the regenerative efficiency of muscle. 
Surprisingly, ER stress exerts a positive effect on myofiber formation (Nakanishi et al., 2007). 
Increased ER stress enhances differentiation-associated apoptosis of myoblasts and 
selectively eliminates vulnerable cells. Remarkably, surviving myoblast results more resistant 
to apoptosis and efficiently differentiate into contracting myofibers (Nakanishi et al., 2007). 
Furthermore, the balance and interaction between inflammatory and growth factors 
determines the maintenance of differentiated phenotype and the regenerative potential of 
muscle (Stewart et al., 2004). 
Notably, both myoblastic and osteoblastic properties are simultaneously expressed in 
the human myogenic cell lineage, prior muscle differentiation (Hashimoto et al., 2007). The 
inhibition of terminal differentiation of myoblasts and their conversion into osteoblast lineage 
cells (but not in mature bone cell), is mediated by the action of bone morphogenetic proteins 
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(BMPs). These are members of TGF-beta superfamily. The BMPs role is proven in bone 
turnover, bone formation and induction and often is superimposed to muscle, in 
musculoskeletal disorders (Hayashi et al., 2008). Besides this, BMPs are also potent 
stimulators of cell migration and angiogenesis. The mechanism underlining myoblast 
conversion into osteoblast is very complex and implies the activation of a multitude of 
competitive factors. Nonetheless, the lost of osteogenic potential of myoblasts appears clearly 
associated with the expression of muscle lineage-specific proteins Pax7 and MyoD. Whilst, 
terminal osteogenic differentiation is accompanied by the expression of two osteoblast-
specific proteins, the bone-specific alkaline phosphatase and Runx2. The Rho signalling 
critically controls the switch between myogenesis and osteogenesis (Hashimoto et al., 2007). 
More recently, gene microarray analyses identified a novel putative inhibitor for myoblast-
osteoblastic differentiation, the paired-like homeodomain transcription factor Pitx2 (Hayashi 
et al., 2008). All data that  emphasise the straight interaction between bone and  muscular  
systems  (Cointry et al., 2005; Ferretti et al., 2001). 
Noteworthy, among the various pathways (p38MAPK, myostatin, TNF-alpha, IL-4, 
TGF-beta , IGF-I, and the mechano growth factor MGF, etc.) that regulate the distinct steps of 
muscle repair and regeneration, the Notch receptor’s system emerges as a key “negative” 
controller of myogenesis.  
Notch is a transcriptional signalling network essential for the proper organ development 
in an embryo, and is indispensable for tissue regeneration in the adult. Regulation of cell 
differentiation and cell fate decision by Notch is achieved by induction of specific 
differentiation programs and by an independent regulation of cell cycle (Sarmento et al., 
2005). Some members of this protein family (Notch-3) maintain proliferation of muscle 
progenitor cells, inhibiting MyoD and inducing myostatin transcription, or induce (Notch-1) 
the premature entry into S phase of cell cycle, via the induction of gene transcription of the S 
phase kinase-associated protein 2, and the degradation of  p27Kip1 and p21Cip1 cyclin-
dependent kinase inhibitors (Sarmento et al., 2005), (Figure 5.1.D). Notch role in human 
muscle atrophy is yet little deciphered. Crucial appears the role of its antagonists Numb and 
the transcription factor Stra13, since they  improve the recruitment of reserve cells that do not 
normally fuse (Kitzmann et al., 2006). Otherwise, Notch pathway results up-regulated by the 
Numb inhibitor Siah1, which in turn contributes to cell cycle arrest and apoptosis of muscle 
stem cells via the activation of the PW1/p53 stream (Relaix et al., 2000). In spite of these 
notions, it is in our opinion that the negative role of Notch in muscle plasticity is simply  a 
moot point.  In other terms, the question is: whether muscle plasticity is impaired or not by 
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the activation of this pathway. Notch up-regulation is straightforward linked to the 
proliferation of undifferentiated myocytes, the aim is to maintain muscle progenitor cells 
(Figure 5.1.D). Thus, Notch may represent a high self-renew potential to muscle, a powerful 
system to counteract “future” damage due to muscle fatigue. The central point is whether 
exercise training potentates or reduces Notch signalling and the consequential physiological 
responses to exercise, for example in athletes. Moreover, as counterpart, may be very 
intriguing establish the effect of muscle unloading on Notch and the consequent impact on 
muscle regenerative potential for example in immobilized persons or during prolonged bed-
rest.  A suggestive interpretation comes from a recent work of  Carey KA and colleagues  
(Carey et al., 2007). These authors suggest that some of the benefits provided by resistance 
training may be mediated through the enhancement of this pathway, especially in elderly. In 
particular the authors compared the expression of Notch3 and 1, Numb, Jagged1, Hes1, and 
Hes6 in skeletal muscle biopsies from older men (60-75 years old) and younger men (18-25 
years old) with supervised resistance exercise training. The authors found that expression of 
Notch1, Jagged1, Numb, and Delta-like 1 were significantly lower in muscle biopsies from 
older men compared to muscle from younger. Notch1 and Hes6 (basic helix-loop-helix 
factors) genes were increased, whereas Delta-like 1 (a member of the Delta/Notch protein 
family) and Numb expression were decreased with supervised resistance exercise training.  
Additionally, the increased expression of these genes either preceded or occurred in parallel 
with the increase expression of myosin heavy chain protein (marker of late differentiation), 
(Carey et al., 2007). In contrast with the strong conviction that Notch signalling pathway 
inhibits myoblast differentiation, the authors suggested that Notch may confer both anti- and 
promyogenic actions. This dissected response may  depend by the precise level or timing of 
activation of the pathway. The premature activation of Notch may have an inhibitory effect on 
normal myogenesis, whereas late activation may be essential for differentiation (Carey et al., 
2007). The study demonstrated also that heavy resistance exercise training was capable of 
attenuating the decline in Notch gene expression  in  elderly.  Resistance exercise improves 
muscle efficiency and strength  in these persons (Narici et al., 2004). Thus, on these 
evidences, Notch might show an additional  “positive” role in the adaptive and/or regenerative 
capacity of human skeletal muscle. Constant exercise training may induced a “chronic or late”  
Notch activation, which in turn might keep ready the muscle  against environmental 
solicitations. Nonetheless, a more extensive understanding of the mechanisms modulating and 
coordinating satellite stem cells differentiation via Notch, may be a powerful tool for cell-
based therapies in high exercise training or wasting conditions.  
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Figure 5.1.D: Model for the development, activation, and maintenance of the satellite cell.  
 
In response to skeletal muscle injury, or in the presence of growth factors, (including IGF-I and MGF),  
quiescent satellite cells expressing Pax-7 and Foxk1 are activated to proliferate, up-regulating the 
myogenic determination factors, MyoD and Myf-5 (Early phases). Satellite cell activation is regulated 
by the Notch signalling pathway. In the early phases Notch sustains proliferation of undifferentiated 
cells (myoblast) and inhibits myoblast differentiation via Myostatin activation..  Once growth factors are 
withdrawn, MyoD and Myf5 are expressed and activate muscle-specific genes needed for entering the 
differentiation program and to the inhibition of Notch (Later phases). TNF-alpha signalling modulates 
Notch traslocation into nucleus. Transition from proliferation to differentiation, which is accompanied 
by the down-regulation of Pax-7 and the up-regulation of Myogenin and MRF-4, is charged by MyoD 
and the Foxk1 signalling. Terminal differentiation is  followed by p21Cip1 that irréversible withdrawn 
the myoblasts from the cell cycle. Muscle-specific structural genes and markers are then expressed to 
allow cell fusion of myotubes formation. TNF-alpha induces the activation and nuclear translocation of 
NF- kB, which suppresses MyoD gene expression, leading to dysfunction of skeletal myofibers and the 
inhibition of myogenic differentiation.  
 
 
 
 
 
 
 23 
 
 
c. Angiogenesis and mechanical force 
Angiogenesis means, formation of new capillary blood vessels from pre-existing 
vessels. 
By this process the microvascular system expands itself to rescue organ growth, 
regeneration and repair, in response to injury or altered tissue metabolic demands. Angiogenic 
mechanisms are tightly regulated by the cross-talk between specific angiogenic factors such as 
vascular endothelial growth factor (VEGF), fibroblast growth factor, angiopoietins, local 
tissue environmental factors, insoluble extracellular matrix molecules, receptor signalling 
pathways and by cell-cell interactions.  
Increased perfusion is a necessary response to restore or increase tissue function, as for 
example, in muscle during rehabilitation following bed-rest, in tissues following stroke or 
ischemia. Nevertheless there can also be problems associated with increased microvessel 
formation in diseases, such as, in atherosclerosis and in solid tumour growth.  The 
understanding of the molecular processes involved in the modulation of new blood vessel 
formation could lead to improved recovery where increased perfusion is advantageous, but 
also more efficient therapies to treat conditions where angiogenesis is a pathological feature.  
Great evidences indicate, muscle mechanochemical transduction, extravascular tissue 
activity, hypoxia and alterations in the hemodynamic forces (vessel wall shear stress), as the 
main triggers of angiogenesis process (Ingber, 2004). In skeletal muscle, angiogenesis is 
clearly linked to the preservation of the adequate intramuscular oxygenation and proper 
metabolic state of the fibers, especially in response to exertion (Degens and Alway, 2006; 
Degens et al., 2006). Key effectors of the process are the NOS/NO (nitric oxide-producing 
synthase/nitric oxide) system, which influences the extent and magnitude of angiogenesis 
cascade. The balance and reciprocal interaction between the gaseous molecule NO and fiber 
metabolism rescue the successful of this vascular network (Grange et al., 2001). NO is low 
produced when a surplus of oxygen or nutrients is available, but its synthesis increased if the 
supply is catabolically consumed. The generation of the NO molecule from eNOS activity 
provides also an obligate upstream signal for shear stress-induced VEGF-dependent muscle 
angiogenesis, which over expression might reflect the extent of oxygen supply or share stress. 
Remarkably, muscle VEGF activates in autocrine and/or paracrine way the angiogenesis 
machinery. By the activation of a yet-unknown mechanosensor, the VEGF is produced in high 
concentrations by skeletal muscle fibers and modulates vessel formation. Furthermore, 
endothelial cells produce this growth factor, to maintain the process. The coupling between 
VEGF to blood vessel recruitment and muscle growth induction is maintained by myogenic 
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PI3-kinase/Akt signalling (Takahashi et al., 2002). An intriguing contribution of the ß-
catenin/Wnt system to VEGF modulation  has been also alo provided (Kim et al., 2005). By 
the up-regulation of VEGF and the direct interaction with the hypoxia inducible transcription 
factor HIF1-alpha, the Wnt/ß-catenin pathway promotes and ameliorates  re-vascularisation of 
ischemic skeletal muscle tissue (Kim et al., 2006). This function may provide a mechanistic 
explanation about the role of this protein in promoting muscle cell survival and adaptation to 
hypoxia (Kaidi et al., 2007). 
Noteworthy, among the vast number of molecules involved in angiogenesis processes, 
recently it has been characterized a novel angiogenic molecule, expressed specifically at the 
level of striated muscle and in the tendon extensions of the fibers, the myodulin. This 
represents a powerful skeletal muscle angiogenic factor operating through the direct cell-to-
cell interaction. A first characterization of the molecule suggested a high sequence 
homologies with the cartilage-specific chondromodulin-I protein, but an opposite mechanism 
of action. The special role of myodulin gains by the fact that in response to activity, its over-
expression is associated with positive variations in muscle mass and microvascularization 
(Pisani et al., 2004), whereas it is strongly down regulated in atrophied skeletal muscle (Pisani 
et al., 2004). 
Remarkable, angiogenesis is also recognized as a feature of atherogenic process. The 
neovascularisation of intima arises frequently from the dense network of vessels in the 
adventitia, adjacent to a plaque (Moulton, 2002). New blood vessels may have an active role 
in plaque metabolic activity and promote its growth beyond the critical limits of diffusion 
from the artery lumen. An irregular nature of blood vessel formation has been associated also 
to tumor angiogenesis. The factors  responsible for their growth may be different from those 
seen during normal wound healing (Folkman, 1995).  
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 5.2 Pathophysiological processes in skeletal muscle atrophy 
 
…The concrete is that phatophysiology of muscle atrophy is a complex multifactor 
process (Figure 5.2.C), in which impaired mechanical action, inflammatory, hormonal or 
stress signals interact to trigger the final overcome of muscle fibres … 
 
a. Muscle plasticity and  mechanotransduction 
Mechanical forces are known to play an important role in the organization, growth and 
function of living tissues, and in the prevention of oxidative stress and inflammation. In 
physiological conditions, when a mechanical deformation is imposed on a muscle, changes in 
cellular and molecular conformation converge the mechanical action to a biochemical signal, 
(so-called mechanotransduction). This activates downstream signalling pathways, related to 
development and maintenance of muscle plasticity, metabolism, but also, intriguingly, 
oxidative response or inflammation (Burkholder, 2007), (Figure 5.1.A).  
Cells can sense, nature, direction, and intensity of mechanical force, through focal 
adhesions to the extracellular matrix and through adherents junctions, mediated by cadherin-
cadherin bridges and integrins or by cytoskeleton-linked adhesion receptors (Ganz et al., 
2006). In response to transient stretch,  the cell membrane permeability changes, cytoskeleton 
fluidises and mechanosensitive ion-channels begin differently regulated, with the further 
activation of downstream  signalling pathways (rapamycin-sensitive- mTOR, MAPK kinases 
and NF-κB pathways). This, in such a way, may be define an universal cellular response 
(Figure 5.2.A). In skeletal muscle, this mechanism is particularly organized, because the 
signalling pathways are selectively activated or inhibited in response to different types of 
mechanical forces in a “fiber-type”- dependent manner (Wretman et al., 2000; Wretman et al., 
2001). Thus, not all skeletal muscle fibers respond at the same extent to mechanical 
stimulation (Figure 5.2.A).  
Pioneering approaches emphasized that different types of muscle contraction (eccentric 
or concentric) and passive stretch act differently on MAPKs (Wretman et al., 2000; Wretman 
et al., 2001). The triggers or effectors coordinating this dissected response, as well as its 
physiological significance are not yet clear. Likely, exposure to ROS, metabolic changes 
(acidosis), inflammatory signals, beta-adrenergic receptor agonist, growth factors, or the 
direction and intensity of  mechanical stress can differentially trigger the final action of the 
pathways (Zhan et al., 2007). Evidences show, ROS generated by contraction and metabolic 
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changes induce  MAPKerk1/2 phosphorylation, whereas, high mechanical stress or 
inflammatory signals activate p38 MAPK (Wretman et al., 2001; Zhan et al., 2007), (Figure 
5.2.A). Furthermore, the activation of ERK may account, at least in part, for the fiber type-
specific hypertrophy induced by beta-adrenergic receptor agonist (Reecy et al., 2006). 
The maintenance of muscle plasticity is also guarantee by the  proper organization of 
neuromuscular junction “architecture”, as well as by the expression and stability of a number 
of neurotrophic or survival neuronal factors (ciliary neurotrophic factor, neurotrophin, 
fibroblast growth factor-2, survival motor neuron protein, etc.), (Sterne et al., 1997), (Figure 
5.2.A). In particular the  current opinion is that the neuregulin-1, a growth factor that 
potentates myogenesis, may be a prime molecule, at the level of synapses, that affects muscle 
metabolism (glucose transport) and cell proliferation in response to mechanical forces 
(Lebrasseur et al., 2003).  
At date, a lot of investigations are needed to underline how mechanical-electrical 
signals underpin muscle fiber metabolism. Goldspink and co-authors demonstrated that the 
mechano growth factor MGF is a crucial effectors in the connection between metabolism, 
muscle contraction and modulation of muscle mass during exercise (figure 5.2.A). MGF 
derives from the alternative splicing of IGF-I transcript. It is pulsar expressed either after 
mechanical stimulation or tissue damage. Compared to the systemic liver type IGF-I, the 
MGF shows different binding protein/receptor affinities (Goldspink, 2005a; Goldspink, 
2005b; Goldspink, 2005a; Goldspink, 2005b). Muscle MGF molecule involves in autocrine 
regulation of muscle mass, activating muscle satellite cells, reducing apoptosis and increasing 
protein synthesis. Early after exercise and/or muscle injury, the IGF-I gene is firstly spliced 
towards MGF, to the recovery of tissue, than, the IGF-I becomes completely spliced towards 
the systemic IGF-I form to exert its systemic anabolic action. In vivo and in vitro 
experimental studies indicate that stretch and particularly stretch combined with electrical 
stimulation, rather than electrical stimulation alone, are important in inducing MGF 
expression. The production of MGF is deficient in certain diseases such as in the muscular 
dystrophies or aging,  in which the mechanotransduction is defective. Possibly, dystroglycan 
complex may represent the “sensing” pathways controlling the IGF-I splicing toward MGF in 
response to the mechano-electrical signal  (Goldspink, 2005a; Goldspink, 2005b). Likely, the 
reduction of MGF synthesis, may account to the muscle loss observed in metabolic disorders, 
chronic inflammatory diseases or prolonged immobilization (bed-rest). Interestingly, another 
muscle splice variant (potentially similar to MGF) of IGF-I has been recently isolated. It is  
similar to the systemic liver type IGF-I  and is expressed in muscle during rest but is also 
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upregulated by exercise. Its physiological significance remains unclear (Goldspink and Yang, 
2001).  
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Adapted from: Flük, M.(2006). Functional, structural and molecular plasticity of mammalian 
skeletal muscle in response to exercise stimuli. J. Exp. Biology 209, 2239-2248. 
 
 
 
 
Figure 5.2.A: Scheme visualizing the complex integration of mechanical, metabolic, neuronal and 
hormonal stimulus, involving and coordinating muscle response during muscle activity. A complex 
mosaic of sensors and effectors molecules convert different homeostatic perturbations into the 
activation of signaling cascades, which in turn, control muscle fiber fate via the regulation of gene 
expression. The final response involves the coordination between nuclear and mitochondrial genomes 
and the specificity of the muscular adaptation with respect to the nature of the respective exercise 
stimulus. Final response may be related to the modulation of protein turn-over, myogenesis, 
angiogenesis, mitochondria biogenesis and metabolism. 
TFAM: Mitochondrial transcription factor; JNK: c-jun N-terminal kinase.
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b. The oxidative stress and fiber survival: perturbations in mitochondria dynamic and 
energy metabolism 
 
Alterations in mitochondria dynamic, due to significant perturbations in gene expression 
of fusion (reduction) and fission proteins (increased), may represent the first mitochondria 
signal in intrinsic pathway of apoptosis (Figure 5.1.C). Mitochondria fuse and divide and 
change morphology in response to a multitude of signals. If  these functions are perturbed, 
mitochondria metabolic destabilization, oxidative stress and apoptosis ensue (Kraft et al., 
2006). Genes controlling mitochondria contents, dynamics and the energy intracellular 
diffusion between them, appear critically linked to twitch, muscle metabolism and fiber 
survival (Figure 5.2.A; figure 5.2.C). In particular, the mitofusins (Mfn) expression is 
essential to mitochondria fusion and morphology, oxidative mitochondria capacity and 
glucose oxidation (Cartoni et al., 2005). Its  down-regulation is critically linked to apoptosis 
and PGC-1 alpha mitochondria dysfunctions (Cartoni et al., 2005; Parra et al., 2008) (Figure 
5.2.A). As counterpart, the increased expression of mitochondria fission proteins (such as Fis1 
and Drp1) accompanied apoptotic cell death (Chen and Chan, 2005; Parra et al., 2008). In 
particular, Drp1 mediates the control of mitochondria shape,  mitochondria fragmentation and 
the inhibition of Ca++ signal spreading along the organelles (Cribbs and Strack, 2007; Parra et 
al., 2008), (Figure 5.2.A). Otherwise, the fiber size, fiber mitochondria contents and the 
energy intracellular diffusion distances between them may be crucial to the extent of fiber 
survival and metabolism (Baserga, 2007; Kinsey et al., 2007; Parra et al., 2008). For example, 
in animal models, a very low rate of aerobic metabolism is observed in some fish white 
muscles, which may destine <1% of fiber volume to mitochondria, whereas extremely high 
metabolic rates are observed in insect flight muscle, where mitochondria may exceed 40% of 
the fiber volume (Kinsey et al., 2007; Parra et al., 2008). The interspaces between 
mitochondria determines the distance over which diffusion must occur (Kinsey et al., 2007; 
Parra et al., 2008). Mitochondria generally are distributed throughout the muscle fiber or are  
clustered at the periphery of the fiber near  the sarcolemmal membrane (Kinsey et al., 2007; 
Parra et al., 2008). Nonetheless, fibers show, in various percentage, both kinds of 
mitochondria distribution (Kinsey et al., 2007; Parra et al., 2008). The disposition and number 
of mitochondria facilitate both rapid O2 flux to mitochondria and ATP flux from 
mitochondria to sites of ATP utilization (Baserga, 2007; Kinsey et al., 2007; Parra et al., 
2008). Critical appears the contribution of muscle fiber size. Excessive cell size may reduce 
capacity for critical oxidative metabolic processes. Conversely, anaerobic contractile process 
doesn’t dependent on transport of O2 neither to the mitochondria nor by ATP flux. The 
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contractile function in these fibers must be affected by the increase in fiber size or changes in  
mitochondrial distribution (Baserga, 2007; Kinsey et al., 2007; Parra et al., 2008). In nature, a 
compensatory mechanism is enrolled to counteract the negative effect of large fiber size on 
burst or high strength contraction. This is provided by increased anaerobic metabolism, or by 
the development of  fiber type that may be as large as possible without incurring diffusion 
limitation ( Kinsey et al., 2007; Parra et al., 2008). 
The generation of oxidative stress is a direct consequence of mitochondria 
destabilization. Reactive oxigen species (ROS) generation plays a central role in several 
human pathological conditions, including cardiovascular dysfunction, diabetes, 
atherosclerosis and malnutrition. But, the physiological accumulation of ROS is also essential 
to cellular functions. Low levels of ROS regulate cellular signalling pathways and play an 
important role in the modulation of normal cell proliferation, whereas, intermediate quantities 
trigger cell apoptosis and high quantities initiate cell necrosis. In this setting, the balance 
between ROS production and antioxidant defence determines the degree of oxidative stress 
and cellular response. Growing evidence tells us that oxidative stress modulates muscle loss at 
multilevel. The rise in oxidant generation (superoxide, hydroxyl radicals, nitric oxide, 
peroxynitrite, and the free radical-derived product hydrogen peroxide), alters muscle via the 
up-regulation and activation of transcription factors (NF-κB and FOXO), the generation of 
reactive aldehydes and the modulation of stress-induced kinases. Marked dephosphorylation 
of the eukaryotic initiation factor 4E-binding protein 1 (eIF4GI), the increased 
phosphorylation of eukariotic elongation factor eEF2 and changes in eIF4GI distribution are 
hallmarks of  decreased muscle protein synthesis induced by ROS (Shenberger et al., 2007). 
Whereas, up-regulation or activation of calpains, atrogin-1, MuRF-1, and the 20 subunit  of 
proteasoma indicate the activation of  protein breakdown  (Du et al., 2004). Nonetheless, at 
date, our knowledge of the exact mechanism linking oxidative stress to muscle mass decline 
is still rudimentary.  
The role of stress response protein p66(ShcA) may be very helpful to clear  this interaction  
(Bosutti et al., 2007b; Zanetti et al., 2007). This adaptor protein is a dominant player in 
modulation of mitochondria homeostasis in physiological or stress conditions (Figure 5.1.C). 
In response to stress, the p66(ShcA) acts in apoptosis and in ROS generations  (Migliaccio et al., 
2006; Zanetti et al., 2007). This protein localizes within the mitochondria intermembrane 
space and induces mitochondrial permeability transition and the generation of ROS. Giorgio 
and co-authors found that the p66(ShcA)  executes an electron transfer reaction on the  Cyt c, 
which implies a transfer of electron between the protein  and the cytocrome, and the 
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generation of  ROS. The mapping of the central core of the molecule, evidenced its functional 
redox  structure, whose mutations impaired mitochondria apoptosis (Giorgio et al., 2005). 
The p66(ShcA)  “per se” is very intriguing.  Its expression is critical in a number of 
pathological or physiological circumstances. Deletion of p66(ShcA)  gene protects against age-
related endothelial dysfunction, thus p66(ShcA) may be a pivot in controlling systemic oxidative 
stress in vascular disease (Napoli et al., 2001; Napoli et al., 2003). Moreover, an increased 
expression was relieved in patients with end-stage renal disease (Geisel et al., 2007), in 
oxidant-dependent tissue injury, cancer and permanent embryo arrest in vitro (Favetta et al., 
2007; Kasuno et al., 2007; Menini et al., 2007). This adaptor involved also in TGF-
beta/Erk/MAP pathway, in the regulation of IGF-I signalling in hyperglycemia, or in the 
promotion of HIF-1alpha accumulation and cell death in hypoxic T cells (Carraro et al., 2007; 
Lee et al., 2007; Miller et al., 2007). Moreover, p66(ShcA)  signalling is implicated in regulation 
of VEGF synthesis in tumor cell angiogenesis (De et al., 2005). More recently, an intriguing 
publication about cell anoikis, shows us that p66(ShcA)  may be also a crucial sensor in cell 
death induced by cell detachment (Ma et al., 2007).  
 
 c. Muscle plasticity in hypoxia 
  
 Oxygen homeostasis is an essential regulatory mechanism for cell energy production 
and survival. A limited muscle O2 delivery (hypoxia state) is a key determinant either of the 
skeletal muscle's oxidative phenotype or mitochondria maintenance (Pisani et al., 2004). 
Normally, changes in muscle O2 delivery in healthy persons can result from modifications in 
arterial O2 content, blood flow, or a combination of both and can be induced via heavy 
exercise at sea level or during acute and chronic exposure to altitude. Otherwise, hypoxic state 
in skeletal muscle is also a common feature of pathological conditions, characterized by a 
deficit or limited  oxygen supply due to altered cardiovascular and respiratory functions as 
well as to a reduced microvascularization of muscle fiber.  Nonetheless, skeletal muscle can 
adapt itself to hypoxic state (Figure 5.1.B; Figure 5.2.C). 
Muscle adaptation to hypoxia requires the activation of cytoprotection machinery, 
converging versus the modulation of mitochondria plasticity and the activation of hypoxic 
inducible transcription factors (HIFs).  The degree of hypoxia, the age at exposure, and the 
duration of exposure are key determinants of mitochondria or muscle adaptation to the limited 
O2 delivery (Figure 5.2.A). Studies indicate that the permanent or long-term exposure to 
severe environmental hypoxia decreases mitochondria contents and increased the generation 
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of reactive oxygen species during oxidative phosphorylation. In parallel muscle adapts itself 
(in a fiber type dependent manner), by shifting oxidative metabolism towards a higher 
reliance on carbohydrates as a fuel, and reducing the intramyocellular lipid substrate stores 
(Pisani et al., 2004). In the mean, the mitochondrial plasticity facilitates adaptations of cell to 
the limited O2 delivery (Figure 5.2.A), integrating a global cellular signal transduction 
system,  including the modulation of mitochondria respiratory capacity, the activation of 
mitochondria biogenesis, the induction of antioxidant defence, the regulation of antiapoptotic 
mitochondrial proteins and finally the modulation of mitochondrial sensitivity to membrane 
permeability transition (Lin et al., 2003; Lynn et al., 2007). 
Particular issues coming from the pharmacological management of critically ill patients, 
reviled that the generation of reactive oxygen species is the main reaction of mitochondria to 
a hypoxic state. The mentioned studies were focused on the effects of ischemia injury 
reperfusion on myocardial - mitochondria functions (Corbucci et al., 2005). The intriguing 
results may be extended also to ischemic skeletal muscle. These studies show that the most 
rapid and prominent adaptive mechanism against hypoxia is the reduce activity of 
mitochondria electron transport chain enzyme complexes. This reduction is linked to NO 
synthesis. Hypoxia induces ROS generation, adenosine triphosphate (ATP) depletion and 
Ca++ overload. To overcome any shortage of oxygen, the cell activates the sarcolemmal and 
mitochondrial K+(ATP) channels, which leads to a significant reduction of Ca++ influx and 
attenuates Ca++ overload (Corbucci et al., 2005). The process is orchestrated by HIF-1 (Figure 
5.2.A). 
Even so, the literature shows conflicting roles of HIF-1 signalling. For instance, the 
analysis of the role of HIF-1 in myoblast differentiation supports the fact that HIF-1 has an 
essential role in regenerative muscle tissue in vivo, in particular  after eccentric exercise. 
Hypoxia promotes the undifferentiated state in various stem and precursor cell populations. A  
strength hypoxia can inhibit differentiation of myogenic satellite cells, by  the stabilization of 
Notch-1 (Gustafsson et al., 2005). Furthermore, severe hypoxia induced  HIF-1-dependent 
signals directed to the remodelling of existing blood vessels,  shifting metabolism towards 
glycolysis and altering myogenesis (Dapp et al., 2006). HIFs improve also angiogenic process 
initiated by mechanical forces, contributing to stretch- but not to shear-stress-induced 
capillary growth (Milkiewicz et al., 2007). How hypoxia modulates the activation of 
angiogenic process still remain to be define, but a direct (via a metabolic stimulus) or indirect 
(via a mechanical stimulus) mechanism is supposed (Deveci et al., 2001). Plausibly, AMPK 
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signalling is required for angiogenic responses in endothelial cells and  the adipokine, 
adiponectin, may be the trigger (Ouchi et al., 2004). 
 
d. When atherosclerosis encounters muscle mass decline: an  inflammatory hypothesis 
 
Cytokines regulate skeletal muscle function, including gene expression and adaptive 
responses (Figure 5.1.A; figure 5.1.B; figure  5.2.B; figure 5.1.C; figure 5.1.D). However, a 
mechanistic link between inflammatory processes and the development of muscle atrophy is 
well documented. Cytokines that affect muscle function can be produced in the muscle 
intrinsically or by neutrophils, macrophages, fibroblasts, vascular smooth muscle cells and 
vascular endothelium. In addition, inflammatory mediators may also originate from local 
sources such as adipose tissue (adipocytokines) leading to an aggravation of local (tissue or 
vessel) and systemic inflammation (Blanc et al., 2000; Iacobellis et al., 2005).   
Inflammation “per se”  is part of the biologic cascade of events that form the body's 
natural defence against injury or infection and is vital part of the immune system. In general, 
this process is an acute response, involving complex interactions between pro and anti 
inflammatory molecules and results in rapid increase and release into the circulation of 
inflammatory mediators (Gabay and Kushner, 1999; Vanden Berghe et al., 2000). The pro-
inflammatory signals are balanced by anti-inflammatory cytokines (i.e. IL-10 and TGF-
beta1), which in a feedback fashion promote the resolution of the process (Conti et al., 2003; 
Stenvinkel et al., 2005a). Elevated concentrations of proinflammatory markers including 
intracellular adhesion molecule-1, matrix metalloproteinase-9, IL-6, and TNF-alpha show 
devastating effects on the vasculature and are implicated in the pathogenesis of accelerated 
atherosclerosis in numerous chronic disease. The activation of critical pathways of  apoptosis, 
angiogenesis and oxidative stress pushes through the process (Slevin et al., 2006; Metzler et 
al., 2000; Napoli et al., 2001). Additionally, a relation between systemic or local 
inflammatory and oxidative milieus has been also provided (Chandel et al., 2000). The 
association of these conditions with traditional atherosclerotic risk factors (altered lipid 
profile, hyperglycemia, hypertension, etc), accounts to the increased cardiovascular events 
and progression of atherosclerosis (Bosutti et al., 2007b).  
Especially, the injury theory of atherosclerosis proclaims the role of lipotoxicity 
(oxidized low density lipoproteins LDL) and hemodynamic factors or stressors, in lesion 
vessel or plaque progression (Figure 5.2.B). The focal accumulation of cholesterol loads 
macrophage cells (foam cells) and the migration and proliferation of smooth muscle cells 
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(SMC) in the intima of large- and medium-sized arteries, with the finally formation of the 
atherosclerotic plaques (Libby, 2003). Increased circulating levels of oxLDL-cholesterol, has 
been found to be capable to stimulate macrophages, endothelial and SMCs, to express a large 
number of genes, involved in inflammatory cascade and in the generation of vascular oxygen 
radicals (Giordano, 2005; Metzler et al., 2000; Napoli et al., 2001), (Figure 5.2.B). Notably, in 
vitro studies indicated that low concentration of oxLDL modulates endothelial and SMCs 
proliferation and hypertrophy via the regulation of the cyclin-dependent kinase inhibitor 
p27Kip1, whereas higher concentrations trigger the apoptotic response, the down-regulation of 
antiapoptotic proteins (Bcl-2 and c-IAP-1), and the release of  cytochrome c and Smac from 
mitochondria (Imanishi et al., 2004; Seibold et al., 2004; Zettler et al., 2003). Albeit, the 
recornized potential of oxLDL in lipotoxicity, little studies have been performed to underline 
the molecular mechanisms related to  LDL action (Figure 5.2.B).  Some issues suggest  the 
activation of  stress-response pathways with further local vascular ROS  generation 
(Giordano, 2005; Metzler et al., 2000; Napoli et al., 2001), which in turn  at the level of 
plaque, induces lipid peroxidation (Figure 5.2.B), and various types of damage, including 
oxidative damage into DNA. DNA damage has been correlated with high fat diet in 
experimental atherosclerotic animals. Rabbits fed with high cholesterol diets shown increased 
oxidative damage in atherosclerotic plaques, increased formation of guanine oxidation 
products 8-oxo-G,  DNA strand breaks,  the up-regulation of the transcription factor p53, the  
induction of apoptosis,  as well as  the activation of DNA repair systems (Martinet et al., 
2001). Interestingly, when cholesterol-fed animals are placed on a normal diet, DNA strand 
breaks, 8-oxoG levels and repair pathways decline progressively since to became normalized 
(Martinet et al., 2001). In humans, patients with atherosclerosis show increased levels of 
DNA strand breaks, oxidised pyrimidines and altered purines in circulating white blood cells, 
vessel wall cells and in the superficial layer of the atherosclerotic plaque (Mahmoudi et al., 
2006); spy-signals of a systemic oxidative stress. On the other hand, cholesterol reduction 
leads to a significant improvement of endothelial vasomotor function and a decrease in the 
rate of cardiovascular events (Levine et al., 1995). Intriguingly, in a recent study, Hesse 
expanded this view, providing evidence that prolonged  muscle unloading (strict bed rest for 
13 days), impaired endothelium-dependent arterial relaxation in healthy individuals. This 
effect of unloading was counteracted by a concurrent moderate hypoenergetic low fat diet 
(energy restriction), that modulated serum lipids and oxidative stress and improved 
endothelium-dependent and independent vasodilatation (Hesse et al., 2005). 
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Noteworthy, peripheral vascular atherosclerosis contributes to peripheral tissue wasting 
(i.e. in muscle), by limiting blood vessel diameter, blood flow and O2 delivery to the tissue 
(Isenberg et al., 2007).  Nonetheless, muscle microvasculature exhibits high plasticity, in 
particular in response to exercise, thus, despite the presence of pathologies, exercise training 
can improve vascular dimension  and endothelial function (Convertino et al., 1977; 
Convertino, 1992; Convertino, 1994; Convertino, 1997). Interestingly, the duration of muscle 
disuse, the degree of residual muscle activity, microvascular blood flow, release of vasoactive 
agents (gaseous molecule NO) from the affecting muscle and the presence of eventual 
associated pathology, might determine the magnitude of vascular adaptation (Tyml and 
Mathieu-Costello, 2001). Recently, Bleeker, highlighted that long term-muscle unloading is 
accompanied by a systemic vascular alterations, that in such a way may represent an 
independent risk factor for atherosclerosis and cardiovascular disease (Bleeker et al., 2005). 
Thus, given the role of circulating levels of LDL, as  pivotal mediators of the atherosclerotic 
process (Figure 5.2.C), the relation between their circulating levels and the activation of pro-
inflammatory/oxidative mediators, may confer a more understanding of peripheral vascular 
pathology associate with muscle fiber damage. In particular, should be intriguing to 
concentrate the attention on the role of two novel players in the field of inflammation and 
oxidative stress, i.e. the acute-phase protein long pentraxin PTX3 (Introna et al., 1996), and 
the above mentioned the oxidative stress response gene p66 (ShcA) (Migliaccio et al.,2006).  
The long pentraxin PTX3, is a novel candidate for local early inflammatory response 
(Introna et al., 1996; Rolph et al., 2002). It shares structural and functional homologies with 
the short-pentraxin C-reactive protein (CRP). Similar to CRP, PTX3 binds to complement 
components, amplifies innate resistance against microbes and regulates DNA scavenging from 
dying cells (Kravitz et al., 2005; Latini et al., 2004). Unlike CRP, PTX3 is synthesized by 
activated macrophages, endothelial cells, and skeletal or cardiac muscle, but not by the liver 
(Introna et al., 1996; Rolph et al., 2002). Its plasma levels increased in vasculites,  infections 
and in several inflammatory conditions (Kravitz et al., 2005; Latini et al., 2004). The clinical 
cardiological setting provided evidence that PTX3 expression is acutely increased after 
myocardial infarction, where it is a strong predictor of 3 months mortality (Latini et al., 
2004). Nonetheless, recent data strongly suggest a cardioprotective  role of PTX3 during this 
condition (Salio et al., 2008). Finally, limited to the in vitro situation, it has been shown that 
atherogenic LDL induce PTX3 expression in human SMC cells (Klouche et al., 2004), but 
protective HDL induced its expression in endothelial cells (Norata et.al., 2008). Furthermore,  
even in endothelial cells, increased levels of  PTX3 has been found to associate with over-
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expression of tissue factor (Napoleone et al., 2002). The recent evidence (Abderrahim-
Ferkoune et al., 2003) that it is expressed also by adipocytes, may provide new suggestions 
about the interplay between adipose tissue and systemic or local tissue inflammation. In 
particular, the expression of this inflammatory mediator in adipose tissue surrounding 
epicardial coronary arteries  (Iacobellis et al., 2005) or other vascular districts  may contribute  
to the altered vessel homeostasis and plaque instability (Abderrahim-Ferkoune et al., 2003). It 
is in our opinion that its expression in adipocytes infiltrating muscle fiber (muscle myopathy, 
obesity, diabetes, cardiovascular diseases, prolonged immobilization (?)), may contribute to 
the inflammatory-atrophy related processes in muscle (Dube et al., 2006; Rolph et al., 2002).  
As documented, p66 (ShcA) gene ablation results in protection from oxidative stress-
related pathologies in mouse diseases models, including muscular and endothelial cell 
apoptosis in acute ischemia and high fat diet-induced atherogenesis (Migliaccio et al., 2006; 
Napoli et al., 2003). In particular, knock-out p66 (ShcA)  mice fed with a high fat diet, show a 
significant reduction of systemic oxidative stress, circulating plasma oxLDL, as well as a 
significant reduction of atherogenic lesion formation. This may suggest a pivotal role of this 
protein in controlling vascular dysfunction and systemic oxidative stress in vivo (Migliaccio 
et al., 2006; Napoli et al., 2003). In addition, in human, the only evidence of a relation 
between p66 (ShcA) and the oxidative stress has been observed in diabetic patients, where, 
limited to circulating PBMCs, p66 (ShcA) expression has been associated with markers of 
systemic oxidative stress (Pagnin et al., 2005). 
Even so, the atrophic muscle action of pro-inflammatory molecules appears a very 
intricate phenomenon. Within the inflammatory milieu, the TNF-alpha is the cytokine most 
prominently linked to muscle pathophysiology.  Systemic TNF-alpha is associated with 
muscle catabolism and loss of muscle function in human diseases that range from cancer to 
heart failure, from COPD and chronic renal failure to AIDS. The modulation of proteolysis, 
the induction of extrinsic pathway of apoptosis in muscle fiber, the apoptosis of muscle 
satellite cells, and the inhibition of myogenes, represent the functional atrophy targets of 
TNF-alpha (Relaix et al., 2000 ; Reid and Li, 2001) . 
 Just to complicate this twisted puzzle, muscle fiber “itself” produces and releases IL-6, 
IL-1 and TNF-alpha into the circulation. This event occurs during exercise. It has been 
proposed that IL-6 exerts an anti-inflammatory role at systemic level, and may represent the 
link from working muscle to other organs such as the adipose tissue, the liver, the vascular 
compartments or brain (Pedersen, 2007). Surprisingly, ones released from exercised muscle, 
this “myokine” stimulates the appearance in the circulation of anti-inflammatory molecules, 
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such as IL-1 receptor antagonist and IL-10 and inhibits the production of TNF-alpha. This 
expression appears modulated by muscle glycogen content and works as an energy muscle 
sensor, enhancing lipid turnover; lipolysis; fat oxidation; basal and insulin-stimulated glucose 
uptake and translocation of glucose transporter GLUT-4. This may explain in which way a 
regular exercise protects against TNF-alpha-induced insulin resistance (Pedersen, 2007). 
Whilst, muscle IL-1 and TNF-alpha production can modulate via autocrine action the 
clearance and repair processes of the tissue and together with angiogenic factors (fibroblast 
growth factor and platelet-derived growth factor) can sustain the viability of muscle cells.  
Noteworthy, after stimulation, cytokine production can  vary widely among individuals. 
Polymorphic bases in the promoter or coding regions of cytokine genes lead to high or low 
productions of these mediators. Studies in healthy subjects and in patients with different 
chronic inflammatory diseases shown that selected polymorphisms of the INF-gamma, IL-6, 
TNF-alpha and IL-10 genes are functionally relevant to determine not only an increased 
cytokine expression but also the degree of activation of inflammatory process and  organ 
failure  (Balakrishnan et al., 2004).  Moreover, the direct relationships among these genetic 
variants and the magnitude of cardiovascular risk factors (such as LDL-cholesterol), 
emphasizes the relevance of genotype in cardiovascular events (Bennermo et al., 2004; Biolo 
et al., 2006a; Menzaghi et al., 2007; Pisani et al., 2004). More recent literature described the 
influence of genetic variations in some cytokines or in  so-called "exercise genes" to some of 
the inter-individual variability in muscle strength or size in healthy people (Stewart and 
Rittweger, 2006). Polymorphisms in IL-1 gene may increase muscle susceptibility to injury. 
These genetic variations in IL-1 gene result linked to inflammatory state of striated muscle, in 
particular after the acute resistance exercise (Dennis et al., 2004). Genetic variation in IL-15 
(the most abundant cytokine found in skeletal muscle), may also affect muscle mass and 
muscle functions and the gain in training-induced muscle ‘quality’. Whilst, genetic variations 
in myostatin gene (a member of the TGF-beta superfamily), may account to some 
intraindividual variability observed in muscle strength or size (Stewart and Rittweger, 2006).  
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Figure 5.2.B: Schematic view  of the roles of hemodynamic factors in enhancing cell turnover to increase vessel 
wall permeability to circulating LDL and oxLDL and inducing  MCP-1 (monocyte chemotactic protein-1 ) 
secretion.  
MCP-1 increases  monocyte entry into the endothelial cells. In the presence of  oxygen reactants,  LDL are 
oxidized in their atherogenic form, the oxLDLs, which activate stress intracellular signaling pathways. In 
particular, at the level of SMCs oxLDL involved in the activation of inflammatory, oxidative or proliferative 
cascades. In the subendothelial intima,monocytes are transformed into macrophages, which swallow the oxidized 
LDL (ox-LDL) to form foam cells.  
The foamcells and the SMCs ,that migrate into the neointima, are the main cellular elements in the atheroma.
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e.  The interplay between anabolic and catabolic hormones  
 
Recently, Wilson  (Wilson and Rotwein, 2006) pointed out a muscle cell model for 
integrated autocrine and paracrine control of muscle mitogenic and metabolic responses via 
the  insulin–like growth factors (IGFs) isoforms (splice variants), whose differential 
expression may  account to the activation or inhibition of competing muscle cellular processes 
such as proliferation and differentiation, increased protein synthesis or decreased protein 
degradation (Suleiman et al., 2007; Wilson and Rotwein, 2006). These IGFs dissected 
responses result from the coordinated activation of both  Ras–Raf–MEK–ERK and 
phosphatidylinositol 3-kinase–(PI3K)-Akt signalling pathways (Figure 5.2.C). More simply, 
the activation of the MEK/ERK pathway by IGF-I mediates myoblast growth and 
differentiation, while the earliest differentiation events are sustained by the  autocrine action 
of IGF-II /PI(3)K- Akt stream (Wilson and Rotwein, 2006). The suppression of protein 
breakdown (atrogenin-1 and MuRF1 ligases down-regulation),  are guided by  PI(3)K -Akt 
activation (Sacheck et al., 2004; Suleiman et al., 2007; Wilson and Rotwein, 2006) ,while 
increased IGF-I/mTOR-p70S6K signalling mediated muscle hypertrophy (Song et al., 2005b). 
In a more chaotic version, by stimulating mTOR and p70S6K and inhibiting the 4E-BP 
(which is a negative regulator of the translation initiation factor eIF-2B), PI(3)K/Akt controls 
cell size and muscle hypertrophy. The  result is an increase in protein translation. Inhibiting 
the glycogen synthase kinase 3β  activity (which blocks protein translation initiated by the 
eIF-2B protein), the IGF-I-Akt1 induces hypertrophy by stimulating protein synthesis in 
mTOR independent manner  (Saini et al., 2006). Moreover, the deactivation of muscle IGF-
I/PI(3)K/Akt pathway causes either  the activation of proteolysis activity or the expression of 
proteolysis genes, even in the presence of insulin or other mitogenic signals (Kandarian and 
Jackman, 2006; Saini et al., 2006). Inhibition of PI(3)K further decreased phosphorylated Akt. 
The dephosphorylated Akt leads to the activation of the forkhead transcription factors 
(FOXOs), which in turn regulate the gene expression of MAFbx/atrogin and MuRF1. 
Interestingly, this data demonstrates that deactivated PI(3)K /Akt during atrophy may not only 
lead to decreased protein synthesis, but causes also increase in protein degradation. In several 
cell types, the absence of growth or survival signals inactivates Akt, leading to 
dephosphorylation of  FOXOs, which localize to the nucleus to activate genes involved in cell 
death, cell cycle inhibition, and metabolism (Kandarian and Jackman, 2006; Saini et al., 
2006). But, when Akt is active (i.e.: treatment with anabolic agent), FOXO is phosphorylated 
and bound to 14-3-3 alpha  proteins that mediate its movement from nucleus to cytoplasm.  
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As consequence the expression of both ligases is inhibited  (Kandarian and Jackman, 2006; 
Saini et al., 2006). Finally, crucial appears the role of PI(3)K/Akt in caspase-mediated protein 
degradation.  Studies showed that activation of caspase-3 is necessary for the initial cleavage 
of actin during atrophy. The inactivation of PI(3)K is necessary for actin fragmentation and 
total protein degradation during this phase (Kandarian and Jackman, 2006; Saini et al., 2006). 
Currently, it is demonstrated that the autocrine and paracrine role of IGF-I on muscle 
works in synergism with insulin’s system (Han et al., 2006). Insulin and the IGFs bind with 
high affinity to their cognate receptor and with lower affinity to the reciprocal non-cognate 
receptor. At pharmacological concentration insulin stimulates IGF-I receptors, as well as at 
high dose IGF-I stimulates the insulin receptor (Gauguin et al., 2008). Insulin links to IGF-I 
receptor to elicit its anabolic and mitogenic role. A high homology  (50 %) between insulin 
and IGF-I molecular structure accounts to this interchange. Despite these homologies, and the 
similarities between insulin and IGF-I signalling cascade, these two hormones show different 
responses. The kinetics and degree of binding with the receptors, as well as the different 
reactivity of receptors in response to relative concentration of their ligands, permit the 
dissection of their role (Suleiman et al., 2007). Moreover, differences between C-domain of 
IGF-I and insulin largely explains the low affinity of insulin for the IGF- I receptor, whereas 
it is yet less clear why the IGFs have lower affinity for the insulin receptor (Gauguin et al., 
2008). The IGFs and insulin pathways have been found impaired in varius chronic or acute 
catabolic conditions, including  immobilization or metabolic disorders. The increased 
inflammatory burden may explain such of these effects.  Take  this as an example, TNF-alpha 
is the main liable to the  induction of IGF-I or insulin resistance in myoblast or differentiated 
muscle cells (Spate and Schulze, 2004), but the increased in circulating IL-10 levels  (in 
response to contraction), either counteracts the TNFalpha-induced resistance to IGF-I or 
restores myogenesis (Strle et al., 2007). Moreover, in a recent review, Saini (Saini et al., 
2006)  argument about the paradox role of TNF-alpha/IGF-I co-incubations on myoblast, 
where alternative signalling pathways culminate in survival or death via MAPK activation 
(Foulstone et al., 2004; Strle et al., 2007). 
A randomized crossover design performed on healthy men and women receiving growth 
hormone (GH), evidenced that increased in plasma GH caused elevations in plasma IGF-I, 
insulin, glucose and free fatty acids, and promotes mitochondrial oxidative capacity (Short et 
al., 2007; Strle et al., 2007). Growth hormone was found to acutely stimulate forearm muscle 
protein synthesis and decreased protein degradation in normal humans. Its function may be 
combined to insulin action in improving whole-body and skeletal muscle protein kinetics 
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(Wolf et al., 1992). The direct effect of GH on muscle morphology provides another positive 
mechanism of modulation of muscle plasticity, since its deficiency relates to significant 
changes in contractile properties and fiber type distribution (Bottinelli et al., 1997). 
Conversely, under condition of glucocorticoids (GLs) excess, the mitogenic and anabolic 
response to IGFs became inhibited. Potentially, the mechanism may involved the p66Shc/Erk 
stream  (Natalicchio et al., 2004). GLs are powerful catabolic factors, that cause the activation  
of proteolysis pathways and apoptosis as well as a decreased myofibrillar (myosin heavy 
chain ) or global  protein synthesis (Distelhorst, 2002; Glass, 2003a; Glass, 2003b; Komamura 
et al., 2003). Their interaction with multiple down-stream signalling pathways common also 
for some inflammatory triggers (TNF-alpha), allows the amplification of catabolic response 
(Distelhorst, 2002; Glass, 2003a; Glass, 2003b; Komamura et al., 2003). 
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Figure.5.2.C: The cross interaction between mitogenic (IGF-I) inflammatory (TNF-alpha) /oxidative 
(ROS/p66ShcA) factors in modulating muscle mass and wasting.  
 
 
Broken lines represent the loop between oxidative stress –p66Shc activation and FOXOs function in 
muscle atrophy. The coupled lines indicate the activity orchestrated by glucocorticoids/inflammatory 
and glucocorticoid/oxidative stress pathways. Briefly, muscle atrophy results from the combined and 
un-balanced action of anabolic (IGF-I systems) and catabolic pathways. Myogenesis, differentiation, 
protein synthesis are all impaired by the combined (or alone) effect of inflammatory and oxidative 
signals. Increased glucocorticoids circulating levels (=trauma, sepsis, uraemia), enhances inflammatory 
and oxidative effect to muscle. Proteolysis activity (Atrogenin-1/Murf-1) is superimposed. Also, 
decreased myogenesis, inhibition of differentiation and activation of apoptotic pathways ensue. 
Hypothesis: in response to oxidative stress, p66ShcA/FOXOs stream may act in the down-regulation of 
protein synthesis and in the activation of mitochondria apoptosis cascade.   
Potential mechanistic explanation of muscle atrophy induction in disuse, reduced
muscle tension, chronic, and acute diseases
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5.3 Atrophy and diseases 
 
A complex mosaic of pathways, triggers and effectors of skeletal muscle atrophy, result 
differentially activated in diseases specific manner… 
 
5.3.1. Skeletal muscle atrophy in healthy conditions: 
 
a. Muscle atrophy in physical inactivity and microgravity simulated condition (Bed-Rest) 
 
Prolonged periods of muscle inactivity due to prolonged immobilization or  bed rest 
condition  can result in significant perturbations  in architecture, mass and strength of skeletal 
muscle  (Pavy-Le Traon et al., 2007). Plausibly, changes in mechano-signalling pathways, 
cardio-respiratory function, energy intake, hormonal profiles, mitochondria biogenesis, 
inflammatory/oxidative milieu, may account to these perturbations (Figure 5.3.A). Microarray 
studies in muscle of rodents, tell us that multiple signalling pathways may be conditioned by 
physical inactivity. But, the exact meaning of this engaged response remains to be grasp.   
For instance, inflammatory genes contribute to the activation of atrophy program during 
inactivity (Figure 5.3.A). Notwithstanding, inflammation is also the primary step to muscle 
remodelling and regeneration (after injury or exertion). Physical exercise and unloading show 
opposite effects on inflammatory milieu (Figure 5.3.A). Long-term exercise reduces chronic 
inflammatory response.  But, acute bouts of mechanical action and prolonged immobilization 
increase concentrations of pro-inflammatory cytokines and acute phase proteins (Biolo et al., 
2007). An inverse relationship and association with cardiovascular risk, has been found 
between the level of physical activity  and plasma CRP concentration in both healthy men and 
women or in selected disease states  (Plaisance and Grandjean, 2006). It is recornized that 
physical activity modulates inflammatory state either at muscular or adipose tissue levels 
(Kraemer et al., 2002a).   Furthermore,  muscle loading  can down regulate inflammation also 
by improving endothelial function and increasing antioxidant defence (Powers et al., 1999; 
Taddei et al., 2000). Thus, it is worthwhile to dissect  the relevance of  the systemic 
(circulating  blood cells or endothelial cells) or peripheral (muscle or  adipose tissue) 
contributions to inflammatory burden in exercised or  non-exercised muscle, respectively.   
Moreover, inactivity leds also to  significant metabolic alterations, including insulin 
resistance, dyslipidemia and altered energy balance which can undermine muscle function  
and inflammatory cascade (Biolo et al., 2005).  Among these, energy balance and body fat 
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clearly  regulate inflammation. Calorie restriction has been found associated with decreased 
inflammatory state, whereas energy excess and fat deposition activate its cascade (Chung et 
al., 2001a). Clinical evidences indicate that such a combination of physical inactivity and low 
energy intake may rapidly lead to protein-energy malnutrition, increased incidence of 
complications, and a poor clinical outcome (Ritz and Elia, 1999a). Despite the fact that the 
combination of hyponutrition and reduced physical activity is so frequently observed, 
interactions between energy restriction and muscle unloading for regulation of lean body mass 
(LBM) and protein kinetics have been poorly investigated. In fact, the specific effects of 
inactivity and energy balance are difficult to separate from confounding variables that arise 
from disease, aging, or prolonged immobilization. 
Notably,  stress mediators and adipokines may further amplify the catabolic response to 
inactivity, as well as undermine cardiovascular functions. In particular, the adipokine leptin, 
may be critically involved in the modulation of muscle atrophy or inflammatory response in 
bed-rest. 
Studies of fasting humans and food-restricted laboratory animals show, not surprisingly, that 
these individuals are leptin-deficient (Hamrick and Ferrari, 2007).  Leptin levels rise with 
increased food intake, which in turn suppress appetite and increase energy expenditure. Leptin 
levels are decreased during periods of food restriction and starvation.  Interestingly, this 
hormone affects both  bone and muscle metabolism, via the direct or indirect induction of 
GH/IGF-I secretion and its further effect on the hypothalamic-pituitary axis (Hamrick and 
Ferrari, 2007). Moreover, leptin can induce inflammatory response acting on cytokine 
production (INF-gamma, IL-6 and TNF-alpha), activating monocytes/macrophages and 
exerting proliferative and antiapoptotic activities on T lymphocytes. A significant association 
between leptin and CRP has been evidenced, providing a mechanistic role of this adipokine in  
the maintenance of chronic low-grade inflammatory state. Otherwise, changes in pro-
inflammatory cytokine expression may also induce leptin synthesis and release, i.e. from 
adipose tissue (Grunfeld et al., 1996). Currently, our knowledge about the  role of leptin in the 
regulation of  lean body mass during bed-rest is still rudimentary. 
Notably, at the inflammatory and metabolic alteration induced by bed rest, also 
dearangements in vascular homeostasis,  angiogenesis, myogenesis or mitochondria 
biogenesis, may account at least in part to muscle atrophy (Figure 5.3.A; Table 5.3). In 
particular, several studies emphasized the critical role of mitochondria biogenesis and 
metabolism in muscle loss due to disuse. Exercise training improves mitochondria biogenesis, 
by activating PGC-1alpha pathways and  Mnf1 and 2 expression (Figure 5.2.A; Table 5.3). 
 45 
 
 
Instead, unloading impairs this stream (Wright et al., 2007). Furthermore, perturbations  in 
skeletal muscle uncoupling protein (UCPs) might predict the changes in energy expenditure 
and anti-oxidant defence during prolonged period of inactivity (Minnaard et al., 2006) 
Currently, it remains to clarify in which extent bed rest affects muscle myogenesis and 
proteolysis/apoptosis cascade (Table 5.3). Increased myostatin activity has been found 
associated with muscle wasting in prolonged bed-rest in young men, but it is little defined the 
involvement of other myogenic genes (Stewart and Rittweger, 2006) or their regulators (such 
as Notch signalling). Furthermore, a reduced mechanical action can affect the myofibrillar 
electromechanical coupling (Carrasco et al., 2004), leading to a long term increased in  
intracellular Ca++ concentrations (the primary mechanism of loss of muscle strength and 
function).  Plausibly, the timing combination of impaired Ca++ overload with 
pathophysiological solicitations (prolonged inflammation, oxidative stress, dyslipidemia, 
hypoxia, etc.), may pitch these responses. 
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Table 5.3: Adapted from: Zhang et al., (2007). Signaling mechanisms involved in 
disuse muscle atrophy. Medical Hypotheses. 69, 310–321. 
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Figure 5.3.A:  Common physiological perturbations experimented by healthy human during prolonged 
period of immobilization or during prolonged periods of microgravity simulated condition (Bed-Rest) 
• Cardiovascular and pulmonary functions
• Blood fluid regulation
• Blood cell mass (GR)
• Blood pressure, heart rate, stroke volume 
and peripheral resistance
• ECG (cardiac dysrhythmias)
• Orthostatic intolerance
• Changes in energy requirements
• Endocrine mechanisms
• Protein metabolism
• Inflammation
• Oxidative stress
• Mineral/vitamins
• Skeletal muscle mass, function 
and strength
• Calcium and  bone metabolism
Physiological perturbations 
during prolonged periods of physical inactivity
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b. Aging process: the sarcopenia 
 
With age, skeletal muscle experiences substantial atrophy and weakness (sarcopenia), 
associated with the decline in performance capabilities regarding coordination, flexibility, 
strength, speed, and endurance  (Hollmann et al., 2007). Especially, the loss of muscle 
strength exceeds that of size (Narici et al., 2004). Changes in muscle architecture (reduction in 
fibre fascicle length and reduction in pennation angle), as well as in tendon mechanical 
properties, contribute significantly to the decline of muscle force, conditioning the movement 
in these persons (Narici et al., 2004). Although, the anabolic response to a single bout of 
contraction results attenuated, a high degree of muscle plasticity is anyway maintained, and 
this is particularly evident after resistive exercise training  (Narici et al., 2004). Nonetheless, 
age-related changes in muscle have been reported among healthy, physically active subjects. 
It has been estimated that 25% of persons under 70 years and 40% of those aged 80 years or 
older are sarcopenic. Multiple factors, including neuronal and hormonal changes, inadequate 
nutrition, low-grade chronic inflammation and physical inactivity contribute to development 
of this shape (Schaap et al., 2006). Suppression of myosatellite cell differentiation and 
alterations of transcriptional activity of myogenic regulatory factors (via TNF-alpha action) as 
well  as a reduced  protein turnover, contribute to  muscle decline in these persons (Degens 
and Alway, 2006).  
 In spite, some common evidences, the sarcopenia is mechanistically different from 
muscle atrophies induced by disuse, disease, or denervation  (Edström et al., 2006). 
Strikingly, in a recent study performed on aging rodent,  Edström ( Edström et al., 2006), 
shows that sarcopenia does not depend by the common atrophy response ensured by the 
activation of MAFbx and MuRF1 ligases, that instead appear down-regulated. The author 
suggests that this down-regulation may be mediated by a mechanism involving IGF-I 
receptor/Akt activation, which in turn inactivates (via phosphorylation) the forkhead 
transcription factor FOXO-4 ( Edström et al., 2006). The evidence indicates that activation of 
Akt is mediated through ShcA-Grb2-GAB adaptors. Intriguingly, dietary restriction delays 
sarcopenia, as well as the aging effects on Akt phosphorylation, FOXO-4 phosphorylation, 
and MAFbx/MuRF1 transcriptional regulation ( Edström et al., 2006). Apparently, this may 
be a paradox. In fact, muscle atrophy is commonly associated with the inactivation of Akt  
signalling (likely due to the withdraw of IGF-I/PI(3)K/Akt signalling). As a consequence, 
forkhead elements (FOXOs) are activated (de-phosphorylated form) and drive cell cycle 
arrest, cell death or proteolysis. Instead, when Akt is in active form (IGF-I/PI(3)K action), 
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forkhead elements began inactive (phosphorylated form), than are sequestrated by the  14.3.3 
alpha protein and  drove  from nucleus versus  cytoplasm (Kandarian and Jackman, 2006; 
Saini et al., 2006). This inactivation in response to IGF-I/PI(3)K pathway guides a mitogenic 
effect on muscle, increasing protein synthesis, cell proliferation or myogenesis. In point of 
fact, the activation or inactivation of FOXOs and Akt not always leads to a so evident 
opposite effect. For instance, in  mammalian cells both the rise or inhibition of forkhead 
activity can induce cell death or apoptosis, whilst Akt activation can show protective or 
harmful roles (Leenders et al., 2000; Lu et al., 2006; Sonoda et al., 1999). The observed 
differences in these protective versus harmful effects may be  related to the concentration, 
nature  or timing of exposure of the used stimulus, the  differences between transient and 
stable forkhead activity over-expression, or  by the cell contest.  
 A clarifying interpretation of Nemoto might help us to untangle this paradox 
(Nemoto and Finkel, 2002). Nemoto provided evidence that forkhead (FKHRL1) activity is 
regulated by intracellular ROS in a p66Shc-dependent fashion, suggesting that increased 
forkhead expression or activity may be essential to counteract oxidative stress, by improving 
hydrogen peroxide scavenging (Lu et al., 2006; Nemoto and Finkel, 2002; Sonoda et al., 
1999). Similarly, a number of studies have indicated a potential protective effect of Akt 
activation after exposure to reactive oxygen species (Nemoto and Finkel, 2002; Sonada et al., 
1999)  but also harmful effects in response to cell death mediators (Lu et al., 2006). 
Consistent with the known role of phosphorylation in regulating forkhead FKHRL1 
subcellular localization, Nemoto, shown that brief hydrogen peroxide treatment resulted in the 
redistribution of the protein (phosphorylated-inactive form) to the cytosol, and confirmed that 
this redox-dependent forkhead inactivation was regulated by p66 (ShcA) (Figure 5.2.C).  The 
authors evidenced that p66(ShcA)  wild-type fibroblasts stimulated with either insulin or 
hydrogen peroxide led to a rapid and significant increase in FKHLR1 phosphorylation. 
However, in cells deficient in p66 (ShcA), no phosphorylation of FKHLR1 was observed after 
oxidative stress, though FKHLR1 phosphorylation was observed in response to insulin. Cells 
without p66(ShcA) also have reduced Akt activation following treatment with hydrogen 
peroxide. Only expression of wild-type p66(ShcA) was capable of restoring oxidative stress-
induced FKHRL1 phosphorylation in p66shc-/- fibroblasts.  
 The authors concluded that oxidant-mediated forkhead inhibition requires p66(ShcA).  
Noteworthy, oxidative stress and genetic of aging are straight linked with p66 (ShcA) and 
forkhead signalling (Purdom and Chen, 2003). In response to oxidative stress, increased 
phosphorylation levels of p66 (ShcA) at Ser 36 correlate with intracellular oxidant levels and 
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increased sensitivity to apoptosis (Purdon and Chen, 2003). Also, preclinical evidences 
indicate that the onset of muscle decline in old individuals is mainly droved by an age-related 
acceleration of myocytes loss via apoptosis, thus a large contribution of this pathway in 
muscle atrophy should be expected (Figure 5.2.c).  
 Nonetheless, the literature delivers us controversial interpretations about apoptosis 
in aging muscle. In rodents, the type II fibers (fast twitch, glycolytic) are preferentially 
affected and may be more susceptible to the extrinsic pathway (Pistilli et al., 2006; Plaisance 
and Grandjean, 2006). In a study on aged rats, Rice KM found that  apoptotic regulatory 
events differ between fiber types but also between muscle types in a manner not always 
linked with the activation of mitochondrial cascade (Rice and Blough, 2006). Whilst, even in 
rodents, Kujoth demonstrated the relevant role of mitochondria dysfunctions. The authors, 
investigated the involvement of mitochondrial DNA (mitDNA) mutations in aging, using a 
novel model of mice expressing a proof-reading deficient mitDNA polymerase γ (Kujoth et 
al., 2005). They observed, an increased rate of mitDNA mutations in these animals associated 
with  signs of premature aging coupled with a decreased life span. Accumulation of these 
mutations was associated with increased apoptosis in several tissues, including skeletal 
muscle. On the other hand, Marzetti  argued that  mitochondrial release of cytochrome c is not 
a crucial responsible for muscle atrophy in elderly (Marzetti and Leeuwenburgh, 2006). But, 
rather ER stress might be particularly crucial. Furthermore, the authors remarked the critical 
role of  the heat shock proteins and of some members (apoptosis repressor with a caspase 
recruitment domain) of the Bcl2 family, in the regulation of mitochondrial pro-apoptotic 
protein  release (Marzetti and Leeuwenburg, 2006). In the meantime, Baker DJ indicated that 
progression of sarcopenia correlates with an increased expression of pro-apoptotic caspase- 3, 
caspase -9, caspase -8, and AIF, and with the decline of  BAX, Bcl-2, and Apaf-1 (Baker et 
al., 2006). Thus, muscle apoptosis machinery in aging appears a very complex phenomenon 
and not yet fully deciphered.  
 Currently, many reviewers report us that constant physical exercise, a proper 
nutrition or hormonal (GH) supplementations may counteract skeletal muscle apoptosis in 
elderly, delaying and/or reversing sarcopenia.  Although it is documented that elderly subjects 
can benefit from resistance training and GH supplementation (Lange et al., 2002; Narici et al., 
2004; Welle et al., 1996), the myogenic response to exercise and the capability to maintain 
muscle mass with GH treatments is anyhow limited. Possibly, a constant low activation of 
inflammatory milieu or a reduced capability of muscle to synthesized MGF may interfere 
with the effects of these positive muscle mass modulators (Adamo and Farrar, 2006; Degens 
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and Alway, 2006; Lange et al., 2002). Goldspink suggested that in elderly, the increased 
inability to maintain muscle mass, may be due at least in part, to the decline in MGF 
production, which correlates with decreased circulating levels of GH. Decreased GH 
apparently lead to loss in IGF-I transcript splicing towards  MGF (Goldspink, 2005a).  
Although aging muscle retains the ability to synthesize IGF-I, a lower ability of exercise to 
induce MGF synthesis is also maintained (Adamo and Farrar, 2006). Whatever, objectionable 
results have been obtained from GH treatments in aged persons. A positive effect of this 
hormone on muscle fiber strength was observed in muscle of healthy  men over 60 yr old, but 
not in elderly (Welle et al., 1996). GH administration induced significant changes in myosin 
heavy chain isoforms, without  increasing muscle strength or hypertrophy, in healthy elderly 
men (Lange et al., 2002). Conversely, GH administration and exercise improved muscle fiber 
type and diameter in moderately frail older people, but without  augmenting muscle fiber 
hypertrophy or the GH/IGFs action in response to training.  Thus, the debate is still open. 
 
5.3.2. Low grade-muscle atrophy: the chronic catabolic conditions 
 
a. Neurodegenerative diseases and skeletal muscle denervation 
 
 In neuromuscular disorders, (such as spinal muscular atrophy, metabolic 
myopathies, denervation, etc.),  proteolysis and apoptosis machinery are both causes of  
muscle mass decline. The loss of neuromuscular junction “architecture” coupled with 
perturbations in cationic channels trigger the activity of both proteolysis and apoptotic 
cascades  (Borisov and Carlson, 2000; Tews, 2002; Tews, 2005; Wang et al., 2006). In a 
recent experimental work on mice experiencing disuse atrophy, Wang and co-authors, reviled 
as (calcium’s channel apart) potassium channel clearly contribute to atrophy (Wang et al., 
2006). The authors show the intriguing role of the Merg1a protein (component of K+-
channel), which over expression initiates muscle atrophy, by up-regulating the ubiqutin–
proteasome system. Conversely, a dysfunctional Merg1a mutant decreases levels of ubiquitin-
proteasome proteolysis and reduce atrophy in response to disuse. Data that prompt to 
speculate about a potential role of this gene for prevention and treatment of denervated 
muscle (Wang et al., 2006).  
Other works argue that both pro and anti-apoptotic pathways are activated in 
neuromuscular disorders, but not always  the apoptosome is the key executioner.  In 
denervation, peripheral neuropathies, amyotrophic lateral sclerosis or spinal muscular 
 52 
 
 
atrophies, apoptosis requires the direct release of two mitochondria endonuscleases (ENDOG 
and AIF-1), but not involved caspase cascade. On contrary, in a number of others 
neuromuscular disorders (muscular dystrophies, congenital myopathies, or mitochondrial 
myopathies), caspase -3 and APAF-1 pilot the process. Interestingly, apoptotic events of the 
extrinsic pathway with activation of death receptors on the sarcolemma and activation of 
caspase-8 do not associated with primary but relates with secondary neuromuscular disorder 
(Tews, 2002; Tews,  2005). Noteworthy, long-term denervated muscle frequently shows the 
presence of areas completely devoid of capillaries. This indicates the development of foci of 
regional hypoxia and a role of microcirculatory changes. Believable, this alteration depends  
by the down-regulation of VEGF and angiopoietin signalling cascade (Borisov and Carlson, 
2000). Furthermore, time of denervation is also one of the most important determinants of 
functional muscle outcome. While, short-term denervation can result in nearly fully reversible 
changes in muscle mass, prolonged denervation leads to irreversible muscle impairment 
characterized by profound atrophy, myocyte death and fibrosis. A multi- expression pattern of 
genes encoding cell cycle regulators, signalling networks and extracellular matrix components 
has been found to be timing recruited at different stages of the disease. 
 
a. Diabetes and Metabolic disorders 
  
Pervasively discussed is the straight relation between muscle function (contraction but 
not only) and metabolism, with particular recall to hyperglycemia, insulin resistance or 
metabolic syndrome (Figure 5.1.A; figure 5.1.B). First one, because skeletal muscle “per se” 
is the primary site for systemic glucose disposal.  Second one, the proper muscle glucose 
uptake is essential to contractile muscle activity and oxidative potential of the tissue.  Muscle 
contraction itself can modulate the rate of glucose uptake to rescues energy demand. Finally, 
muscle glucose uptake pilots the control of glycemic state reducing hyperglycemia, which if 
not controlled increased oxidative stress via non-enzymatic glycation, glucose autoxidation, 
and alterations in polyol pathway activity (Varvarovska et al., 2004). As result, both twitch 
and insulin action influence muscle glucose uptake, activating different signalling pathways 
converging toward a common effectors, the glucose transporter GLUT-4  (Kim et al., 2006; 
Rittweger and Rauch, 2001). The mechanisms modulating these responses, in particular those 
related to mechanical action, are not yet fully characterized. But, changes in this system 
clearly lead to significant decrement on muscle metabolism (Kim et al., 2006; Rittweger and 
Rauch, 2001).  It is this reduction of metabolic function and muscle glucose uptake that 
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determines the mechanism, rate and degree of muscle atrophy and the decline in muscle 
health (Pasini et al., 2003; Zhan et al., 2007). 
Recent evidence suggests that oxidative stress mediates alteration in glucose dynamics 
contributing, at least in part, to insulin resistance, inflammation  and muscle atrophy. The 
proposed mechanism is that oxidants can modulate the synthesis of inflammatory cytokines 
and adipokines in monocytes, endothelial cells and in adipose tissue, contributing to the 
generation of a chronic low grade of systemic and local inflammatory response, which in turn 
impairs the insulin intracellular signalling cascade (Borradaile et al., 2006). Several 
investigations remarked that at fibre level the first initiator of muscle atrophy cascade is the 
inactivation of the well discussed IGF/PI(3)K/Akt pathway. Down-regulation of PI(3)K 
induces the activation of proteolysis and apoptotic system. The latter, requires a 
conformational change in pro-apoptotic BAX, release of cytochrome c from mitochondria and 
caspase-3 activation. The caspase-3 initially cleaves myofibrils, yielding substrates for the 
proteasome and than guides apoptosis. Remarkable, the catabolic response in diabetic muscle 
need the atrogin-1/MAFbx over-expression, as well as  the nuclear translocation of FOXOs 
(Lee et al., 2004). 
 
b. Muscle wasting in chronic obstructive pulmonary diseases (COPD) 
 
Chronic obstructive pulmonary disease (COPD) is a complex and irreversible chronic 
disease of the respiratory system that is highly prevalent in elderly persons having a history of 
smoking. The patient shows a significant loss of muscle mass, strength, size, and shows 
intolerance to exercise. Several are the causes of this  muscle wasting, but it seems mainly 
dictated by the imbalance between ATP utilization  and new synthesis, perturbations in 
aerobic energy metabolism (related to shift of type I fibers toward type II), muscle oxidative 
capacity,  or by a reduced  oxidative enzyme activities (Figure 5.1.A; figure 5.1.B). 
More recent observations tell us that COPD is a metabolic disorder, where metabolic 
alterations guide muscle suffering.  Impaired β-adrenoreceptor-mediated lipolysis, 
deregulation of UCP-3 expression (down-regulation), alterations in amino acid profile 
(decreased concentrations of skeletal muscle glutamate or plasma branched chain amino acid) 
and a disturbed protein turn-over are the central points  in muscle dysfunction (Jagoe and 
Engelen, 2003). Despite these relevant elements, the reduced physical activity (clear 
consequence of pulmonary and heart debilitating symptoms), appears the major player. This 
evidence comes also by the fact that, the equilibration of muscle anabolism (for example in 
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response to GH supplementation) does not improve exercise tolerance and muscle function 
“per se” in the presence of reduce loading (Jagoe and Engelen, 2003). Disappointed 
evidences came also from the adaptation response. A strong reduction in cross- sectional area 
of calf and quadriceps muscle has been found in relation to the loss of lean body mass. But, 
the degree of mass loss in relation to the severity of airflow obstruction not always has been 
pointed out (Jagoe and Engelen, 2003). Moreover, the fiber type proportion relates to 
respiratory function and exercise tolerance. The clashing signs observed in muscle adaptation 
(fiber type proportions, adaptation or oxidative enzyme capacity) may depend on the type of 
muscle take in exam (for instance: diaphragm muscle, vastus lateralis or deltoid biopsy 
studies got different results), (Jagoe and Engelen, 2003). Notwithstanding, the findings 
obtained by the use of stable isotope methodologies, reinforced the point that loss of body 
lean mass is guided by crucial alterations in protein turn-over. Protein breakdown and 
synthesis appear both increased in normal weight COPD patients, whilst depleted emphysema 
subjects have a prominent decrement of whole body protein synthesis (Engelen et al., 2000; 
Morrison et al., 1988). Additionally, the presence of hypoxia (due to a reduce inspiratory 
oxygen fraction), acidosis, glucocorticoids, a chronic low grade of systemic inflammation, 
insulin and IGF-I resistances, increase proteolysis rates and impair protein synthesis. In 
particular, the chronic inflammatory state observed in these patients affects muscle health 
either by a indirect or direct action  (Jagoe and Engelen, 2003). Myocyte regeneration and 
differentiation are also severely hit in this condition (Agusti et al., 2002; Langen et al., 2006; 
Remels et al., 2007). 
Despite this wide picture explaining almost in part the pathophysiological line of 
muscle loss in COPD, the precise contribution of each one mechanisms remains to be fully 
characterized (Jagoe and Engelen,  2003). 
 
 
c. Chronic renal failure  
 
 Patients with chronic kidney disease including those who are treated with 
haemodialysis, frequently develop cachexia with loss of muscle and fat stores (Figure 
5.1.A;figure 5.1.B). Microarray studies tell us that in response to the uremic milieu, skeletal 
muscle goes through a very active transcriptional and translational changes. CRF activates a 
network of genes linked to cell signalling,  tissue morphology, protein turnover and apoptosis 
(Shah et al., 2006). Studies on protein kinetics determined by isotopically labelled amino 
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acids in patients with uncomplicated uraemia and on conservative treatment, show that the 
rates of either protein synthesis or degradation are decreased, both at whole body and skeletal 
muscle levels. On the other hand, if a complication is superimposed (i.e., acidosis or 
infection), protein turnover accelerates (Guarnieri et al., 2003). Nonetheless, muscle loss 
appears to arise primarily from the activation of muscle protein breakdown (Figure 5.1.B). 
The initial step is the activation of caspase-3, which cleaves the myofibril into its components 
(actin, myosin, troponin, and tropomyosin), to provide substrates for the ubiquitin-proteasome 
pathway (atrogin-1/MAFbx and MuRF1). Hallmark of this process is the presence of the 
characteristic 14-kDa actin fragment in the insoluble fraction of a muscle biopsy specimen 
(Rajan and Mitch, 2007). Noteworthy, the metabolic acidosis (reduction in systemic pH and 
bicarbonate concentration) is critical in CRF patients (Figure 5.1.B), since drives significant 
alterations in the musculoskeletal system (Krieger et al., 2003; Mitch et al., 1994). 
Glucocorticoids excess dictated by acidosis, mediates muscle loss via apoptosis and ubiquitin-
proteasome up-regulation. Our previous investigations relieved that the muscle lysosomal 
cathepsin system is activated in hemodialysis patients with moderate metabolic acidosis, 
whereas the ubiquitin system does not seem to play a major role in determining muscle 
protein depletion (Bosutti A et al 2001). Additionally, muscle protein synthetic capacity, 
expressed as total RNA to DNA ratio, was reduced. Taken together, these observations 
indicate that protein turnover in chronically uremic patients could be either decreased, normal, 
or increased depending on degree of impairment of renal function, type of treatment, presence 
of metabolic complications, and selective activation or inhibition of the different catabolic or 
anabolic pathways (Bosutti A et al 2001, Guarnieri G  et al 2003). 
 Also, increased level of pro-inflammatory cytokines and other inflammatory 
markers contributes to the immune, metabolic and muscular dysfunctions in CRF (Bosutti et 
al., 2007a; Stenvinkel et al., 2005b). The activation of the inflammatory response has been 
recognized as the key risk factor for cardiovascular complications in CRF. During CRF, the 
progressive decrease in glomerular filtration rate, affects inflammatory extent and the 
frequency of clinical consequences of inflammation, e.g., atherosclerosis, hypertension, 
cardiovascular disease and muscle wasting (Bosutti et al., 2007a). Nonetheless, plasma 
cytokine concentrations may not accurately reflect the activation of  inflammatory response, 
because cytokine clearance in these persons  is impaired (Bosutti et al., 2007a). Thus, 
cytokine mRNA levels may represent a better index of synthetic capacity than their plasma 
concentrations. The relationship between the progressive unbalance between pro- and anti-
inflammatory cytokines synthetic capacity and residual renal function in patients with CRF on 
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conservative treatment could clear some aspects conditioning muscle atrophy  and the 
cardiovascular risk in this pathological condition. Uremic patients on haemodialysis often 
show signs of chronic inflammation even in the absence of acute complications (Stenvinkel et 
al.,2005). The causes of inflammation in dialysis have been studied in detail. Uraemia and 
blood-membrane contacts are the most relevant factors that induce changes in cytokine 
secretion (Stenvinkel et al.,  2005). This activation may also contribute, via NFkB pathways, 
to the extent of inflammatory milieu (Zanetti et al., 2007). Nonetheless, the degree of 
systemic inflammatory response exhibits great inter- and intra-individual variability that 
cannot be explained only by renal disease, dialysis or other clinical inflammatory events 
(Stenvinkel et al.,  2005). Single nucleotide polymorphisms in the promoter or coding regions 
of inflammatory markers may explain such variability. In particular, polymorphisms in IL-6 
and TNF-alpha have been found to be strictly associated with clinical and biochemical indices 
of comorbidity in end-stage renal disease or haemodialysis (Balakrishnan et al., 2004). The 
relationships between genotypes of the anti-inflammatory cytokine IL-10 and the acute phase 
response have been studied in haemodialysis patients. The IL-10 ‘low-producer’ genotype is 
more permissive for frequent elevations of C-reactive protein (CRP) and is significantly 
associated with a greater frequency of cardiovascular events. Recent data, shown the critical 
role of genetic variability of INF-gamma cytokine, in particular in inflammatory response 
activated by NFkB pathway. IFN-gamma is encoded by a single gene mapped on 
chromosome 12 (12q15) (Pravica et al., 2000). In the first intron of the IFN-gamma  gene, 
there is a CA repeat polymorphism that affects transcription. Moreover, an adenine (A) to 
timine (T) transition at position +874 (intron 1) has been associated with increased IFN-
gamma expression (Pravica et al., 2000). The transcription factor NF-kB binds preferentially 
to this allele (Rossouw et al., 2003). A potential transactivation role on other inflammatory 
markers or mediators mediated by this polymorphism may be hypothesised, as well as its 
contribution on muscle mass loss in CRF but also in other chronic pathological conditions or 
muscle disuse. 
 
d. Chronic heart failure, cardiovascular diseases and muscle mass decline 
 
Experimental rodent model with heart failure gained evidence that leg muscles undergo 
atrophy and isomyosins shift during this condition (Vescovo et al., 1998; Vescovo et al., 
2001). The same was demonstrated also in patients with heart failure (Vescovo and Dalla 
Libera, 2006). The mechanisms involved in these processes are mainly due to muscle cell 
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apoptosis induced by TNF-alpha and its second messenger sphingosine (Dalla Libera et al., 
2001). Oxidative stress plays also a role in determining muscle atrophy and reduced strength 
in animal model of skeletal muscle myopathy (Dalla  Libera et al., 2005).  
Interestingly, several investigations pointed out a synergistic interaction between 
muscle architecture, cardiovascular dysfunction and angiotensin II (ACE) genotypes. The 
ACE II ”per se” is a powerful cachexia inducers in cardiac diseases (Delafontaine and Akao, 
2006).  The angiotensin II-induced muscle atrophy results by the decrease phosphorylation of 
Akt, mTOR, and p70S6K, and the activation of caspase-3 activity (Song et al., 2005a; Song et 
al., 2005b). In animals, ACE II produces weight loss through a pressure-independent 
mechanism, accompanied by decreased levels of circulating and skeletal muscle IGF-I and the 
up-regulation of atrogin-1 and Murf-1. Interestingly, Dalla Libera proposed that the ACE II 
converting enzyme inhibitors and angiotensin II receptor blockers may reduce the shift from 
myosin heavy chain 1 (MHC1) to MHC2a and MHC2b forms in skeletal muscle of heart 
failure patients, opening a new argument about the alternative use of common anti-
hypertensive therapeutics to the possibly recovery of skeletal muscle (Dalla  Libera et al., 
1997). 
More recently, Yamin C and colleagues gained knowledge about the association of 
(ACE) insertion/deletion (I/D) polymorphism with skeletal muscle atrophy or adaptation to 
exercise (Yamin et al., 2007). The ACE ID genotype may contribute to the wide variability in 
individuals' response to a given bout of contraction  (Stewart and Rittweger, 2006). Anyway, 
contradictory results have been reached us.  In fact, the longer allele of the polymorphism 
coordinates with a reduced ACE enzyme activity and appears associated with an enhanced 
efficiency of muscle contractions (Stewart and Rittweger, 2006). But, the I/I genotype also 
increased the risk for developing muscle damage (Yamin et al., 2007). On the other hand, the 
D-allele has been found to be associated with enhanced quadriceps responses to resistance 
training in young adults, and appears to have protective effects against exertion muscle injury  
(Yamin et al., 2007).  
Many aspects of the syndrome of heart failure such as progressive left ventricular 
dysfunction, left ventricular remodelling, pulmonary edema, cardiomyopathy, reduced 
skeletal blood flow, endothelial dysfunction, muscle mass loss (Figure 5.1.B), anorexia and 
cachexia can be explained by the known biological effects of proinflammatory cytokines. The 
‘cytokine hypothesis’ for heart failure holds that heart failure progresses, at least in part, as a 
result of the toxic effects exerted by endogenous cytokine cascades on the heart and 
peripheral circulation (Okopien et al., 2002). It bears emphasis that the cytokine hypothesis 
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does not imply that cytokines cause heart failure, per se, but rather that overexpression of 
cytokine cascades contributes to the heart failure progression (Okopien et al., 2002). Thus, the 
elaboration of cytokines may represent a biological mechanism that  is responsible for 
worsening heart failure. Atrial fibrillation (AF) represents the most common arrhythmia 
encountered in clinical practice. As generally known, the development of AF leads to 
electrophysiological and cellular changes in the atria that tend to sustain AF, a process known 
as electrical remodelling. The pathophysiology of AF is complex, but in most cases it may be 
caused by multiple random factors (Korantzopoulos et al., 2003). Recent findings suggested a 
mechanistic link between oxidative stress , inflammation, and the development of alteration of 
heart rhythm (Neuman et al., 2007). It has been demonstrated that oxidative modification by 
hydroxyl radicals on atrial myofibrils are increased in AF, contributing to cardiomyocyte 
apoptosis, ventricular remodelling and mechanoelectric uncoupling (Korantzopoulos et al., 
2003). On the other hand C-reactive protein (CRP) and the pro-inflammatory IL-6 have been 
found to be increased in both persistent and paroxysmal AF (Chung et al., 2001b), indicating 
that inflammation may participate in the process of atrial remodelling. Nevertheless, the 
molecular mechanisms involved in these processes,  as well as the contribution of peripheral 
sources of inflammatory mediators (such as adipose tissue),  remained to be elucidated. 
 
5.3.3. Intermediate grade muscle atrophy: the shift from chronic towards acute catabolic 
conditions 
 
a. Cancer cachexia 
 
Cancer cachexia is a metabolic process characterized by a puzzle of  abnormalities in 
protein,  fat and carbohydrate metabolism, despite an adequate nutritional intake. Either 
metabolic, biochemical or molecular alterations dictate the phenotypic features of cachexia in 
cancer (Baracos, 2000). Chiefly, the breakdown of skeletal muscle is the main harmful 
phenotypic derangement (Baracos, 2000). Accelerated protein degradation coupled to a 
significant decreased in protein synthesis (Figure 5.1.B), enhances the rate of protein turnover 
in these patients  and accelerates muscle suffering (Biolo et al., 2006b). Studies, largely 
performed using rodents, indicate that the acceleration of proteolysis is guided by the 
activation of the ubiquitin-proteasome pathway, in particular by the over-expression of the 
two ligases MAFbx and MuRF1 and the 20S proteasome subunits (Glass, 2003a; Jagoe and 
Engelen, 2003). But, it is not excluded that the activation of other proteolysis systems 
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(cathepsins or calpains) might accompany or precede the activation of proteasome units 
(Jagoe and Engelen, 2003). Believable, this response is mediated by the parallel reduction 
(and/or suppression) of growth factors (IGFs) and the enhancement of circulating pro-
inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, INF-gamma and proteolysis-inducing 
factor), (Figure 5.1.B).  
A more recent interpretation is that these two biochemical processes are finely co-
ordinated by a network of intricate signalling pathways (Saini et al., 2006).  For instance, the 
circulating and intramuscular concentrations of IGF-I result reduced in most pathological 
conditions where circulating cytokines are elevated and muscle wasting is clearly over-shot 
(Saini et al., 2006). Chronic TNF-alpha exposure sustains wasting associated with cachexia 
(Argiles and Lopez-Soriano, 1999), and experimental rat models of cachexia have 
demonstrated enhanced fractional rates of muscle protein degradation associated with 
increased levels of this cytokine (Argiles and Lopez Soriano, 1999). In general, the cachetic 
state is particularly problematic to cancer patients, since often it reduces the response to 
chemotherapy or radiation treatments, and impairs prognosis. This because cancer cachexia is 
not simply associated with weight loss, but represents a highly complex metabolic disorder 
involving insulin resistance, fat loss and significant alteration in amino acids profiles.  
Decreased arginine availability, even without weight loss,  suggests a specific feature of the 
presence of cancer. The disturbances in arginine metabolism could contribute to the cascade 
of metabolic events leading to this shape (Vissers et al., 2005). The massive reduction in 
circulating glutamine impairs organ and immune functions and anti oxidant defence of the 
organism (Biolo et al., 2006). Systemic inflammation impairs tryptophan handling, promoting 
oxidative stress, and hypothalamic serotonergic activity (Laviano et al., 2007). Both 
contribute to development of anorexia and cachexia and to the loss of muscle mass (Laviano 
et al., 2007).   
Finally, the impact at cellular level of physical exercise, diet, hormones and age, should 
be included in the vast mosaic of pathomechanisms, conditioning  muscle mass in these 
subjects.  
 
 
b. Cachetic acquired immunodeficiency syndrome 
 
 Changes in body weight and lean tissue increase morbidity and mortality during 
AIDS. This HIV-associated wasting is important also because is linked with limitations in 
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activity, muscle function, strength, and metabolism, and leads to increased susceptibility to 
secondary infection or cancer (Scott et al., 2007). Multiple pathophysiological mechanisms 
are key determinants in muscle withering during this condition. As expected, decreased rate 
of muscle protein synthesis and a significant acceleration of protein degradation are the main 
causes of atrophy in AIDS/skeletal muscle loss (Figure 5.1.B).  The measure, by stable 
isotope tracers, of the fractional rate of mixed muscle protein synthesis and appearance of 
plasma glutamine in HIV subjects before and after initiating their first or a salvage 
antiretroviral therapy regimen, indicates that AIDS/muscle wasting is markedly associated 
with an inadequate rates of muscle protein synthesis and with a deregulation of muscle amino 
acid metabolism (Yarasheski et al., 2005). In point of fact, the studies of muscle atrophy in 
AIDS patients are still at embryonic level. Some investigations show increased expression of 
ubiquitin and proteasome units, explaining at least in part some lines observed in protein 
degradation profiles. Microarray analysis in muscle biopsies from HIV patients treated with 
testosterone supplementation, highlighted a down-regulation of muscle plasticity, myogenesis 
and protein synthesis (Montano et al., 2007). Other investigators discussed the increased 
activity of myostatin in HIV-infected men. Certainly, malnutrition and specific dietary 
deficiencies and alterations in several circulating signalling molecules, such as TNF-alpha, 
TGF-beta, IL-1, GH and IGF-I are implicated too  (Dudgeon et al., 2006). 
Finally, also the interactions between mitochondria function, muscle loss and  HIV 
infection received careful attention from the investigators. Other studies have implicated 
depletion of glutathione and production of reactive oxygen intermediates in the regulation of 
HIV virus and possibly in that of muscle atrophy. A pioneer research pointed out different 
aspects of the interactions between the virus and mitochondria DNA damage. In particular it 
has been remarked the possible muscle negative role of highly active antiretroviral therapy 
(nucleoside reverse transcriptase inhibitors or protease inhibitors). The therapy may damage 
mitochondria and cause a clinical metabolic syndrome called lipodystrophy. It is known that 
this organelles might play a crucial role in the pathogenesis of lipodystrophy. The hypothesis 
is that drug-induced damage to mitochondrial DNA and alters mitochondria functionality 
(Cossarizza et al., 2002). It should be noted that lipodystrophy  induces a relative lack of 
peripheral adipose tissue storage associated with dyslipidemia. This implies that the excess of 
circulating and dietary lipid metabolites are deposited in muscle and liver, where impair 
insulin action and glucose up-take. This leads to a dysmetabolic loop of insulin resistance, 
lipotoxicity (muscle damage) and lipoatrophy, which determines a clinical phenotype similar 
to the metabolic syndrome. All conditions that can impair muscle health (Noor, 2007). 
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Despite all these intriguing findings, more investigations are needed to clear muscle withering 
in AIDS cachexia. Should take care the evaluation of the cross-effects between atrophy 
pathomechanisms induced by HIV infection and the atrophy pathomechanisms induced by 
therapies. Microarray studies may help us in this field.  A proper nutritional supplementation, 
cytokine reduction, hormone therapy and resistance exercise training may control HIV-
associated wasting. 
 
 
5.3.5. Accelerated grade muscle atrophy: the hypercatabolic conditions  
 
a. The acute critical illness:  the sepsis and … 
 
Patients with acute illness, such as sepsis or severe trauma, are characterized by a long-
lasting catabolic state   due to a chronic perpetuation of wasting state for several days 
(Breuille et al., 1999). General loss of muscle mass, muscle strength and an increased muscle 
fatigue is also commonly encountered by the patient, who experiments enhanced 
inflammation, reduced wound healing, respiratory  and cardiovascular complications and 
difficulties in mobilisation (Figure 5.1.A; figure 5.1.B). Changes in hormone profile, 
increased stress, inflammation, or neuronal activity activate signal transduction pathways, 
which influence protein synthesis and protein degradation  at whole body level  (including 
muscle),  (Strasser et al., 2007). Experimental animal models of sepsis gained knowledge that 
muscle wasting in sepsis occurred in a fiber-type specific fashion, as shown by the reduction 
in cross-sectional area observed in type 1 than type 2A and 2B/X fibers. Both the inherent 
function of a muscle and the muscle fiber-type distribution can affect the responsiveness to 
catabolic signals (Minnaard et al., 2005). Several studies have been focused to understand the 
molecular mechanisms activating proteolysis and  causing muscle atrophy in sepsis 
hypercatabolic conditions.  Data show that a small but persistent level of protein degradation 
or decrease protein synthesis results in substantial loss of muscle mass. At least three 
catabolic  signals can be involved: the metabolic acidosis; defective insulin action and 
increased glucocorticoids circulating levels. The ubiquitin-proteasome system appears the 
major target.  In spite, a potential role of TNF-alpha was demonstrated, the contribution of 
inflammatory milieu appears more complicated to be explained, because a suppressive effect 
of cytokines on ubiquitin system during sepsis, unless the presence of glucocorticoids, has 
been observed (Price et al., 2001). 
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 Often, sepsis is associated to burn injury and to secondary complications such as 
myopathies (specific failure of the organ muscle).  Burn injury superimposed by sepsis results 
in significant loss of muscle tissues (Figure 5.1.B). Studies in animal model explained this 
loss as a consequence of a marked alteration in protein turn-over. The marked acceleration in 
protein degradation arises from the up-regulation of some components of the proteasome 
pathway (ubiquitin-conjugated enzymes) and from a significant increase of oxidative damage. 
Additionally,  sepsis induces also the release of myofilaments, activating a proteolysis 
calcium-dependent mechanism. Likely, Ca++ -independent proteinases such as caspases and 
cathepsins  contribute to total or myofibrillar protein breakdown in this condition (Price et al., 
2001). Plausibly, caspases guide the activation of apoptosis cascade triggered by 
inflammatory (TNF-alpha) and steroid (glucocorticoids) mediators (Almendro et al., 2003). 
Otherwise, the marked reduction in protein synthesis may be  explained via the down-
regulation of muscle heat-shock protein (such as HSP60, 70 , 27, HSPbeta6), and the 
decreased expression of  metabolic enzymes related to energy production. Sepsis decreases 
protein synthesis also by affecting the peptide-chain initiation and eIF-2B expression (Voisin 
et al., 1996), and the anabolic response to amino acids. Finally, it is worth of note that 
“myotoxic" humoral factors produced during myopaty, change the excitation-contraction 
cascade and activate  proteolysis. Altered glucose transporter expression, MyoD suppression, 
impaired respiratory chain enzymes, ATP depletion, glucose toxicity and insulin resistance 
may be additional atrophy pathomechanisms, that amplify atrophy response in these patients 
(Friedrich et al., 2005). 
 
 … the acute trauma 
 
On the other hand, the metabolic response to trauma involves an accelerated rate of 
protein turn-over, which in turn leads to a marked loss of body proteins (Figure 5.1.B). In 
skeletal muscle, the accelerated rate of proteolysis is accompanied by an increased rate of 
protein synthesis, but  not enough to counteract or match the increase in degradation (Biolo et 
al., 2000b; Biolo et al., 2000a). Currently, no adequate human studies have been performed to 
obtain a clear evidence about the molecular pathways activated in muscle during acute 
trauma. Thus, the  catabolic consequences of trauma are not yet thorough defined. Some 
studies  indicate that muscle catabolism is associated with an increased expression and 
activity of critical components of proteolytic and apoptotic systems. In particular, effects on 
the ubiquitin-proteasome pathway have been found (Mansoor O et al 1996). The influence of 
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the gene expression of critical components of the cellular proteolytic pathways on the rate of 
protein degradation has been also evaluated (Biolo et al., 2000b; Biolo et al., 2000a; Bosutti et 
al., 1999; Bosutti et al., 2002). For instance, in our recent work we defined that after acute 
trauma, the rate of muscle proteolysis appears to be closely related with the level of gene 
transcription of some components of ubiquitin-proteasome system (Biolo et al., 2000b; Biolo 
et al., 2000a). Despite, muscle cathepsin B mRNA levels appear also increased (Biolo et al., 
2000b; Biolo et al., 2000a; Bosutti et al., 1999; Bosutti et al., 2002), any association with the 
rate of protein degradation has been found. This suggests that cathepsin B up-regulation might 
be not exhaustively involved in protein turn-over during acute trauma. 
Close relationships between proteolytic pathways and apoptotic response in human 
skeletal muscle have been also demonstrated (Du et al., 2004). However, the molecular 
mechanisms underlining this cross-interaction remain to be elucidated. In this view, the 
eukaryotic elongation factors 1A (EEF1A), p66 (ShcA) and c-MYC may be candidate genes to a 
more understanding of the relationships between muscle proteolysis and apoptosis in skeletal 
muscle in hypercatabolic patients. Just to recall, the EEF1A proteins play a key role for the 
translation machinery (Browne and Proud, 2002). In mammals, the eEF1A proteins are 
encoded by the EEF1A1 and EEF1A2 genes mapped on different chromosomes. In human 
tissues EEF1A1 is ubiquitously expressed, with the exception of skeletal muscle, heart and 
brain, where it progressively declines at early phases of development. In adult muscle 
EEF1A2 takes over the EEF1A1 specific function for protein synthesis ( Carlson et al., 2002; 
Khalyfa et al., 2001; Lee et al., 1993; Lund et al., 1996). Changes in the expression levels of 
these two elongation factors relate to pro and anti-apoptotic responses and could be 
informative on the molecular events underlying accelerated catabolism in skeletal muscle in 
acute trauma.  On the other hand,  increased muscle p66(ShcA) mRNA levels have been 
demonstrated to be significantly related to sarcopenia in rats (Jiang et al., 2003). Moreover, 
the oncogene c-MYC  was found up-regulated in muscle of patients with acute quadriplegic 
myopathy. This condition is often experienced by patients with severe systemic critical illness 
(Di Giovanni et al., 2004).  Albeit, c-MYC is an essential mediator of cell growth and 
proliferation (Dang, 1999), its overexpression relates also to ROS production, cytochrome-c 
release from mitochondria, mitochondrial membrane destabilization and apoptosis (Dang, 
1999).  
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6. AIMS OF THE STUDY 
 The phatophysiology of muscle atrophy is a complex multifactor process. Persistent 
low-grade or acute activation of inflammatory/oxidative cascade, acute stress, altered energy 
intake, or reduced mechanical action, contribute to muscle mass loss, cardiovascular risk, as 
well as to the progression of chronic and acute associated diseases. A more comprehension on 
when these molecular processes occur may be the basic line to design new therapeutic 
interventions. Thus, we pointed our investigations to clear the molecular relationships 
between muscle atrophy, inflammation and cardiovascular risk in different human clinical 
models characterised by the association between these three factors. 
Hypothesis: We hypothesised that: a) the combination of reduced physical activity and 
negative energy balance would accelerate the loss of lean body mass in healthy subjects 
through changes in whole body protein kinetics; b) a moderate energy restriction may prevent 
the activation of inflammatory markers induced by  inactivity and adipose tissue may be a 
pivotal player in this reaction; c) cytokine genotypes and kidney function may be responsible 
of the different degree of inflammatory response activation, in the course of chronic catabolic 
conditions; d) translational machinery, proteolysis pathways and apoptotic response may 
cross-interact in the orchestration of skeletal muscle atrophy induced by acute stress, in 
humans.   
Specific objectives: this project has been focused to the evaluation of: 
1. The interaction between energy restriction and muscle unloading in the regulation of 
lean body mass, protein kinetics or inflammatory response in healthy subjects; 
2. The synergistic interaction between cardiovascular risk, organ failure and cytokine 
genotypes in chronic renal disease;  
3. Identification of novel inflammatory and oxidative stress markers related to 
cardiovascular risk and inflammatory response at whole body and adipose tissue 
levels,  in heart diseases; 
4. The relationships among protein turnover, the gene expression of the stress response 
protein p66(ShcA) and the eukariotic elongation factor EEF1A1, in muscle atrophy 
induced by acute stress.  
We have used the following experimental models: short-term experimental bed rest (14 days) 
in healthy volunteers; chronic renal failure patients on conservative treatment at different 
levels of disease progression; patients with chronic renal failure on haemodialysis; heart 
failure patients undergoing pace-maker implantation;  and  severely hypercatabolic 
traumatized patients. 
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7. MATERIALS AND METHODS 
 
7.1  Muscle protein synthesis and proteolysis calculation 
 Rates of muscle protein synthesis and degradation were determined as rate of 
intracellular phenylalanine disposal and appearance by the isotope dilution technique during 
primed-continuous infusion of L-[ring- 2H5] phenylalanine (Mass Trace, Woburn, MA), as 
previously described (Biolo et al., 2000b; Biolo et al., 2002; Biolo et al., 2003). Blood 
samples from the femoral artery and vein and muscle biopsies by a Bergström needle (Stille, 
Stockholm, Sweden) from the vastus lateralis muscle were taken to measure steady state 
values of the phenylalanine concentration and enrichment by gas chromatography/mass 
spectrometry (Finnigan, MAT, Bremen, Germany). Leg blood flow was measured by the dye-
dilution technique using indocyanine green (Infracyanine; SERB, Paris, France). Calculations 
were performed as previously described (Biolo et al., 2000b; Biolo et al., 2002; Biolo et al., 
2003). 
 
7.2. Leg Metabolic Study  
 
Indwelling catheters were placed in a central vein (subclavian or internal jugular) for 
isotope infusion and in the femoral artery and vein of one leg for blood sampling. The femoral 
artery catheter was also used for continuous infusion of indocyanine green (Infracyanine, 
SERB, Paris, France) to measure leg blood flow (Biolo et al., 1995b; Biolo et al., 1995a). 
Indocyanine  green recycling was assessed by measuring dye concentration in the left 
antecubital vein. Most of the catheters were placed for clinical purposes. At hour 19 (8 AM) 
femoral venous blood samples were obtained to measure background amino acid enrichments 
and indocyanine green concentration. Then a primed continuous infusion of L-[ring-
2H5]phenylalanine (MassTrace) and L-[1-
13C]leucine (MassTrace). Tracer infusions were 
maintained constant throughout the experiment. The following tracer infusion rates (IR) and 
priming doses (PD) were used: L-[ring-2H5]phenylalanine: IR = 0.05 µmol · kg
1 · min 1, 
PD = 2 µmol/kg; L-[1-13C]leucine: IR = 0.08 µmol · kg 1 · min 1, PD = 4.8 µmol/kg. Isotope 
infusions were not started simultaneously, because the equilibration period of each tracer 
varied (Biolo et al., 1995b; Biolo et al., 1995a). L-[ring-2H5]phenylalanine and L-[1-
13C]leucine were infused for 3 h.  
To measure leg blood flow, at hour 23 a primed continuous infusion of indocyanine 
green dye (IR = 0.5 mg/min; PD = 5 mg) into the femoral artery was started and maintained 
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for 30 min. During the last 15 min of indocyanine green infusion, four blood samples were 
taken every 5 min from the femoral and left antecubital vein for spectrophotometric 
determination of steady-state dye serum concentrations. The rate of leg plasma flow was 
calculated at steady state from the ratio between the dye infusion rate and the difference 
between serum dye concentrations in femoral and antecubital veins. Leg blood flow was 
calculated from the hematocrit.  A blood sample was taken before stopping the tracer and a 
muscle biopsy was taken to measure enrichments and concentrations of free amino acids and 
mRNA levels of target genes.   
 
7.3 Calculation of Kinetic Parameters  
At the whole body level, amino acid rates of appearance (Ra) were calculated by dividing 
isotope infusion rates by arterial enrichments. Changes in the Ra of
 the essential amino acids 
phenylalanine and leucine can be considered as markers of changes in whole body proteolysis. 
The net leg balance for amino acids was calculated from the Fick  principle (Biolo et al., 
1995b). A positive value indicates net uptake, whereas a negative value indicates net release. 
Skeletal muscle is considered to account largely for amino acid metabolism in the whole leg 
(Biolo et al., 1995b). In the steady-state condition of muscle free amino acid concentrations, 
amino acid uptake or release across the leg reflects the balance between intracellular 
production and disposal for that particular amino acid. Thus net phenylalanine, tyrosine, and 
lysine release from leg muscle are markers of net protein catabolism, because these amino 
acids are not synthesized or oxidized in muscle tissue. We assumed that amino acids are 
released from proteolysis in proportion to their relative content in muscle protein (Biolo  et al., 
1995a; Biolo  et al.. 1995b) 
Muscle protein synthesis and proteolysis were calculated as rates of intracellular 
phenylalanine disposal and appearance (Biolo et al., 1995a , Biolo et al,. 1995b), respectively. 
 
7.4 Skeletal muscle biopsies 
Muscle biopsies were taken from the lateral portion of the vastus lateralis muscle, 
about 20 cm above the knee using a Bergström biopsy needle (Stille, Stockholm, Sweden). 
The biopsy procedure is easily performed under local anaesthesia.  Each biopsy yielded 40–80 
mg of muscle tissue. This procedure yields a sample of mixed skeletal muscle. Blood, visible 
fat, and connective tissue were quickly removed from the specimen, and the tissue was 
immediately frozen in liquid nitrogen and stored at -80°C for later analysis.  
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7.5 RNA extraction and quantification from skeletal muscle biopsies 
Total RNA was extracted from 20 to 30 mg of muscle by the guanidinium thyocyanate 
procedure (Chomczynski and Sacchi, 1987). The RNA quality was checked by bioanalyzer 
2100 expert assay (Agilent 2100)  and denaturing agarose gel electrophoresis and ethidium 
bromide staining. All sample selected showed a RNA integrity number (RIN) between 2.9 
and 5.7. RNA concentration were evaluated by spectrometric analysis and the presence of 
contamination from genomic DNA in the extracted total RNA was checked by amplification 
with primers for glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) (Bosutti et al., 1999; 
Bosutti et al., 2002; Bosutti et al., 2007c).  If contaminations were detected, the samples were 
treated with RNase-free DNase I (10 U/l) (Boehringer Mannheim, Mannheim, Germany) and 
extracted with phenol/chloroform/isoamylic alcohol, and then checked again by GAPDH 
amplification (Bosutti et al., 1999). Furthermore, to avoid any co-amplification of genomic 
DNA, the amplified targets gene regions were choosen to included the splicing site regions 
(Bosutti et al., 1999). 
 
7.6  RNA isolation from total blood cells and cDNA synthesis 
Total RNA was extracted in the presence of highly denaturing guanidine 
isothiocyanate (GITC)-containing buffer (6 M), from either 3ml of whole blood taken in the 
post-absorptive state as previously described (Chomczynski and Sacchi, 1987). The quality 
and integrity of total RNA was evaluated by both gel electrophoresis and spectrophotometric 
determination. All samples were treated by RNAse and DNAse I (10 U/l) (Boehringer 
Mannheim, Mannheim, Germany) and subsequently extracted with 
phenol/chloroform/isoamylic alcohol (Bosutti et.al., 1999; Bosutti et al., 2002; Bosutti et al., 
2007c). For each sample, 2 µg of  total RNA were incubated together with 100 ng of the oligo 
dT NOT18 (Pharmacia, Uppsala, Sweden) for 10 min at 68°C and then reverse transcribed in 
a final volume of 50 ml at 42°C for 1 h using 10U of MMLV reverse transcriptase (Gibco 
BRL Life Technologies LTD, Paisley, Scotland) in the presence of an RNAse inhibitor 
(Gibco BRL). cDNA were then subjected to quantitative RT-PCR (Applied Biosystems-
Applera Corporation, USA).  
 
7.7 RNA  isolation from fractionated peripheral mononucleate blood cells (WBCs)  
 White blood cells (WBCs), i.e. peripheral blood leukocyte, monocytes, mononuclear 
cells (PMBC), and polymorphonucleated cell (PMNs) were isolated from seven ml of total 
blood sample stored at room temperature for at least 10 minutes in EDTA solution, using a 
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mixture of polysaccharide and a radiopaque contrast medium (HISTOPAQUE-1007, Sigma 
Aldrich, Germany). HISTOPAQUE-1007, is a solution of polysucrose and sodium diatriozate, 
adjusted to a density of 1.077 g./ml. This medium facilitates the recovery of mononuclear 
cells from small volume of blood. Total RNA was extracted and purified from fractionated 
peripheral blood mononucleated cells using a minicolumn procedure (RNeasy Mini Kit, 
Qiagen). All samples were treated by RNase-free DNase I (10 U/l) (Boehringer Mannheim, 
Mannheim Germany) and subsequently extracted with phenol/chloroform/isoamilyc alcohol. 
The quality and integrity of total RNA was evaluated by both gel electrophoresis and 
spectrophotometric determination. 
 
7.8 RNA isolation from adipose tissue fragments 
Approximately 500 mg of subcutaneous adipose tissue fragment was surgically 
obtained, immediately after incision, before pacemaker battery and electrodes implantation. 
After removal of blood and visible blood vessels, tissue fragment was frozen in liquid 
nitrogen and stored at -80ºC before RNA isolation. Total RNA from adipose tissue samples 
was obtained using minicolumn purification procedure (RNeasy Mini Kit, Qiagen). Briefly, 
40-60 mg of adipose tissue were homogenized in the presence of highly denaturing guanidine 
isothiocyanate (GITC)-containing buffer. After ethanol addition, the samples were applied to 
an RNeasy mini column (RNeasy Mini Kit, Qiagen) and RNA eluted with 30 µl of RNase-
free water. All samples were treated by RNase-free DNase I (10 U/l) (Boehringer Mannheim, 
Mannheim Germany) and subsequently extracted with phenol/chloroform/isoamilyc alcohol. 
The concentration, quality and integrity of total RNA were evaluated by spectrophotometric 
determination (Bosutti et al., 2007b). 
 
7.9 Qualitative mRNA analysis: hGAPDH PCR (Polymerase Chain Reaction): 
amplification (Bosutti et al., 1999). 
To exclude the presence of contamination from genomic DNA in the extracted total 
RNA,  RNA samples  were checked by polymerase chain reaction, using the following 
primers for cDNA of the human glyceraldehyde-3-phosphate-dehydrogenase (hGAPDH): 
sense primers 5¹CCATCACCATCTTCCAGGAGCG3¹ (nucleotides 278-299 of file M33197 
in GenBank) and antisense primer  5¹ACGGAAGGCCATGCCAGTGA3¹  (762-743) for the 
anti-sense strand. Amplification was conducted in PCR buffer containing the two primers 
(100 ng), the four dNTPs (0,2 mM), 2.5 U of Taq DNA polymerase enzyme (Boehringer 
Mannheim, Mannheim Germany), 1 µl of cDNA, using a DNA Thermo Cycler (Perkin-Elmer 
 69 
 
 
Cetus). The amplification was carried out in the following condition: precycles denaturation 
step: 95° C - 45 sec; denaturation, 95° C - 45 sec; annealing, 68°C for 1 min-30 sec; 
extension, 72°C for 1 minute ; repeated for 38 cycles. After amplification, PCR products were 
resolved on an 8% nondenaturing polyacrylamide gel, visualized under ultraviolet light after 
ethidium bromide staining, and photographed (Bosutti et al., 1999). 
 
7.10 cDNA synthesis (Bosutti et al., 1999). 
For each sample, 2 µg of total RNA were incubated together with 100 ng of the oligo 
dT NOT18 (Pharmacia, Uppsala, Sweden) for 10 min at 68°C and then reverse transcribed in 
a final volume of 50 µl at 42°C for 1 hr using 10 U of MMLV reverse transcriptase (Gibco 
BRL Life Technologies LTD, Paisley, Scotland) in the presence of an RNAse inhibitor 
(Gibco BRL). cDNA were then subjected to Quantitative Real Time PCR. 
 
7.11 Quantitative-Competitive PCR (Polymerase Chain Reaction)  
 
7.11.1 Quantitative competitive PCR (Bosutti et al., 1999): 
Quantitative PCR amplifications were performed by mixing scalar amounts of 
competitor DNA to the cDNA obtained from muscle samples followed by PCR amplification 
with the appropriate primer pairs. All amplifications were conducted in 40 µl of PCR buffer 
(50 mM KCl, 10 mM Tris-HCl, 2 mM MgCl2) containing the two primers (100 pmol each), 
the four dNTPs (200 µM each), 2.5 U of Taq DNA polymerase (Perkin Elmer Emmeryville, 
CA), 1 µl of cDNA, and 1 µl of appropriately diluted competitor DNA. Samples were 
submitted to 38 cycles of amplification with the following cycle profiles: GAPDH 
amplification: pre-PCR denaturation at 95°C for 45 sec, denaturation at 95°C for 45 sec, 
annealing at 68° for 90 sec, extension at 72°C for 60 sec.; cathepsin B amplification: pre-PCR 
denaturation at 95°C for 45 sec, denaturation at 94°C for 45 sec, annealing at 63° for 50 sec, 
extension at 72°C for 60 sec.; ubiquitin UBB amplification: pre-PCR denaturation at 95°C for 
45 sec, denaturation at 95°C for 45 sec, annealing at 56° for 60 sec, extension at 72°C for 60 
sec. After amplification, 10 µl of each PCR product were resolved on a 8% non denaturing 
polyacrylamide gel, visualized under UV light after  ethidium bromide staining and 
photographed. Quantification of the amplification product was obtained by densitometry 
scanning of the ethidium-bromide stained gels. According to the principles of competitive 
PCR, the ratio between the amount of PCR product for the target cDNA and the competitor 
DNA are linearly correlated with the initial amount of cDNA in the reaction.  
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7.11.2. Primers and competitors for PCR amplification (Bosutti et al., 1999): 
Amplification of GAPDH cDNA was performed using primers 
5'CCATCACCATCTTCCAGGAGCG3' for the sense strand (nucleotides 278-299 of file 
M33197 in GenBank) and 5'ACGGAAGGCCATGCCAGTGA3' (nucleotides 743-762). 
Amplification of cathepsin B was performed using primers 5' 
GGGCACAACTTCTACAACGTGG3' (nucleotides 307-328 of file L16510 in GenBank) and 
5'GTGTGGATGCAGATGCGGTC3'  (nucleotides 532-550). The sense strand primer for 
ubiquitin UBB cDNA amplification was 5'CAGTCATGGCATTCGCAGTGCC3'  
(nucleotides 1789-1809 of file X04803 in GenBank), while oligo dNOT18-
polyT)[ANCHORS] was directly used as antisense primer. Competitors for cathepsin B and 
ubiquitin UBB were constructed by an application of the recombinant PCR methodology. 
Briefly, for compeitor corresponded to the sequence amplified by the primers reported above 
plus an insertion of 26 bp in the middle. These competitors were constructed by two separate 
PCR amplifications using one of each external primer and one internal primer on the opposite 
strand having 3¹ ends corresponding to the amplified sequence and 5¹ tails unrelated to the 
sequence itself.  
Sequences of these internal primers were as follows. For the cathepsin B competitor: 
5'TATAGTCGTCGGAATTCTATGTTTACCACAGTGTCCCACCATCAA 3¹ for the sense 
strand and 5'TAAACCATAGAATTCCACGACTATACCATTGTTCCCGTGCATCGA3'  
for the antisense strand. For the ubiquitin UBB competitor, internal primers were 5' 
TCAAGCCTAAGCTTACTCCGGTGTAGCCAACTTAAGTTTAGAA3¹ for the sense 
strand and  5'CTACACCGGAGTAAGCTTAGGCTTGAGGCAAATGGCTATAGTGCA3'  
for the antisense strand. After two separate PCR amplifications for each cDNA using one of 
these internal primers plus the external primer on the opposite strand, the PCR products 
obtained were recovered, denatured and annealed by virtue of the complementarity between 
the two tails.  
The competitor for GAPDH quantification was plasmid pBLUGAPDH 260, kindly 
donated by F.E. Baralle (ICGEB Trieste, Italy). The insert of this plasmid contains a 
competitor DNA segment constructed by the insertion of 260 bp within the sequence of the 
rat GAPDH cDNA. The primer recognition sequences on this competitor are exactly identical 
to those of human GAPDH cDNA. All competitors were quantified by spectrophotometric 
determination of DNA concentration. 
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7.12 Quantitative Real Time PCR by SYBR green chemistry ( Bosutti et al., 2007c): 
Quantitative real time PCR was performed using the SYBR Green dye chemistry in 
single-plex reactions and the 7900/HT Sequence Detection System (Applied Biosystems). 
Primers (300 nM) were selected using the Primer Express Software (Applied Biosystems).  
SYBR Green dye chemistry  quantities the amplicon production (including non-specific 
amplification and primer-dimer complex) by the use of a non-sequence specific fluorescent 
intercalating agent (SYBR-green I). It binds only to dsDNA. SYBR green is a fluorogenic 
minor groove binding dye that exhibits little fluorescence when it is free in solution but emits 
a strong fluorescent signal upon binding to double-stranded DNA. Disadvantages of SYBR 
green-based real-time PCR include the requirement for extensive optimisation. Furthermore, 
non-specific amplifications require follow-up assays (melting point or dissociation curve 
analysis) for amplicon identification. In addition, to avoid stronger signal, primers were 
selected to create a short amplicon (no more than 200 bp).  Target and housekeeping genes 
were run separately and their final quantisation was achieved using a relative standard curve. 
Results for each gene were divided by the corresponding 28S rRNA abundance and expressed 
as percent of average control value.  
• All amplifications were conducted in a final volume of 25 µl of SYBR/Master Mix 
buffer (Applied Biosystems-Applera Corporation,USA), containing the two primers 
(300 nM each), SYBR green, the four dNTPs (200 µM each), Taq DNA polymerase 
and 1 µl of cDNA. 
• Fluorescent levels of amplified products were detected and quantified by ABI Prism 
7900 machine; subsequently they were converted into number of molecules according 
to an external standard curve by means of the following equation y=A*EXP(-kxn), 
where y and x are the number of cycles and the number of molecules, respectively, 
and A, K and n are the coefficients of the equation. The standard curve was performed 
using a dilution series of an external standard.  
• Copy numbers of unknown samples were calculated from the linear regression of that 
standard curve, with the y-intercept giving the sensitivity and the slope giving the 
amplification efficiency. mRNA amounts of target genes were normalized by 28S 
rRNA content. 
 
7.13 Quantitative Real Time PCR by TaqMan chemistry 
Quantitative real time PCR was performed using the TaqMan chemistry and the 7900/HT 
Sequence Detection System (Applied Biosystems). Primers (300 nM) and probes (200 nM), 
 72 
 
 
were selected using the Primer Express Software (Applied Biosystems). Probe-based 
chemistries make use of amplicon-specific fluorescent probes and a fluorescent signal is only 
generated if the probe hybridizes with its complementary target, introducing an additional 
level of specificity.  
• All amplifications were conducted in 25 µl of Master Mix PCR buffer (TaqMan 
chemistry , Applied Biosystems-Applera Corporation,USA), containing the two 
primers (300 nM each), specific  probe (200 nM) the four dNTPs (200 µM each), Taq 
DNA polymerase and 1 µl of cDNA.  
• The quantities of the amplified products were based on the florescent levels of each 
sample, detected by ABI Prism 7900 machine, which were subsequently converted 
into number of molecules on the base of a standard curve by means of the following 
equation y=A*EXP(-kxn), where y and x are the number of cycles and the number of 
molecules, respectively, and A, K and n are the coefficients of the equation. 
• The standard curve was obtained using serial dilutions of a standard DNA fragment of 
known concentration. mRNA amounts of target genes were than normalized by the 
mRNA content of GAPDH and  expressed as fraction of GAPDH. The obtained 
numbers were then converted into logarithm.  
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Table 7.13: Sequences of primers and probes selected to real time investigations 
 
TARGET 
GENES 
 
GenBank 
accession 
no. 
 
Sense primer 
 
Anti sense primer 
 
Probe 51 FAM label and 3' 
TAMRA quencher 
 
 
 
C-MYC 
 
NM_002467.3 
51AAGCTCGTCTCAGAGAAGCT31 
nucleotides 996-1015 
51CTTCTTGTTCCTCCTCGAAG31  
nucleotides 1322-134 
SyBR green 
 
EEF1A2 
 
.AF163763 
51GCCACCGTCAATAGGTGGAC31 
nucleotides 2073-2092 
51TGATGTGGGTCTTCTCCTTG31 
nucleotides 3438-3457 
SyBR green 
 
EEF1A1 
 
J04617 
51AACATTGTCGTCATTGGACA31 
nucleotides 1606 -1625 
51ACTTGCTGGTCTCAAATTTC31  
nucleotides 2181-2200 
SyBR green 
 
GAPDH 
 
M33197 
20x Assays-on-Demand Gene 
Expression Assay Mix (Applied 
Biosystems-Applera 
Corporation,USA). 
  
 
INF-gamma 
 
NM_619 
20x Assays-on-Demand Gene 
Expression Assay Mix (Applied 
Biosystems-Applera 
Corporation,USA). 
  
 
IL-6 
 
NM_000600 
20x Assays-on-Demand Gene 
Expression Assay Mix (Applied 
Biosystems-Applera 
Corporation,USA). 
  
 
IL-10 
 
NM_000572 
20x Assays-on-Demand Gene 
Expression Assay Mix (Applied 
Biosystems-Applera 
Corporation,USA). 
  
 
PTX3 
 
X63613 
51ATCCCACTGAGGACCCCAC31 
nucleotides 183-200    
51GATGAAGAGCTTGTCCCATTC
C31 
nucleotides 228-250 
51CGTGCGACTGCGGT31 
 nucleotides 204-217. 
 
p66(ShcA) 
 
NM_183001 
51CACGGGAGCTTTGTCAATAAGC
31 
nucleotides 409-430 
51CCCCGGGTCCCATGACTTT31 
nucleotides 461-479 
51CTGGCTGCATCCCA 31 
nucleotides 441-454 
 
TNF-alpha 
 
M10988 
51GCAGGTCTACTTTGGGATCATT
G31 
nucleotides 757–779 
51GCGTTTGGGAAGGTTGGA31 
nucleotides 800–817 
51CTGTGAGGAGGACGAA
C31  
nucleotides 782–799 
 
28S rRNA 
 
M11167 
5
1TGGGAAATGCAGCCCAAAG31  
nucleotides 282-299 
51CCTTACGGTACTTGTTGACTA
TGC31  
nucleotides 342-365 
SyBR green 
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7.14  Western blotting and protein extraction from skeletal muscle biopsies ( Bosutti et 
al., 2007c): 
Twenty mg of muscle biopsies were homogenized on ice in ice-cold lyses buffer (0,25 
M sucrose and 0.3% Triton X-100, 1 mM DTT) in the presence of the protease inhibitor 
cocktail. Following centrifugation at 2000 g for 10 min at 4°C the supernatants were 
collected. Thirty micrograms of protein, assayed by Bradford method (Biorad Laboratories, 
Herts, U.K.) were mixed with one volume of SDS-glycerol/ß -mercaptoethanol/bromophenol 
blue loading buffer, heated to 95°C for 5 min, and electrophoresed alongside molecular 
weight markers (Fermentas) on 4% stacking and 10–12% resolving denaturing SDS-PAGE 
gels. Protein samples were electroblotted (20 V and 70 mA for 1h and 45 min) onto 
nitrocellulose membrane (Schleicher & Schuell Biosciences GmbH Whatmann, Germany). 
The membranes were then incubated with a blocking solution (3-5% non-fat milk 
powder/PBS/0.05% Tween 20) for 30 min at room temperature, followed by incubation with 
primary antibodies diluted in PBS or PBS/0.05% Tween 20. The only commercially available 
anti-eEF1A mouse monoclonal antibody (1:1000 dilution, Upstate) did not distinguish 
eEF1A1 from eEF1A2 forms and only total eEF1A content can be determined. The other 
antibodies used were: anti-actin rabbit polyclonal antibody (1:1000 dilution, Sigma-Aldrich, 
St Louis, MO, USA), anticleaved poly(ADP-ribose) polymerase (PARP) mouse monoclonal 
antibody CD2-10 (1:1000 dilution, purchased from BD Biosciences, San Jose, CA, USA), 
anti-GAPDH rabbit polyclonal antibody (1:800 dilution, Santa Cruz Biotechnologies). The 
eEF1A and the cleaved PARP primary antibody incubations were performed overnight at 4°C. 
The actin and the GAPDH primary antibody incubations were performed at room temperature 
for 1h. Secondary antibodies conjugated to horseradish peroxidase (Santa Cruz 
Biotechnologies and Sigma-Aldrich, St Louis, MO, USA) were incubated at room 
temperature for 1 h. The bands were visualized using the chemiluminescence substrate 
(Pierce, Rockford, IL, USA), exposing the membrane to autoradiograhic film within its linear 
range; the signal was quantified by scanning laser densitometry ( Bosutti et al., 2007c).  
 
7.15  Evaluation of the lipid profile   
LDL-cholesterol levels have been calculated using the empirical relationship of 
Friedewald et al. (Friedewald et al., 1972): [LDL-cholesterol]=[Total-cholesterol]-[HDL-
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cholesterol]-([TG]/5).  Total cholesterol, HDL-cholesterol and triglycerides levels were 
measured according to standard laboratory procedures ( Bosutti et al., 2007b). 
 
7.16  High sensitivity plasma CRP protein assay 
Plasma CRP levels were determined on 10 µml of plasma using a high sensitivity hs-
CRP ELISA assay Kit (Diagnostics Biochem, Canada Inc.). CRP values were expressed as 
ng/mL. CRP range values indicated in the Kit for normal condition were as follow: (subjects: 
n=43; sex: male; age:17-87; CRP range values: 0-2696 ng/mL). 
 
7.17  Plasma cytokine protein assays 
Plasma levels of pro (IL-6 and INF-gamma) and anti (IL-10 and TGF-beta1) 
inflammatory cytokines  (IL-10, INF-gamma, IL-6 and TGF-beta1) were determined on 100 
or 200 µl of plasma using Quantikine ELISA assay Kits (R&D Systems, Minneapolis, MN, 
USA). TGF-beta1 was activated from the latent form to immunoreactive form detectable by 
the Quantikine ELISA TGF-beta1 immunoassay as followed. To 0.1 mL of platelet-poor 
plasma, were added 0.1 mL of 2.5 N Acetic Acid/10 M urea. After incubation at room 
temperature, the sample solutions were neutralized adding 0.1 mL 2.7 N NaOH/ 1 M HEPES. 
 
7.18  Plasma PTX3 protein assays 
Plasma levels of PTX3 protein were quantified by sandwich ELISA detection system 
(Alexis Bichemical), as followed: 96 well-ELISA plates were coated with 100µl of MAb to 
PTX3 (human), 700ng/ml in 100µl coating buffer (15mM carbonate buffer pH 9.6) and 
incubated overnight at 4°C. After incubation, the plates were washed and then 300µl of 5% 
dry milk in washing buffer were added to block non-specific binding. The plates were 
incubated for 2 hours at room temperature and then washed three times with washing buffer. 
50µl of diluted plasma or 50µl (in duplicate) recombinant human PTX3 standard (scalar 
dilution: 75pg/ml to 2.4ng/ml) were added and then incubated for 2 hours at 37°C. The plates 
were washed five times with washing buffer, and then 25ng/ml of PAb to PTX3 (human) 
(Biotin) were added in each well. 100µl/well streptavidin-horseradish peroxidase diluted 
1:4'000 were added and the plates incubated for 1 hour at room temperature. After incubation 
the plates were washed 5 times and 100µl of chromogen substrate ABTS were added. Plates 
were read after 15 minutes at 405nm in an automatic ELISA reader. 
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7.19  Cytokine genotyping 
Cytokine genotyping assay for IFN-gamma was based on the PCRSSP methodology 
(Amoroso et al., 2001), briefly, it provides sequence-specific oligonucleotide primers for 
amplification of selected IFN-gamma alleles by the PCR reaction. The control primer pair 
amplifies a conserved region of the humanb1-globin gene, which is present in all DNA 
samples and is used to verify the integrity of the PCR reaction. DNA was isolated from 
EDTA collected peripheral whole blood using standard laboratory techniques. The analysis of 
cytokine genotype was performed using the Cytokine Genotyping Primer Pack of the One 
Lambda, Inc. (CA). 100 ng of DNA were amplified following the PCR reaction profile 
described in the cytokine genotyping kit protocol. After the PCR process, the amplified 
DNAfragments were separated by a 2.5% agarose gel and visualized by staining with 
ethidium bromide. The results were interpreted using a worksheet provided with the product. 
 
7.20   Evaluation of the Glomerular filtration rate (GFR) 
The glomerular filtration rates have been calculated using the simplified Modification of 
Diet in Renal Disease (MDRD) formulas, widely used to estimate renal function (Hallan et 
al., 2004; Levey et al., 1999) : 
[MDRDa mL/min/1.73m2] 
F= 186.3x[serum creatinine]-1.154x[age]-0.203 x 0.742  
M=186.3x[serum creatinine]-1.154x[age]-0.203  
NOTE. Creatinine is measured as milligrams per deciliter. 
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8. MATERIALS AND METHODS IN SPECIFIC STUDIES 
8.1 Skeletal muscle atrophy in healthy conditions: Interaction between energy restriction 
and muscle unloading in the regulation of lean body mass, protein kinetics or inflammatory 
response in healthy subjects 
8.1.1. Calorie restriction accelerates the catabolism of lean body mass during 2 wk of 
bed rest (Biolo  et al., 2007) 
8.1.2. Calorie restriction prevents inactivity-induced systemic inflammatory response: 
evidence for inverse regulation of CRP and PTX3 by energy balance (Bosutti et al., 2007 
JCEM submitted) 
 
Subjects: 
Nine healthy, male, sedentary subjects [mean (±SEM) age: 24 ± 1 y; body weight: 77 ± 
2 kg; LBM: 61 ±1 kg; fat mass: 16 ± 2 kg; body mass index (BMI; in kg/m2): 23 ± 1] 
participated in the STBR-IP study at the Clinical Research Center of the German Aerospace 
Institute (Cologne, Germany). Written informed consent was obtained from all subjects. The 
experimental protocol was in accordance with the local ethical standards on human 
experimentation and approval was obtained from the Ethics Committee of the Ärztekammer 
Nordrhein (Düsseldorf, Germany).  
 
Protocol: 
The study protocol was divided into 4 phases. During the first and second phases (July–
August 2001 and February–March 2002, respectively), subjects received weight-maintaining, 
eucaloric diets in either bed rest or ambulatory conditions. During the first and second phase 
(July-August 2001 and February-March 2002, respectively), nine subjects received weight-
maintaining, eucaloric diets either in bed rest or ambulatory conditions according to a cross 
over design. During the third and fourth phase (July-August 2002 and February-March 2003, 
respectively), the same subjects received low-calorie diets  containing about 80% of total 
energy requirement either in bed rest or ambulatory conditions according to a cross over 
design (Table 8.1). Four subjects were studied in ambulatory conditions during the first and 
third phases and in bed rest conditions during the second and fourth phases. The other 5 
subjects were studied in bed rest conditions during the first and third phases and in 
ambulatory conditions during the second and fourth phases (Table 8.1). During the 14 days of 
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bed rest participants were exposed to 6° head-down-tilt bed rest for 24 h/day. During the 
ambulatory periods, participants were in normal upright position during the day, were allowed 
to walk around in the ward, and performed light muscular workload (including bicycle 
ergometry for 10 min three times a day).  
During the adaptation and the recovery periods, all subjects received weight-
maintaining, eucaloric diets in ambulatory conditions. At the beginning of each examination 
period, resting energy expenditure was calculated for each individual according to the 
FAO/WHO equations. Energy content of diets was reduced during bed rest and hypocaloric 
periods. During eucaloric phases, participants received a specifically prepared diet containing 
1.4 or 1.1 times their calculated resting energy expenditure during ambulatory and bed rest 
periods, respectively. During hypocaloric phases, participants received a specifically prepared 
diet containing 1.1 or 0.9 times their basal metabolic rate during ambulatory and bed rest 
periods, respectively. Ten percent of total kcal was added to account for dietary induced 
thermogenesis. Total energy intake during ambulatory and bed rest periods was, 
respectively, 36±0.4 and 28.5±0.3 kcal·kg-1·day-1 in eucaloric conditions and 28.8±0.4 and 
23.4±0.4 kcal·kg-1·day-1 in hypocaloric conditions. Dietary fat content was planned to be 
about 30% of the energy during eucaloric periods. Fatty acid composition was provided as 
saturated and polyunsaturated fatty acids. During hypocaloric periods, energy restriction was 
achieved by decreasing fat intake to a minimum of 60 g/day. The remaining energy was 
composed of carbohydrates. Subjects received 1g protein/kg body weight per day in all study 
phases. Daily intakes of water (50 mL/kg), sodium (2.5 mmol/kg), calcium (1000 mg) and 
vitamin D (400 IU) were monitored during the experimental periods. No caffeine, 
methylxanthine, or alcohol was allowed. Six meals were given daily—i.e., 3 main meals 
(breakfast, lunch, and dinner) and 3 snacks. All foods were exactly weighed for each 
participant, and volunteers were asked to consume the complete meal.  On the morning of the 
last day of bed rest or ambulatory periods in eucaloric or hypocaloric conditions, after a 12-h 
overnight fast, a stable isotope infusion study was performed as described previously (Biolo et 
al., 2004). Briefly, blood and breath samples were taken before the start of isotope infusion to 
determine baseline natural enrichments of [1-13C]-ketoisocaproic acid ([13C]KIC)  in 
arterialized plasma and of 13CO2 in the expired air, and plasma concentrations and mRNAs 
contents in blood cells (by Real time PCR), of representative acute phase proteins (CRP and 
PTX3), pro- (TNF-alpha, IL-6 and INF-gamma) and anti-inflammatory cytokines (TGF-beta1 
and IL-10) and hormones (insulin and leptin). Thereafter, a bolus injection (0.08 x mol/kg) of 
[13C] sodium bicarbonate (Cambridge Isotope Laboratories, Andover, MA) was 
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intravenously administered and was followed by a primed (5.4 µmol/ kg) continuous (0.09 
µmol xkg-1 xmin -1) infusion of L-[1-13C]leucine ([13C]leucine) (Cambridge Isotope 
Laboratories), which was continued for 6 h. After 160 min had been allowed for isotope 
equilibration, 3 blood and breath samples were obtained over 20 min to determine [13C]KIC 
enrichment and to measure amino acid concentrations in arterialized plasma and 13CO2 
enrichment in the breath. Between 120 and 180 min, indirect calorimetry was performed to 
measure the rate of total carbon dioxide expiration by using a ventilated hood system (MBM-
200; Deltatrac, Datex, Finland), which is an open-circuit computerized indirect calorimeter. A 
primed (0.13 g/kg LBM) constant (0.13 g x kg LBM-1 xh-1) intravenous infusion of an amino 
acid solution (Freamine III 8.5%; Clintec, Milan, Italy) was initiated; the infusion was 
continued for 3 h. The amino acid concentrations reported by the manufacturer were 590, 770, 
870, 450, 480, 340, 130, 560, 600, 810, 240, 500, 18, and 1190 mg/100 mL for isoleucine, 
leucine, lysine, methionine, phenylalanine, threonine, tryptophan, valine, alanine, arginine, 
histidine, serine, cysteine, and glycine, respectively. The infusion rates of the unlabeled 
leucine under the ambulatory and bed rest conditions respectively, were 1.46 ±0.04 and 1.49 ± 
0.03 -mol - min-1 x kg-1 during the eucaloric phase and 1.46±.04 and 1.46 ±0.04 -mol - min-1 x 
kg-1 during the hypocaloric phase. Amino acid concentrations in plasma were measured by 
using HPLC. Plasma [13C]KIC and breath 13CO2 isotopic enrichments were determined by 
using gas chromatography–mass spectrometry (5973 Mass Spectrometer; Agilent–HP, 
Albertville, MN) and isotope ratio–mass spectrometry (Delta S; Finnigan MAT, Bremen, 
Germany) as previously described (Biolo et.al., 2004). Body composition of all subjects was 
measured by DXA at the end of the adaptation period and at the beginning of the recovery 
period with a Hologic QDR-2000 (Waltham, MA). The enhanced whole-body scans were 
analysed for lean tissue mass. 
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Table 8.1. Experimental  bed-rest cross-over design 
    
Eucaloric diet
(100% of total energy expenditure)
Hypocaloric diet
(80% of total energy expenditure)
Phase 1: eucaloric diet, ambulatory
(July-August 2001)
Phase 2: eucaloric diet, bed rest
(February-March 2002)
Phase 4:  hypocaloric diet, bed rest
(February-March 2003)
Phase 3:  hypocaloric diet, ambulatory
(July-August 2002)
 
 
Table 8.1. Line diagram representing the respective distribution of the studied subjects among seasons, the 
two experimental phases (ambulatory and bed rest) as well as the two nutritional interventions. 9-days of 
adaptation were followed by 14 days of bed rest, where the volunteers were at random designed to 
ambulatory or bed rest and vice-versa. Four subjects were studied in ambulatory conditions during the 
first and third phases and in bed rest conditions during the second and fourth phases. The other 5 subjects 
were studied in bed rest conditions during the first and third phases and in ambulatory conditions during 
the second and fourth phases. Phases 1 and 2 were performed in eucaloric condition, whereas the phases 3 
and 4 were performed in hypocaloric condition. 
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Analysis: 
 
Plasma levels of inflammatory markers and mediators (Bosutti  et al., 2007  JCEM 
submitted): 
Plama levels of CRP were determined using a high-sensitivity CRP ELISA assay kit 
(Diagnostics Biochem, Canada Inc.).  Plasma leptin concentrations were determined by 
ELISA (ELISA Cat. DLP00, R&D System, Minneapolis, MN, USA). Plasma insulin 
concentrations were determined by radioimmunoassay (Insulin RIA, Adaltis, Montreal, 
Canada). Plasma levels of IL-6, INF-gamma, TNF-alpha, IL-10 and TGF-beta1 were 
determined using Quantikine ELISA assay kits (R&D Systems, Minneapolis, MN, USA). 
Plasma PTX3 concentrations were quantified by sandwich ELISA detection system (Alexis 
Biochemical Italia, Vinci).  
  
RNA extraction and cDNA synthesis  (Bosutti  et al., 2007  JCEM  submitted): 
Total RNA was extracted from  3 ml of total blood,  collected in post-absorptive state. 
The quality and integrity of total RNA was evaluated by both gel electrophoresis and 
spectrophotometric determination. All samples were treated by RNAse and DNAse I (10 U/l) 
(Boehringer Mannheim, Mannheim, Germany) and subsequently 3 µl of total purified RNA 
were reverse transcribed into cDNA followed by Real time analysis. 
 
Cytokines cDNA quantifications: Real Time PCR (TaqMan Chemistry) (Bosutti et al., 2007  
JCEM submitted) 
7900/HT Sequence Detection System (Applied Biosystems) 
a) TNF-alpha cDNA amplifications  (GenBank accession no. M10988):  
b) IL-6, INF-gamma, TGF-beta1, IL-10 and GAPDH. A 20x Assays-on-
Demand Gene Expression Assay Mix (Applied Biosystems-Applera Corporation, 
USA) was used for all the amplification reactions according to manufacturers’ 
instructions.  
 
PCR conditions:       40 cycles  
              -enzyme activation at 50°C for 2 min,  
              -pre-denaturation at 95°C for 10 min,  
               -denaturation at 95°C for 15 sec,  
                    -annealing and extension at 60° for 60 sec. 
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The standard curve was obtained using serial dilutions of a standard DNA fragment of 
known concentration. Cytokine mRNA amounts are expressed as fraction of GAPDH used as 
a reference gene. 
 
Plasma Amino acid concentrations  (Biolo  et al., 2007): 
 
Amino acid concentrations in plasma were measured by using HPLC (Biolo G. et.al. 
2004). Plasma [13C]KIC and breath 13CO2 isotopic enrichments were determined by using 
gas chromatography–mass spectrometry (5973 Mass Spectrometer; Agilent–HP, Albertville, 
MN) and isotope ratio–mass spectrometry (Delta S; Finnigan MAT, Bremen, Germany) as 
previously described (Biolo et.al. 2004). 
 
Estimation  of whole-body leucine kinetics (Biolo et al., 2007): 
 
Estimates of whole-body leucine kinetics were made at isotopic steady state, which 
was attained at the end of each study period. Mean values of [13C]KIC and 13CO2 
enrichments and of total carbon dioxide production in each study period were used for data 
calculation. The intracellular leucine rate of appearance [(Ra) an index of proteolysis], 
oxidation, and rate of nonoxidative disappearance [(Rd) an index of protein synthesis] were 
calculated as previously described (Biolo  et. al., 2004, Biolo  et. al., 1995a, Biolo  et. al., 
1995b). During amino acid infusion, the rate of net leucine deposition into body protein was 
calculated from the difference between nonoxidative leucine Rd (protein synthesis) and Ra 
(proteolysis) (effect; P=0.54 for interaction).  
 
Statistics: 
All data were expressed as means±SEMs. Effects of bed rest in eucaloric conditions 
were assessed according to a crossover design during study phases 1 and 2. Effects of bed rest 
in hypocaloric conditions were assessed according to a crossover during study phases 3 and 4. 
Results in the 4 different experimental conditions (ambulatory with eucaloric diet, bed rest 
with eucaloric diet, ambulatory with hypocaloric diet, and bed rest with hypocaloric diet) 
were analyzed by using a repeated measures analysis of variance (ANOVA) with activity 
(ambulatory or bed rest) and diet (eucaloric or hypocaloric) as the 2 factors. Post hoc analysis 
was performed, when appropriate, by using a t test with Bonferroni’s adjustment. Regression 
analysis was performed in individual data obtained from the four experimental periods (n=36) 
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to define determinants of variability of hormones and inflammatory markers. Statistical 
analysis was performed with SPSS software (version 12; SPSS Inc, Chicago, IL). 
All data about the study on inflammatory response ( Bosutti et al., 2007 JCEM 
submitted), were log-transformed when appropriate and analyzed by repeated measures 
analysis of variance (ANOVA) with activity (ambulatory or bed rest) and diet (eucaloric or 
hypocaloric) as the 2 factors. 
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8.2.  Low grade-muscle atrophy: the chronic catabolic conditions 
8.2.1 Associations between cardiovascular risk and inflammatory response at whole body and 
adipose tissue levels. 
 
Relation between the plasma levels of LDL-cholesterol and the expression of the early marker 
of inflammation long pentraxin PTX3 and the stress response gene p66 (ShcA) in pacemaker 
implanted patients. (Bosutti et  al., 2007b) 
Patients  enrolment: 
 Twenty two patients, undergoing a pacemaker implantation, have been enrolled in our 
study. Eligible for the study were patients with normal or high level of circulating LDL. 
Exclusion criteria were the presence of diabetes, acute and chronic inflammatory diseases, 
chronic renal failure, liver disease and cancer. For all patients anthropometric and clinical data 
are reported in table 8.2.1. The study was approved by the ethic committee of the University 
Hospital of Cattinara – Trieste and a written consent for the study has been obtained from 
each patient. Patients groups, divided according to the level of circulating LDL (Table 8.2.1.), 
were comparable for their C-reactive protein (CRP) plasma levels, BMI, age, sex, blood 
parameter, blood cells count, lean and fat body mass composition . 
 
Analysis: 
LDL-cholesterol profile  : empirical relationship of Friedewald et al.  
 
RNA isolation : 
- from fractionated peripheral blood mononucleated cells (peripheral blood  leukocyte, 
monocytes, mononuclear cells and polymorphonucleated cell ).  
- 500 mg of subcutaneous adipose tissue fragment 
 
cDNA synthesis and Quantitative Real Time PCR (TaqMan Chemistry):  
7900/HT Sequence Detection System (Applied Biosystems) 
a) p66(ShcA) cDNA amplifications  (GenBank accession no. NM_183001):  
b) PTX3 cDNA amplifications (GenBank accession no. X63613):  
c) GAPDH (glyceraldehydes phosphate dehydrogenase) 20x Assays-on-
Demand Gene Expression Assay Mix (Applied Biosystems-Applera 
Corporation,USA).  
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PCR conditions: GAPDH and PTX3 cDNAs :   40 cycles 
              -enzyme activation at 50°C for 2 min,  
              -pre-denaturation at 95°C for 10 min,  
               -denaturation at 95°C for 15 sec,  
 
PCR conditions: p66 (ShcA) cDNAs :    40 cycles  
     -annealing and extension at 60° for 60 sec.  
             -enzyme activation at 50°C for 2 min, 
             -pre-denaturation at 95°C for 10 min,  
              -denaturation at 95°C for 15 sec,  
              -annealing and extension at 56° for 60 sec. 
 
The standard curve was obtained using serial dilutions of a standard DNA fragment of known 
concentration. mRNA amounts of target genes were than normalized by the mRNA content of 
GAPDH and  expressed as fraction of GAPDH. The obtained numbers were then converted 
into logarithm.  
 
Statistics: 
Data are presented as mean ± SEM. P values were calculated using the Student's t-test 
for unpaired sample led by MS Excel. P values < 0.05 were considered to be statistically 
significant. Regression and multiple regression analysis were carried out according to standard 
method provided by MS Excel and to SPSS version 12, respectively. Results were considered to 
be statistically significant at values of  P < 0.05. 
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Mean ±SEM; Student t distribution 
 MEAN±SEM  MEAN±SEM  
NS 
NS 
NS 
NS 
NS 
NS 
 
NS 
 
NS 
 
<0.001 
NS 
 
NS 
 
 
P 
 
121,14±28,66  99,15±3,13 Glucose (mg/dL) 
1,31±0,08  1,23±0,11 Creatinine 
(µmol/L)  
52,5±7,43  47,00±4,12 HDL (mg/dL)  
135,25±24,16  93,18±8,75 Triglyceride 
(mg/dL)  
12,28±8,71  17,07±5,33 C-reactive protein 
(mg/ml)  
23,68±1,07  26,03±1,09 BMI 
75,22±3,82  72,15±3,22 Lean body  mass  
[% ] 
24,78±3,82  27,83±3,22 Fat  body  mass 
[%]  
147,75±4,66  99,70±4,94 LDL (mg/dL) *  
4/4  4/10 Gender (F/M)  
75,6±3,65  75,5±3,23 Age, y  
8  14 N. of patients  
         PATIENTS GROUP  WITH 
HIGH LEVELS OF CIRCULATING 
LDL  
         (>125 mg/dL) 
 
         PATIENTS GROUP WITH LOW 
LEVELS OF CIRCULATING LDL  
         (<125  mg/dL) 
CLINICAL  AND  ANTHROPOMETRICAL DATA 
Table.8.2.1. Clinical, anthropometrical, pharmacological data  
and diagnosis  
 
(Bosutti et al., 2007b) 
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Student t distribution 
NS 1  2 Hydrochlortiazide  
NS 
 
4  3 Amiodarone 
NS 
 
2  2 Omeprazole  
NS 
 
NS 
NS 
NS 
NS 
 
NS 
 
NS 
 
NS 
NS 
 
NS 
 
 
P 
 
2  0 Allopurinol  
1  3 Spironolactone  
3  4 Furosemide  
3  3 Statins  
1  1 ACE inhibitors  
4  1 Digitalis  
3  2 Nitrates  
0  0 Clopidogrel  
4  2 Warfarin  
0  1 Nonsteroidal anti-inflammatory 
drugs  
4  5 Acetylsalicilic acids  
    NUMBER OF PATIENTS 
 
NUMBER OF PATIENTS 
 
PHARMACOLOGICAL TREATMENTS 
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DIAGNOSIS  
 
         NUMBER OF PATIENTS     NUMBER OF PATIENTS  
P 
Hyperthension  8   5   
Smoking  2   2  NS 
Diabetes  0   0  NS 
Ischemic cardiomyopathy 6   3  NS 
Atrio-ventricular block  4   3  NS 
CMP val.Sy br-ta  1   0  NS 
Hyperthensive cardiomyopaty  2   0  NS 
Ischemic cardiomyopathy and 
myocardial infarction  
0   2  NS 
Dilatative cardiomyopaty  0   1  NS 
Atrial fibrillation  4   3  NS 
Sinus rhythm  9   5  NS 
Student t distribution 
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8.2  Low grade-muscle atrophy: the chronic catabolic conditions  
8.2.2  Contribution of cytokine genotypes on inflammation and cardiovascular risk in chronic 
renal failure 
 
Association of interferon-gamma 1874A polymorphism with reduced long-term inflammatory 
response in haemodialysis patients (Biolo et al.,2006a) 
 
Patients  enrolment: 
 
  A cohort of 127 subjects (69 males and 58 females) with chronic renal failure was 
randomly sampled from the haemodialysis patients in the Nephrology and Dialysis Unit of 
Cattinara Hospital of Trieste, Italy. Patients gave informed consent. The study was conducted 
according to the Declaration of Helsinki. Haemodialysis modalities or type of renal disease 
were not considered as exclusion criteria. Patients with ongoing immunosuppressive 
treatment or malignancy were excluded. These patients were on haemodialysis since 78±8 
(mean±SEM) months, their age was 67±1 years. All patients were on haemodialysis treatment 
with a three-times-per-week schedule. Twenty-one patients had type 2 diabetes mellitus. 
Primary renal diseases of patients were as follows: hypertensive and ischemic nephropathy 
n=38; chronic glomerulonephritis n=30; tubulointerstitial nephropathy n=17; diabetic 
nephropathy n=10; polycystic kidney disease n=8; in 34 patients the etiology of renal disease 
was unknown (Table 8.2.2). Base-line examinations in 1999–2000 were followed by monthly 
examinations for 2 years, in which CRP concentration was determined in serum. Patients 
were not excluded from the analysis if complication developed after the initiation of dialysis. 
Twenty-five patients died during the observation period and completed only 10±3 monthly 
examinations. Of the total, 102 patients survived and completed 24±1 monthly CRP 
determinations. In the patients who completed the observation period, a blood sample was 
taken in the post-absorptive state to determine cytokine mRNA levels in circulating blood 
cells. IFN-gamma genotype frequencies were determined in the 102 patients who survived, in 
21 deceased patients and in 54 healthy, unrelated subjects, mainly composed of blood donors 
matched for the same ethnic origin of patients. IFN-gamma genotype frequencies have not 
been determined in four deceased patients. 
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Analysis: 
Cytokine genotyping assay: for IFN-gamma was based on the PCRSSP methodology;  
 
RNA extraction and cDNA synthesis: Total RNA was extracted from  3 ml of total blood,  
collected in post-absorptive state. The quality and integrity of total RNA was evaluated by 
both gel electrophoresis and spectrophotometric determination. All samples were treated by 
RNAse and DNAse I (10 U/l) (Boehringer Mannheim, Mannheim, Germany) and 
subsequently 3 µl of total purified RNA were reverse transcribed into cDNA to Real time 
analysis. 
 
Cytokines cDNA quantifications: Real Time PCR (TaqMan Chemistry):  
7900/HT Sequence Detection System (Applied Biosystems)   
a) TNF-alpha cDNA amplifications  (GenBank accession no. M10988)  
b) IL-6, IFN-gamma, IL-10, TGF-beta1 and GAPDH (A 20x Assays-on-
Demand Gene Expression Assay Mix (Applied Biosystems-Applera Corporation, 
USA) was used for all the amplification reactions according to manufacturers’ 
instructions.  
 
PCR conditions:       40 cycles  
              -enzyme activation at 50°C for 2 min,  
8 Polycystic kidney diseases 
34 Unknown etiology 
 
N 
 
 
10 Diabetic neprhopathy 
17 Tubulo interstitial nephopathy 
30 Chronic glomerulanephritis 
38 Ischaemic nephropathy 
Table 8.2.2 Primary renal diseases of patients 
(Biolo et al., 2006a) 
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              -pre-denaturation at 95°C for 10 min,  
               -denaturation at 95°C for 15 sec,  
                    -annealing and extension at 60° for 60 sec. 
 
The standard curve was obtained using serial dilutions of a standard DNA fragment of 
known concentration. Cytokine mRNA amounts are expressed as fraction of GAPDH used as 
a reference gene 
 
C-reactive protein: 
CRP was detected by conventional immunoturbidimetric method (CRPLX Tina-quant 
Roche, Diagnostics) using automated analyser systems every month in all patients. The 
overall level of systemic inflammation was expressed as percent of altered CRP values over 
the total number of determinations. An abnormal serum CRP concentration was defined as 
higher than 5 mg/l according to the laboratory reference values at the University of Trieste, 
Cattinara Hospital 
 
Statistics: 
 
Data are presented as mean±SEM. Results in different IFN-gamma genotype groups 
were compared by one-way analysis of variance or t-test where appropriate. Cytokine mRNA 
levels in different IFN-gamma genotype groups were compared after logarithmic 
transformation. Results were regarded as significant at P<0.05. The primary goal of this study 
was to determine the influence of IFN-gamma genotype on long-term systemic inflammation, 
expressed as percent of altered CRP values over the total number of monthly determinations, 
during a 2-year follow-up period.  
Thus, statistical analysis was performed first in the patients who survived the observation 
period and completed the same number of monthly CRP determinations. Then, the results 
were confirmed by including in the analysis the patients who died and completed a lower 
number of monthly CRP determinations and were as expected from the Hardy-Weinberg-low.
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8.2  Low grade-muscle atrophy: the chronic catabolic conditions  
8.2.3 The inflammatory milieu and organ failure 
 
Decreased IL-10 mRNA expression in patients with advanced renal failure undergoing 
conservative treatment (Bosutti et al.,  2007a) 
 
Patients  enrolment: 
We have studies two groups of CRF patients with GFR lower or greater than 15 ml/min 
per 1.73m2 as determined by the MDRD II equation  and a group of healthy controls (Table 
8.2.3.A). Patients gave informed consent. The study was conducted according to the 
Declaration of Helsinki. Age, gender distribution and body mass index were not significantly 
different in the three groups (Table 8.2.3). The groups of patients with far-advanced and less-
advanced CRF exhibited similar mean values of blood C-reactive protein, haemoglobin and 
albumin concentrations (Table 8.2.3).  Except for renal insufficiency, patients had no 
evidence of major organ system disease. Twenty seven uremic patients (far-advanced CRF, n 
=11; less-advanced CRF n = 16) and 14 controls had systemic hypertension. They were taking 
calcium-antagonist drugs. None of the patients and controls was taking glucocorticoids or 
other medications known to affect inflammatory response. Urinary protein excretion was 
lower than 0.6 g/24h. The etiology of the renal disease was glomerulonephritis (far-advanced 
CRF, n = 4; less-advanced CRF n = 5), interstitial nephritis (far-advanced CRF, n = 2; less-
advanced CRF n = 3), polycystic kidney disease (far-advanced CRF, n = 2; less-advanced 
CRF n = 3) and idiopathic kidney disease (far-advanced CRF, n = 3; less-advanced CRF n = 
5). All patients with uraemia and controls were in good clinical conditions at time of blood 
sample collection. There were no infections in the month before, at time of and the week after 
blood collection. The patients and controls consumed a weight-maintaining diet containing 
about 0.8 g protein/kg/day and at least 300 g carbohydrate/day. Their body weight had been 
stable for at least 3 months before the study. Blood samples were taken from patients and 
controls in the post absorptive state. 
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Table 8.2.3: Characteristics of CRF patients 
(Bosutti et al., 2007a) 
 
 
Table 8.2.3: CRF, chronic renal failure. MDRD 2 equation (Lin J. et.al. 2003). Far- and less-
advanced CRF were defined by GFR (MRD2 equation) (Lin J. et.al. 2003). lower or greater 
than 15 ml/min per 1.73 m2. Data are means±SEM;  The control group consisted of 14 
healthy subjects (male/female, 11/3; age, 71±1 yrs; BMI, 26±1). * p<0.01, versus Far-
advanced CRF. 
 
Analysis: 
TNF-alpha, IL-6 and IL-10 protein concentrations: TNF-alpha plasma levels were 
determined on 100 or 200 µl of plasma using Quantikine ELISA assay Kits (R&D Systems, 
Minneapolis, MN, USA). 
 
RNA extraction and cDNA synthesis: Total RNA was extracted from  3 ml of total blood,  
collected in post-absorptive state. The quality and integrity of total RNA was evaluated by 
both gel electrophoresis and spectrophotometric determination. All samples were treated by 
RNAse and DNAse I (10 U/l) (Boehringer Mannheim, Mannheim, Germany) and 
subsequently 3 µl of total purified RNA were reverse transcribed into cDNA to Real time 
analysis. 
 Far-advanced CRF Less-advanced CRF Healthy Controls 
n° 11 16 14 
Age (years) 64±3 71±3  71±1 
Gender (male/female ratio) 8/3 10/6 11/3 
Body mass index (kg/m2) 25±1 24±1  26±1 
Serum creatinine (mg/dL)  6.6±0.4 3.3±0.2*  
GFR  (mL/min/1.73m2) 9.5±0.7 23.0±.1.5*  
C-reactive protein (mg/L) 0.81±0.22 1.20±0.42   
Haemoglobin (mg/dL) 11.0±0.5 11.0±0.4  
Albumin (g/L) 60.7±1.4 53.9±2.3  
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Cytokines cDNA quantifications: Real Time PCR (TaqMan Chemistry)  
7900/HT Sequence Detection System (Applied Biosystems) 
 
a) TNF-alpha cDNA amplifications  (GenBank accession no. M10988):  
b) IL-6, IL-10 and GAPDH  A 20x Assays-on-Demand Gene Expression 
Assay Mix (Applied Biosystems-Applera Corporation, USA) were used for all the 
amplification reactions according to manufacturers’ instructions.  
 
PCR conditions:      40 cycles  
              -enzyme activation at 50°C for 2 min,  
              -pre-denaturation at 95°C for 10 min,  
               -denaturation at 95°C for 15 sec,  
                    -annealing and extension at 60° for 60 sec. 
 
The standard curve was obtained using serial dilutions of a standard DNA fragment of 
known concentration. Cytokine mRNA amounts are expressed as fraction of GAPDH used as 
a reference gene 
 
Evaluation the Glomerular filtration rate (GFR): 
The glomerular filtration rates have been calculated using the simplified Modification of 
Diet in Renal Disease (MDRD) formulas, widely used to estimate renal function. (Levey AS 
Ann Intern Med 1999, Hallan S Am. J. Kidney diseases 2004). 
 
Statistics: 
Data were expressed as means ± SEM. Results obtained in pooled CRF patients (n=27) 
were compared by the Wilcoxon test. Results obtained in ERSD (n=11) and MS GFR (n=16) 
patients and controls (n=14) were compared by the Kruskal-Wallis and Mann-Whitney tests, 
according to standard method provided by the SPSS program version 12.0. Results were 
considered to be statistically significant at values of p < 0.05. Log transformation was performed 
for correlation analyses between GFR and IL-10 mRNA due to non-normal data distribution.. 
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8.3 Accelerated grade muscle atrophy: the hypercatabolic conditions  
8.3.1 Mechanisms of skeletal muscle atrophy induced by acute stress 
 
Overexpression of the Elongation Factor 1A1 relates to muscle proteolysis and pro-apoptotic 
p66 (ShcA) gene transcription in hypercatabolic trauma patients (Bosutti et al., 2007c) 
 
Patients  enrolment: 
Seven adult patients (5 males, 2 females; age 38±6yr, weight 72±43 kg, height 171±3 
cm, BMI 24±0.8) with multiple injuries (APACHE II score 15 ± 1) were studied between days 
7 and 12 after admission to the Intensive Care Unit of the University Hospital of Cattinara, 
Trieste, Italy. Informed consent was obtained from the patients' close relatives. The protocol 
was approved by the competent hospital authority. All patients received continuous combined 
intravenous (80% of total energy) and enteral (20% of total energy) nutrition providing 35 
kcal kg-1 day-1 with 250 mg of nitrogen kg-1 day-1. Nutrient administration was constant 
during the study and for at least one day before the study.  
 
Healthy Controls: 
The control group consisted in five male healthy subjects matched for age (40±3 yrs) 
and body mass index (24±1 kg/m2) to trauma patients. The choice of our controls was based 
on BMI and age matched to those of trauma patients. Additionally, the number of controls 
investigated demonstrated homogeneous results. Being biopsy procedure an invasive method 
no female health volunteers were found. However, individual data of the two female patients 
were within the range of variability of the five male patients. Since, no difference between 
male and female on catabolic trauma conditions was found, only male were enrolled as 
normal healthy controls.  
 
Muscle protein synthesis and proteolysis calculation: 
Rates of muscle protein synthesis and degradation were determined as rate of 
intracellular phenylalanine disposal and appearance by the isotope dilution technique during 
primed-continuous infusion of L-[ring- 2H5] phenylalanine (Mass Trace, Woburn, MA), as 
previously described (Biolo et.al., 1995a; Biolo et.al.,1995b; Biolo et.al., 2000 a; Biolo  et.al., 
2000b) 
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Western blotting : 
Protein extraction from skeletal muscle biopsies 
Target Proteins :  -   Total eEF1A 
  -   Cleaved poly(ADP-ribose) polymerase (PARP)  
    -   Total actin  
    -   Total tubulin 
  -    GAPDH 
 
RNA extraction from skeletal muscle biopsies: Total RNA was extracted from muscle samples 
and reverse transcribed as previously described (Bosutti et.al,.1999; Bosutti et.al., 2000). The 
RNA quality was checked by bioanalyzer 2100 expert assay (Agilent 2100) and all sample 
selected showed a RNA integrity number (RIN) between 2.9 and 5.7. 
 
cDNA synthesis and Quantitative Real Time PCR (SYBR Green dye chemistry in single-plex 
reactions) 
  7900/HT Sequence Detection System (Applied Biosystems): 
  
 Transcripts of EEF1A1, EEF1A2, p66 (ShcA), C-MYC and 28S were chosen with 
particular attention in order to obtain the specific amplicons without significant contaminants 
bands or genomic products. The specificity of the obtained amplicons was checked by 
digesting the PCR product with appropriate restriction endonucleases (data not shown). 
Furthermore, samples were treated with DNase prior to perform reverse transcription to 
completely exclude the possibility that amplicons of EEF1A1 could be derived from non-
actively transcribed retropseudogenes. Although the coding regions of EEF1A genes are very 
similar, the introns, UTRs and the promoters are highly divergent. 
 
a) p66(ShcA) cDNA amplifications  (GenBank accession no. NM_183001);  
b) EEF1A1 cDNA amplifications (GenBank accession no.J04617); 
c) EEF1A2 cDNA amplifications (GenBank accession no. AF163763);  
d) C-MYC cDNA amplifications (GenBank accession no. NM_002467.3); 
e) 28S rRNA, cDNA amplifications (GenBank accession  no. M11167.); 
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PCR conditions: 28S rRNA, EEF1A1, EEF1A2 and c-MYC cDNAs :  
       40 cycles  
              -enzyme activation at 50°C for 2 min,  
              -pre-denaturation at 95°C for 10 min,  
               -denaturation at 95°C for 15 sec,  
              -annealing and extension at 62° for 60 sec.  
 
PCR conditions: p66 (ShcA) cDNAs :           40 cycles  
             -enzyme activation at 50°C for 2 min, 
             -pre-denaturation at 95°C for 10 min,  
              -denaturation at 95°C for 15 sec,  
              -annealing and extension at 56° for 60 sec. 
Statistics: 
Data were expressed as means ± SEM. Results obtained in patients and controls were 
compared by the Wilcoxon two sample test. Regression analysis was carried out according to 
standard methods, using log transformed data for parametric analysis.. Results were considered 
to be statistically significant at values of P < 0.05.  
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9. RESULTS 
 
9.1  Skeletal muscle atrophy in healthy conditions: Interaction between energy restriction 
and muscle unloading in the regulation of lean body mass, protein kinetics or inflammatory 
response in healthy subjects.  
Muscle inactivity and low energy intake commonly occur in persons with acute or 
chronic disease, in astronauts during space flight, or during aging and may have negative 
effect on muscle or body health. We studied the interaction between energy restriction and 
muscle unloading in the regulation of lean body mass, protein kinetics or inflammatory 
response in healthy subjects. Prolonged bed rest is  an appropriate model to investigate the 
effects of muscle unloading on physiologic functions, thus to develop our investigations we 
used as model of study a group of nine healthy volunteers assigned to prolonged bed rest. 
These investigations were conducted within the frame of the Short-Term Bed Rest Study of 
Integrated Physiology (STBR-IP) set up by the German Aerospace Institute (DLR) and the 
European Space Agency 
9.1.1. Calorie restriction accelerates the catabolism of lean body mass during 2 wk of bed rest  
(Biolo  et al., 2007). 
We have hypothesized that the combination of reduced physical activity and negative 
energy balance would accelerate the loss of lean body mass (LBM) in healthy subjects 
through changes in whole body protein kinetics, as assessed by using stable isotopes of amino 
acids. Our data evidenced that REE relative to LBM did not differ significantly between the 
ambulatory and bed rest conditions during the eucaloric (25.7± 0.6 and 25.0±0.6 kcal/d/kg 
LBM,respectively) and hypocaloric (24.8 ±0.7 and 24.7 ± 1.1 kcal/d/kg LBM, respectively) 
diets (P =0.70 for activity effect; P = 0.57 for diet effect; P =0.65 for interaction). The 
respiratory quotient did not change significantly during the eucaloric periods in the 
ambulatory (0.87 ±0.01) or bed rest (0.85 ± 0.01) conditions or during the hypocaloric periods 
in the ambulatory (0.85±0.02) or bed rest (0.82±0.02) conditions (P =0.17 for activity effect; 
P =0.29 for diet effect; P =0.54 for interaction). Changes in body weight and in lean and fat 
masses during the ambulatory and bed rest periods with eucaloric and hypocaloric diets are 
shown in Table 9.1.1.A. Initial body weight and fat mass were greater during the hypocaloric 
periods (study phases 3 and 4) than during the eucaloric periods (study phases 1 and 2). 
During the eucaloric periods, in both the bed rest and ambulatory conditions, body weight and 
lean and fat masses did not change significantly. During the hypocaloric periods, body weight 
 99 
 
 
decreased significantly from baseline. Nonetheless, during the hypocaloric period in 
ambulatory conditions, changes in body weight were largely accounted for by decreases in fat 
mass, whereas LBM did not change significantly. In contrast, during the hypocaloric period in 
bed rest, a decrease in fat mass was paralleled by a significant decrease in LBM. Calorie 
restriction increased serine, glycine, threonine, arginine, methionine, valine, isoleucine, and 
leucine concentrations. Bed rest increased plasma concentrations of serine, valine, leucine, 
and phenylalanine but decreased those of alanine. None of the activity by diet interactions 
was significant. Intravenous infusion of the amino acid mixture resulted in variable 
increments in plasma concentrations of the infused amino acids. Increments from the post 
absorptive values varied according to the infusion rates and pool sizes of the individual amino 
acids. Increments in plasma concentrations of amino acids (except alanine and serine) did not 
differ significantly between the ambulatory and bed rest conditions during eucaloric or 
hypocaloric diets. There were significant effects of calorie restriction in enhancing the 
infusion-mediated increases in serine and alanine concentrations and of bed rest in enhancing 
the increase in alanine. Results of whole-body intracellular leucine kinetics in the post 
absorptive state and during amino acid infusion at the end of the 4 study phases are shown in 
Table 9.1.1.B. In the baseline post absorptive state, intracellular Ra (proteolysis) did not 
exhibit significant differences in the 4 study phases. In contrast, nonoxidative leucine Rd 
(protein synthesis) was significantly decreased by bed rest. The baseline post absorptive 
values of leucine oxidation, an index of net protein catabolism (i.e., difference between 
proteolysis and protein synthesis), did not differ significantly in the ambulatory conditions 
with the eucaloric or the hypocaloric diet. However, the activity effect and the activity x diet 
interaction were both significant. Baseline rates of leucine oxidation during bed rest with the 
hypocaloric diet were significantly greater than those during either the ambulatory or bed rest 
condition with the eucaloric diet. Amino acid infusion increased nonoxidative leucine Rd 
(protein synthesis) and leucine oxidation and decreased leucine Ra (proteolysis) in all 
conditions. 
Amino acid–mediated changes in leucine Ra (proteolysis) and leucine oxidation did not 
differ significantly during the 4 experimental conditions. In contrast, amino acid–mediated 
increases in nonoxidative leucine Rd (protein synthesis) were significantly blunted by bed 
rest, although no significant activity x diet interaction was found. The rates of net leucine 
deposition into body protein—i.e., nonoxidative Rd (protein synthesis) minus Ra (proteolysis) 
during amino acid infusion were significantly lower in the bed rest than in the ambulatory 
condition; however, no significant activity x  diet interaction was found (Figure 9.1.1). 
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Body weight and composition before and at the end the four experimental phases 
(Biolo et al., 2007) 
 
 
 
 
 
 
Table 9.1.1.A:   *, changes were significantly different from zero (P<0.01, paired t-test). 1Data were analyzed 
with 2-factor (activity × diet) ANOVA with interaction. Means not sharing a common superscript letter are 
significantly different at P<0.01 based on Bonferroni’s post hoc analysis.  
 
 
 Eucaloric Diet Hypocaloric Diet P1 
 Ambulatory Bed Rest Ambulatory Bed Rest 
Activity 
effect 
Diet 
effect 
Interaction 
Initial weight 
(kg) 77.1±2.9 77.0±3.0 80.3±3.1 80.9±3.0 
 
0.47 <0.01 0.72 
Change (kg/14 
days) 0.0±0.3 -0.6±0.2 -1.4±0.3* -2.1±0.2* 
 
<0.01 <0.01 0.68 
Initial  lean  
mass (kg) 61.1±1.2 61.2±1.3 61.7±1.4 61.6±1.6 
 
0.88 0.53 0.56 
Change (kg/14 
days) -0.1±0.1a -0.3±0.2 a -0.3±0.3 a -1.1±0.1* b 
 
<0.01 0.04 0.03 
Initial fat mass 
(kg) 16.0±2.0 15.9±1.9 18.6±2.2 19.3±1.8 
 
0.57 <0.01 0.56 
Change (kg/14 
days) 0.1±0.3 -0.3±0.2 -1.0±0.3* -1.0±0.3* 
 
0.35 0.01 0.24 
 101 
 
 
 
Whole-body intracellular protein kinetics in the baseline postabsorptive state and the 
percentage changes from after intravenous amino acid infusion 
(Biolo et al., 2007) 
 
 
 
 
 
Eucaloric Diet Hypocaloric Diet 
 
P1 
 Ambulatory Bed Rest Ambulatory Bed Rest 
 
Activity 
effect 
 
Diet 
effect 
Interaction 
Leucine Ra 
(proteolysis) 
Baseline 
 
 
 
2.47 ±0.053 2.36 ±0.05 2.44 ±0.12 2.34 ±0.08 0.20 0.72 
 
 
 
0.97 
 
 
 
Change (%) 
 
-15±2 
 
-20±2 
 
-12±4 
 
-18± 4 
 
0.08 
 
0.47 
 
 
0.81 
 
Leucine Rd 
 (protein 
synthesis) 
Baseline 
 
 
 
2.24 ± 0.05 
 
2.11±0.04 
 
2.22±0.12 
 
2.05±0.07 
 
0.04 
 
0.60 
 
 
 
0.68 
 
 
 
 
 
 
Change (%) 
 
 
 
 
 
35 ±2 
 
30±2 
 
41 ±3 
 
32±2 
 
<0.01 
 
0.06 
 
 
 
0.35 
 
 
 
 
 
Leucine 
oxidation 
baseline 
 
0.23±0.01a,b 
 
0.25 ±0.01a 
 
0.23± 0.01a 
 
0.28 ± 0.01b 
 
0.04 
 
0.17 
 
0.04 
 
 
Change (%) 
 
136±12 
 
155± 21 
 
124±16 
 
139 ± 21 
 
0.53 
 
0.40 
 
0.83 
 
 
Table 9.1.1.B: 1 Ra, rate of appearance; Rd, rate of disappearance. The rate of leucine oxidation in the basal post 
absorptive state is a marker of net protein catabolism (i.e., difference between proteolysis and protein synthesis). 
All amino acid–mediated changes from baseline are significantly different from zero, P <0.001 (Student’s t test). 
Means in a row with different superscript letters are significantly different, P<0.01 (Bonferroni’s post hoc 
analysis). 2 Data were analyzed with a 2-factor ANOVA (activity by diet interaction). 3 x±SD (all such values). 
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Rates of net leucine deposition into body protein 
 
(Biolo et al., 2007) 
 
 
Figure 9.1.1: Rates of net leucine deposition into body protein, i.e. nonoxidative rate of disappearance 
(Rd) of (protein synthesis) minus the rate of appearance (Ra) (proteolysis) during amino acid infusion in 
ambulatory and bed rest conditions with eucaloric and hypocaloric diets. LBM, lean body mass. Data 
were analyzed by using ANOVA with activity x diet interaction. P = 0.01 for activity effect; P =0.94 
for diet effect; P =0.17 for interaction. 
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9.1.2 Calorie restriction prevents inactivity-induced systemic inflammatory response evidence 
for inverse regulation of CRP and PTX3 by energy balance (Bosutti et al., 2007 JCEM 
submitted) 
 
Stress mediators, such as cytokines, may further amplify the catabolic response of LBM 
to inactivity and hyponutrition (Ferrando et al., 1999; Paddon-Jones et al., 2004). Moreover 
alteration in circulating levels of adipocytokine leptin may impair muscle, either by affecting 
the GH/IGF-I axis or systemic and fat cytokines gene  expression (Hamrick and Ferrari, 
2007). Our hypothesis was that moderate energy restriction may prevent activation of 
inflammatory markers induced by inactivity, and leptin may be a pivotal player in this 
response. To test it, we determined the gene expression of some markers and mediators of 
inflammatory response and circulating levels of leptin hormone. In addition to better 
understand the association between cardiovascular risk and prolonged immobilization, and its 
potential coupling with muscle loss, we pointed our attention on the role performed in  bed 
rest of the novel marker of  inflammatory/arthrosclerosis response , the long pentraxin PTX3.  
We  provided evidence that  two weeks of bed rest led to significant activation of the 
pro-inflammatory cascade, whereas combination of calorie restriction and bed rest completely 
prevented CRP and IL-6 increases. Absolute values and changes in body weight and in lean 
and fat masses during the ambulatory and bed rest periods with eucaloric and hypocaloric 
diets have been previously reported (Biolo et al., 2007). Fat mass was greater (P<0.01) at the 
beginning of the hypocaloric periods in ambulatory (18.6±2.2 kg) or bed rest (19.3±1.8 kg) 
conditions (study phases 3 and 4) than at the beginning of the eucaloric periods in ambulatory 
(16.0±2.0 kg) or bed rest (15.9±1.9 kg) conditions (study phases 1 and 2). During eucaloric 
periods, fat mass did not change significantly both in ambulatory (0.1±0.3 kg) and bed rest (-
0.3±0.2 kg) conditions. During hypocaloric periods, fat mass decreased from baseline 
(P<0.001) both in ambulatory (-1.0±0.3 kg) and bed rest (-1.0±0.3 kg) conditions. Table 
9.1.2.A shows mean values of plasma concentration of selected hormones and acute phase 
proteins. Bed rest did not change insulin and leptin plasma concentrations either during 
eucaloric or hypocaloric diets. There was a significant bed rest effect in increasing PTX3 
plasma concentration, without significant activity-by-diet interaction. Bed rest significantly 
increased CRP concentrations in eucaloric conditions. Bed rest-mediated changes in CRP 
concentrations were significantly greater (P=0.04) in eucaloric conditions than during 
hypocaloric diet. There was a significant effect of hypocaloric diet in decreasing plasma CRP 
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concentration by 143±53%, with significant activity-by-diet interaction (Figure 9.1.2.A). 
Cytokine concentrations and mRNA levels in plasma and blood cells, respectively are shown 
in table 9.1.2.A. TNF-alpha and TGF-beta1 concentrations and mRNAs were determined in 
eucaloric conditions only. There was significant activity-by-diet interaction for plasma 
concentration of IL-6. Bed rest-mediated changes in IL-6 concentrations were significantly 
greater (P<0.01) in eucaloric conditions (299±74%) than during hypocaloric diet (Figure 
9.1.2.A). Changes mediated by either bed rest or hypocaloric nutrition in plasma 
concentrations of the other cytokines were not observed.  mRNA levels of the anti-
inflammatory cytokines IL-10 decreased by -51±23% in bed rest and eucaloric diet, while  did 
not change significantly in bed rest in hypocaloric conditions. There was significant activity-
by-diet interaction for IL-10 mRNA levels. Bed rest-mediated changes in IL-10 mRNA levels 
were significantly lower (P=0.03) in eucaloric conditions than during hypocaloric diet (Figure 
9.1.2.A). Significant changes mediated by either bed rest or hypocaloric nutrition for mRNA 
levels of the other three cytokines were not observed.  Additionally, there were significant 
activity-by-diet interaction for the ratios between IL-6 and IL-10. Bed rest in eucaloric 
conditions increased the ratios between IL-6 and IL-10 plasma concentrations by 4±1 times 
(P<0.01) and between IL-6 and IL-10 white blood cell mRNAs by 5±1 times (P<0.001). 
Energy restriction prevented bed rest-mediated increases in IL-6/IL-10 concentrations and 
mRNAs (Table 9.1.2.A). Regression analysis was performed in individual data obtained from 
the four experimental periods (n=36) to define determinants of hormone and inflammatory 
marker variability (Table 9.1.2.B).  Plasma insulin and leptin concentrations were directly 
correlated with fat mass, energy intake and CRP concentration. In addition, leptin correlated 
directly with energy balance, as expressed by changes in fat mass over the intervention 
periods, and indirectly with PTX3. Insulin also directly correlated with INFgamma plasma 
levels. A multiple regression model predicting plasma leptin concentrations using nutritional 
and anthropometric determinants indicated that fat mass (coefficient±SEM, 0.00046±0.00006) 
and energy intake (coefficient±SEM, 0.00328±0.00149) independently explained most of 
leptin variability (multiple R= 0.86; P < 0.0001). Thus, in order to determine the effect of bed 
rest on leptin variability, plasma concentrations of this hormone were normalized by units of fat 
mass and of energy intake.  Results (Figure 9.1.2.B), indicate that bed rest in eucaloric conditions 
significantly (P<0.01) increased normalized values of leptin concentrations (from 0.18±0.02 to 
0.23±0.02) but such effect was not observed in hypocaloric conditions (0.18±0.03 and 0.17±0.02 
pg/kg/kcal, respectively). The two inflammatory markers, CRP and PTX3 were inversely 
correlated (Table 9.1.2.B). CRP directly correlated with fat mass and energy balance as well 
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as with insulin and leptin levels, while PTX3 inversely correlated with the same parameters. 
In addition, PTX3 concentrations were directly correlated with IL-10 (Table 9.1.2.B). To 
further define the relationships between inflammatory and nutritional variables, multiple 
regression analysis was performed with CRP and PTX3 as dependent variables. Models only 
included independent variables exhibiting significant correlations with the dependent 
variables. Results show that only leptin concentrations independently predicted CRP 
concentrations (P<0.001) (Figure 9.1.2.B). In contrast, the best model predicting variability of 
PTX3 (multiple R=0.59; P=0.001; Table 9.1.2.C) included changes in fat mass 
(coefficient±SEM, -0.19±0.08) and IL-10 (coefficient±SEM, 95±33). 
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Effects of bed rest at different energy intake levels on selected hormones,  
acute phase proteins and cytokines. 
 
 
 
 
Table 9.1.2.A: Long pentraxin 3, PTX3; C-reactive protein. 1Data were analyzed with 2-factor (activity × diet) ANOVA with 
interaction. *, significantly different from ambulatory condition at P<0.025 based on Bonferroni’s post hoc analysis to assess 
the effects of bed rest either in eucaloric or hypocaloric diets.  IL, interleukine; INF, interferon; TGF, transforming growth 
factor. 1Data were analyzed with 2-factor (activity × diet) ANOVA with interaction. *, significantly different from 
ambulatory condition at P<0.025 based on Bonferroni’s post hoc analysis.  IL, interleukine; INF, interferon; TGF, transforming 
growth factor. Units are fraction of GAPDH mRNA ·10-6. 1Data were analyzed with 2-factor (activity × diet) ANOVA with 
interaction. *, significantly different from ambulatory condition at P<0.025 based on Bonferroni’s post hoc analysis.  
 
 
 
 
 Eucaloric Diet Hypocaloric Diet P1 
 Ambulatory Bed Rest Ambulatory Bed Rest 
Activity  
effect 
Diet  
effect 
Interaction 
Plasma 
concentrations 
    
 
  
Insulin (µU/ml) 6.8±0.6 6.1±0.4 7.3±1.1 6.4±0.8 0.29 0.45 0.76 
Leptin (ng/ml) 5.2±1.1 4.1±0.8 5.2±1.4 4.2±1.0 0.17 0.27 0.86 
PTX3 (pg/ml) 808±126 934±177 901±178 1139±205 0.03 0.28 0.72 
CRP (µg/ml) 1.2±0.4 2.3±0.6 * 1.1±0.4 0.8±0.2 0.20 0.02 0.03 
IL-6 (pg/ml) 3.4±1.0 11.4±3.4* 3.4±0.7 1.7±0.3 0.23 0.08 0.01 
INF-γ (pg/ml) 5.1±0.5 6.2±0.5 6.6±0.6 6.8±0.7 0.21 0.19 0.35 
TNF-α (pg/ml) 16±2 22±4 - - - - - 
IL-10 (pg/ml) 9.2±0.5 9.5±0.9 9.0±0.5 9.9±1.1 0.75 0.99 0.74 
TGF-β (pg/ml) 1143±190 1055±164 - - - - - 
IL-6/IL-10 0.4±0.1 1.4±0.5* 0.4±0.1 0.2±0.1 0.33 0.08 0.01 
White blood 
cell mRNA 
    
 
  
IL-6 4.9±0.8 5.2±1.3 6.3±1.3 6.8±1.8 0.63 0.59 0.81 
INF-γ 143±28 188±52 75±21 173±49 0.21 0.09 0.12 
TNF- α 0.6±0.1 0.9±0.4 1.0±0.2 0.8±0.2 0.37 0.08 0.47 
IL-10 0.72±0.20 0.24±0.08* 0.47±0.09 0.50±0.13 0.02 0.45 0.01 
TGF- β 111±22 67±9 66±31 51±24 0.16 0.03 0.84 
IL-6/IL-10 9±2 44±15* 16±3 20±5 0.06 0.64 0.02 
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Pearson r correlations 
 
Variable Insulin  Leptin CRP PTX3 
Fat mass (g) 0.59‡ 0.78‡ 0.62‡ -0.35* 
Changes in fat mass (g/14 days) 0.31 0.40* 0.51† -0.43† 
Energy intake (kcal) 0.51† 0.60‡ 0.40* -0.24 
Insulin (µU/ml) - 0.51† 0.45† -0.14 
Leptin (ng/ml) 0.51† - 0.63‡ -0.53‡ 
CRP (µg/ml) 0.45† 0.63‡ - -0.61‡ 
PTX3 (pg/ml) -0.14 -0.53‡ -0.61‡ - 
IL-6 0.19 0.31 0.49† -0.38* 
INFgamma 0.11 0.12 0.06 0.22 
IL-10 -0.17 -0.35* -0.37* 0.52† 
 
Table 9.1.2.B: Long pentraxin 3, PTX3; C-reactive protein; IL, interleukine; INF, interferon; TGF, transforming 
growth factor.*, P<0.05 ; †, P < 0.01;  ‡.P < 0.001 
 
 
 
 
 
 
Multiple regression analysis between changes (g) in fat mass during the four 15-day 
experimental periods,  IL-10 (pg/ml) and PTX3 (mg/l) as dependent variable. 
  
 
Table 9.1.2.C: Multiple R= 0.59 ; P = 0.001 
Variable Coefficient SEM P 
Changes in fat mass -0.19 0.08 0.03 
IL-10 95 33 0.01 
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Figure 9.1.2.A:  Bed rest mediated changes of CRP, IL-6 and INFgamma plasma levels and 
IL-10 mRNA contents in blood cells in eucaloric and hypocaloric conditions. Data are 
mean±standard error. *: P<0.05 
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9.2. Low grade-muscle atrophy: the chronic catabolic conditions  
9.2.1 Association between cardiovascular risk and inflammatory response at whole body and 
adipose tissue levels. 
 
Relation between the plasma levels of LDL-cholesterol and the expression of the early marker 
of inflammation long pentraxin PTX3 and the stress response gene p66 (ShcA) in pacemaker 
implanted patients (Bosutti et al., 2007b) 
 
 The relevance of the lipid profile with regard to the up-regulation of genes involved in 
inflammation and oxidative stress responses, has long been recognized (Napoli et al., 2001; 
Steinberg, 2005). Our goal was to set up a pilot study to explore the possible relation between 
the expression of p66 (ShcA) and PTX3, two emerging regulators of stress response and 
inflammation processes, respectively,  and the circulating levels of LDL-cholesterol (LDL), a 
factor implicated in the development of inflammation and oxidative-stress associated diseases 
such as atherosclerosis, in adipose tissue and in circulating WBCs of non-diabetic 
cardiovascular patients which underwent pacemaker implantation for therapeutic purposes. 
By real time PCR we determined the mRNA contents of  p66 (ShcA)  and PTX3 either  
locally, in subcutaneous adipose specimens of non diabetic pacemaker implanted patients, or 
systemically, in the circulating white blood cells (WBC), obtained from the same patients. 
Moreover, the mean of the circulating LDL levels (125 mg/dl) was chosen as a threshold to 
identify two groups here considered to have high (> 125 mg/dl) and low (<125 mg/dl) LDL 
plasma levels. Clinical/anthropometrical data (Table 8.2.1) do not significantly differ between 
the two groups. Remarkably, no differences concerning the lean body mass content was 
relieved between the two groups of patients. We pointed out a marked relation between the 
circulating levels of LDL and PTX3 mRNA contents in adipose tissue fragments and in WBC 
cells respectively. Our data indicate that patients with high levels of circulating LDL, show a 
significant increase of PTX3 mRNA levels in adipose tissue (p=0.01, figure 9.2.1.A) and in 
WBC cells (p=0.01, figure 9.2.1.A). Notably, neither the underlying pathology (Table 8.2.1), 
nor the therapeutic treatment (data not shown) significantly affected PTX3 mRNA levels. 
Additionally, a multiple regression analysis indicates that among LDL, TG, HDL, total 
cholesterol, CRP, creatinine and glucose levels, and the only variable significantly (Table 
9.2.1) affecting PTX3 mRNA expression was represented by the circulating amount of LDL.  
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Moreover, we found a straight relation between the circulating levels of LDL and 
p66(ShcA) mRNA contents in adipose tissue fragments and in WBC cells, too. 
p66(ShcA) mRNA contents were evaluated in the same samples used for the 
quantification of PTX3 mRNA. Our data indicate that patients with high levels of circulating 
LDL show significantly higher p66(ShcA) mRNA content both in subcutaneous adipose tissue 
(p= 0.002, figure 9.2.1.B) and in peripheral WBCs (p= 0.005, figure 9.2.1.B). As shown in the 
case of PTX3, neither the underlying pathology nor the therapeutic treatment (data not shown) 
significantly affect p66(ShcA) mRNA levels. Additionally, multiple regression analysis 
indicates that among LDL, TG, HDL, total cholesterol, CRP, creatinine and glucose levels, 
the only variable significantly (Table 9.2.1) affecting p66(ShcA)  mRNA was represented by the 
circulating amount of LDL. Finally, the correlation observed among the LDL plasma levels 
and both PTX3 and  p66(ShcA) mRNA contents,  prompted us to  evaluate whether a correlation 
also occurs between  the amounts of PTX3 and p66(ShcA) mRNAs. As shown in figure 9.2.1.C, 
we observed a strong correlation between the levels of the two mRNA species either in 
adipose tissue or in WBC, respectively. 
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Figure 9.2.1.A: PTX3 mRNA levels in relation to the levels of circulating LDL.  
PTX3 mRNA levels were quantified by real time PCR in the adipose tissue of patients with high (> 125 
mg/dl) and low (<125 mg/dl) circulating content of LDL: it is evident the increase in PTX3 mRNA 
levels, expressed as logarithm, in patients with high LDL content both in adipose tissue or WBCs.  
Data are expressed as means ± SEM. 
Adipose tissue and WBCs PTX3 mRNA levels  in relation  
to the level of circulating LDL-cholesterol 
(Bosutti et al., 2007b) 
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Figure 9.2.1. B: p66(ShcA)  mRNA levels in relation to the levels of circulating LDL.  
The p66(ShcA) mRNA levels were quantified by real time PCR in the adipose tissue and WBCs of patients 
with high (> 125 mg/dl) and low (<125 mg/dl) circulating content of LDL: it is evident the increase in 
p66(ShcA) mRNA levels, expressed as logarithm, in patients with high LDL content in both tissues. Data 
are expressed as means ± SEM.  
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Figure 9.2.1.C: Linear regression between p66(ShcA) and PTX3  mRNA levels expressed as logarithm, 
measured in adipose tissue (R=0.717, p<0.001) and in WBCs (R=0.954, p<0.001). 
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Table 9.2.1: Multiple regression analysis 
 
  
ADIPOSE TISSUE 
 
WBC CELLS 
  
mRNA 
 
P66 (ShcA) 
 
 
mRNA 
 
PTX3 
 
mRNA 
 
P66 (ShcA) 
 
mRNA  
 
PTX3 
  
P* 
 
 
P* 
 
P* 
 
P* 
 
LDL * 
(mg/dL) 
 
0.012* 
 
0.020* 
 
0.015* 
 
0.007* 
 
TG 
(mg/dL) 
 
0,616 
 
0,598 
 
0,347 
 
0,395 
 
HDL 
(mg/dL) 
 
 
0,583 
 
0,415 
 
0,238 
 
0,599 
 
TOTAL-
CHOLESTEROL 
(mg/dL) 
 
0,370 
 
0,216 
 
0,317 
 
0,760 
 
CRP 
(mg/ml) 
 
0,157 
 
0,915 
 
0,324 
 
0,094 
 
CREATININE 
(µmol/L) 
 
 
0,372 
 
0,531 
 
0,461 
 
0,292 
 
GLUCOSE 
(mg/dL) 
 
0,510 
 
0,283 
 
0,344 
 
0,258 
(Bosutti et al., 2007b) 
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9.2.  Low grade-muscle atrophy: the chronic catabolic conditions.  
9.2.2. Contribution of cytokine genotypes on inflammation and cardiovascular risk in chronic 
renal failure 
 
Association of interferon-gamma 1874A polymorphism with reduced long-term inflammatory 
response in haemodialysis patients (Biolo et al.,2006a) 
 
We have studied the effects of interferon (IFN)-gamma allelic variations on the overall 
2-year inflammatory status in haemodialysis patients. Additionally, the effects of interferon 
IFN-gamma allelic variations on expression levels of pro and anti-inflammatory cytokines in 
haemodialysis patients were also investigated. 
Table 9.2.2.A. shows, the allele frequencies of the IFN-gamma gene polymorphism at 
position ±874 in the 102 dialysis patients who completed the 2-year follow-up period. Table 
14.2.A. also shows the characteristics of the groups of patients who completed the 2-year 
follow-up period with the ±874 A/A ‘low-producer’, A/T ‘intermediate producer’ and T/T 
‘high producer’ genotypes. The three groups were matched for age, sex distribution, body 
mass index, haemodialysis duration and prevalence of type 2 diabetes mellitus. Results in 
IFN-gamma allele frequencies of the patients were similar to those of the control population 
(data not shown) and were as expected from the Hardy–Weinberg law. The allele frequencies 
in 21 of the 25 patients who died before the end of the follow-up period were not significantly 
different to those of the surviving patients, i.e. A/A, n=5; A/T, n=11; T/T, n=6.  
In Table 9.2.2.B. are reported the values of selected pro- and anti inflammatory 
cytokines mRNA content in white blood cells of the groups of patients who completed the 2-
year follow-up period with the IFN-gamma ±874 A/A ‘low producer’, A/T ‘intermediate 
producer’ and T/T ‘high producer’ genotypes. As we expected, IFN-gamma expression was 
lower in the A/A ‘low-producer’ genotype than in both the A/T ‘intermediate producer’ and 
T/T ‘high producer’ genotypes. IL-6 mRNA levels were also lower in the A/A ‘low-producer’ 
genotype group than in the pooled groups with the A/T ‘intermediate producer’ and the T/T 
‘high producer’ genotypes. In contrast, mRNA levels of TNF-alpha, IL-10 and TGF-beta1 
were not significantly different in the three groups of patients. CRP concentration was 
determined 24±1 times in the patients who completed the follow-up period, whereas it was 
determined only 10±3 times in the patients who died during the observation period. In all 
patients, the percentage of altered CRP individual values over the total number of 
determinations exhibited a great inter-individual variability. In the patients who completed the 
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follow-up period, the average value of this indicator of overall 2-year inflammatory response 
was 54% (the median was equal to 53%) with a coefficient of variation of 60%. The patients 
who died before the end of the observation period exhibited 67% of altered CRP values over 
the total number of determinations. At the end of the follow-up period, absolute CRP value 
tended (P<0.01) to be lower in the IFN-gamma A/A ‘low producer’ genotype group (9.3±2.3 
mg/l) than in the A/T ‘intermediate producer’ (20.1±5.0 mg/l) and the T/T ‘high producer’ 
(18.9±4.7 mg/l) genotype patients. Figure 9.2.2  shows the influence of IFN-gamma gene 
polymorphism at position ±874, on the percentage of altered PCR individual values over the 
total number of monthly determinations in the patients who completed that 2-year follow-up. 
This indicator of long-term inflammatory response was  significantly lower in the IFN-gamma 
A/A ‘low producer’ genotype group than in the other two groups with the A/T ‘intermediate 
producer’ and the T/T ‘high producer’ genotypes (Figure 9.2.2).  
In addition, we have determined the influence of IFN-gamma gene polymorphism on 
long-term inflammatory response in pooled patients who survived and deceased patients. The 
analysis in pooled patients confirmed that the percentage of altered CRP values over the total 
number of monthly determinations was significantly lower in the IFN-gamma A/A ‘low 
producer’ genotype group (38±6 mg/l) than in the other two groups with the A/T 
‘intermediate producer’ (63±4 mg/l) and the T/T ‘high producer’ (60±5 mg/l) genotypes. IFN-
gamma ‘low-producer’ patients the frequency of abnormally elevated CRP over 2 years 
averaged only 37%, whereas in the ‘high and intermediate-producer’ groups this feature was 
similar to that of the entire haemodialysis population, i.e. 57%. 
We also studied the effects of IFN-gamma polymorphism on gene transcriptions of 
several pro- and anti inflammatory cytokines including IFN-gamma. Expression of cytokine 
genes has been evaluated at the level of individual cytokine mRNA content in circulating 
blood cells because cytokine serum levels do not accurately reflect rate of expression during 
haemodialysis. In the IFN-gamma high- and intermediate-producer genotype patients mean 
mRNA levels of IFN-gamma were 27 and 14 times greater than in the low-producer patients. 
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Table 9.2.2.A: IFN ±874 A/A ‘low-producer’, A/T ‘intermediate producer’ and T/T ‘high producer’ allele 
frequencies were similar to those of the control population and were as expected  from the Hardy–Weinberg law. 
The three groups were matched for age, sex distribution, body mass index, haemodialysis duration and 
prevalence of type 2 diabetes mellitus. Data of patients who completed the 2-year follow up period. Allele 
frequencies in 21 deceased patients were as follows: A/A: 5; A/T: 11; T/T: 6. BMI: Body max index 
 
 
 
 
 
 
 
 
 
 
 
Patients characteristic according to INF-gamma gene polymorphism  at position +874 
4483 ±2717 3243 ±1203 2026 ±480 TGF-beta1 
29 ±6 23 ±3 19 ±3 IL-10 
8 ±1 32 ±21 15 ± 4 TNF-alpha 
23087 ±13207 5082 ±3113 674 ± 132** IL-6 
44832 ±27170 22623 ±13508 1638±337* INF-gamma 
T/T 
 
‘high-
producer’ 
A/T  
 
‘intermediate-
producer’ 
A/A 
+874  
‘low-
producer’ 
 
 
Influence of INF-gamma  polymorphism at position +874 on cytokine  mRNA levels in  
blood cells of haemodyalisis patients at the end of 2- year follow up period 
Table 9.2.2.B: Cytokines mRNA levels  in white blood cells multiplied  
by 107, are expressed as fraction of GAPDH mRNA contents 
*p<0.05 A/A vs A/T, T/T groups 
** p<0.05 A/A vs  pooled A/T, T/T groups 
(G. Biolo et al., 2006) 
22 52 28 n Gender (%male) 
 
20 22 18 Diabetic patients 
(%) 
59 ±11 93 ±18 70 ±14 Months of dyalisis 
25 ±1 25 ±1 25 ±1 BMI (kg/m2) 
69 ±2 67 ±2 65 ±2 Age (years) 
52 55 55  
T/T A/T A/A  
(G. Biolo et al., 2006) 
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Figure 9.2.2.: Influence of INF-gamma polymorphism at position +874  
on percentage of  altered CRP individual values over the total number 
 of monthly determination in 2 years 
*P< 0.05 A/A vs A/T and T/T groups 
(G. Biolo et al., 2006) 
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9.2.  Low grade-muscle atrophy: the chronic catabolic conditions.  
9.2.3. The inflammatory milieu and organ failure 
 
Decreased IL-10 mRNA expression in patients with advanced renal failure undergoing 
conservative treatment (Bosutti et al.,  2007a) 
In CRF patients, progressive decrease in glomerular filtration rate (GFR) is paralleled 
by increased frequency of clinical consequences of inflammation, e.g., cardiovascular disease 
and muscle wasting (Poole et al., 1990; Stenvinkel et al., 2005a). Nonetheless, in this 
condition plasma cytokine concentrations may not accurately reflect activation of the 
inflammatory response because cytokine clearance is impaired, thus  cytokine mRNA levels 
may represent a better index of synthetic capacity than plasma concentrations. In this study, 
we have investigated the relationship between synthetic capacity of key pro- and anti-
inflammatory cytokines and residual renal function in patients with CRF on conservative 
therapy, in order to test the hypothesis that the balance between synthetic capacities of pro- 
and anti-inflammatory cytokines is progressively impaired during decline of GFR. 
Patients with far-advanced CRF (GFR lower than 15 ml/min per 1.73 m2) were 
compared to patients with less-advanced CRF (GFR greater than 15 ml/min per 1.73 m2). 
mRNA abundance of TNF-alpha, IL-6 and IL-10 in circulating blood cells was determined in 
each group. TNF-alpha mRNA levels were greater in the patients with far-advanced CRF than 
in those with less-advanced CRF. IL-6  typology mRNA levels were not significantly 
different in the two groups.  Both groups of patients exhibited greater TNF-alpha and IL-6 
mRNA levels than the healthy controls. mRNA levels of the anti-inflammatory cytokine IL-
10 were greater in the patients with less-advanced CRF that in the healthy controls (table 
9.2.3.A.). These results suggest that a down regulation of expression of the anti-inflammatory 
cytokine IL-10 may contribute to the pronounced inflammatory status and cardiovascular risk 
associated with far-advanced CRF.  Nonetheless, in the patients with far-advanced CRF, IL-
10 mRNA levels were lower than in the patients with less-advanced CRF and not significantly 
different than in the healthy controls. Plasma concentrations of cytokine proteins were not 
significantly different in the two groups of patients with far-advanced or less-advanced CRF 
(Table 9.2.3.B.). Both groups of patients exhibited greater TNF-alpha concentrations than the 
healthy controls. IL-6 and IL-10 plasma concentrations were not determined in the healthy 
controls. Finally, a significant direct relationship (R=0.48, P=0.01) between glomerular 
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filtration rate and interleukine-10 mRNA levels in mixed blood cells of patients  with far- and 
less-advanced CRF was found.  
 
 
Table 9.2.3.A:  Plasma cytokine concentrations (pg/ml)  in patients  
with far- and less-advanced CRF. 
 (Bosutti et al., 2007a) 
 
 
 Far-advanced CRF Less-advanced CRF Healthy  Controls 
TNF-alpha  39±20 a 35±171a   6±1 b,c 
IL-6  3.2±0.4  3.7±1  - 
IL-10 13 ±6  6.7±3.9  - 
 
 
 
 
 
Table.9.2.3.B: Cytokine mRNA levels in mixed blood cells of patients  
with far- and less-advanced CRF. 
(Bosutti et al., 2007a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are mean±SD. ESRD: End stage renal diseases (creatinine renal clearance between 5 and 
13ml/min/1.73 m2); MS GFR: Moderate or severe low glomerular filtration rate (creatinine renal 
clearance between 15 and 37 ml/min/1.73 m2). Data are means±SEM; and are expressed as fraction of 
GAPDH mRNA. 
 
 
Mann-Whitney test: a, P<0.01, versus controls; b, P<0.05, versus ESRD; c, P<0.05, versus MS GFR; 
Far- and less-advanced CRF are defined by GFR (MRD2 equation) () lower or greater than 15 ml/min 
per 1.73 m2. Data are means±SEM;  Mann-Whitney test: a, P<0.05, versus controls; b, P=0.038, versus 
Far-advanced CRF c, P=0.001, versus Less-advanced CRF; Wilcoxon test:d, P=0.04, versus controls. 
 
 
 
 
 Far-advanced CRF Less-advanced CRF Healthy Controls 
TNF-alpha  35±5 a,c 14±3 a,b 3±1 b,c 
IL-6  476±301a 524±193 a 16±5 b,c 
IL-10 20±10 c  65±18a,b 12±2 c 
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9.3 Accelerated grade muscle atrophy: the hypercatabolic conditions.  
9.3.1. Mechanisms of skeletal muscle atrophy induced by acute stress 
 
Overexpression of the Elongation Factor 1A1 relates to muscle proteolysis and pro-apoptotic 
p66(ShcA) gene transcription in hypercatabolic trauma patients (Bosutti et al., 2007c) 
 
We were interested in analysing the gene expression in term of mRNA levels of the 
stress response protein p66(ShcA)  and its association with muscle depletion in human 
hypercatabolic condition. Despite the fact that  its over-expression is coupled with stress-
induced apoptosis (Migliaccio et al., 2006) and with muscle wasting and sarcopenia (Jiang X 
et al., 2003) its contribution in muscle atrophy induced by acute stress still remained to be 
fully deciphered.  Given that, the involvement of the two eEF1A protein products, i.e. 
eEF1A1 and eEF1A2, as pro-apoptotic and anti-apoptotic factors in muscle cells (Khalyfa et 
al., 2001), leads us to examine their relation with the p66(ShcA)   and some genes whose role in 
catabolic muscle was not yet fully elucidated.  
To this aim, we evaluated  the relationships between proteolysis and apoptotic response 
in  skeletal muscle of hypercatabolic trauma patients, by determining the mRNA levels of 
EEF1A2, EEF1A1, p66(ShcA)  and c-MYC genes in biopsy specimens, the protein levels of 
actin and tubulin, (both markers of cytoskeleton and sarcomeric disorganization) and the 
cleavage status of  PARP protein, (a known marker of apoptosis).  
Finally, the rates of muscle protein synthesis and degradation were determined as rate of 
intracellular phenylalanine disposal and appearance by the isotope dilution technique during 
primed-continuous infusion of L-[ring- 2H5] phenylalanine (Mass Trace, Woburn, MA), as 
previously described (Biolo et al., 2000b; Biolo et al., 2002; Biolo et al., 2003).  
We found that trauma patients were in catabolic condition, because the rate of muscle 
proteolysis significantly exceeded (P<0.05) that of protein synthesis (57±5 and 30±3 
nmol/min per 100 ml leg volume, respectively) (Figure 9.3.1.A.). By real time PCR we 
determined mRNA levels of the EEF1A1, EEF1A2, c-MYC and  stress response protein 
p66(ShcA)  , whose mean values in skeletal muscle of patients and controls are shown in Table 
9.3.1. We found that  mRNA levels of EEF1A1 and of EEF1A2  were significantly increased 
in traumatised patients. Nonetheless, the increase of EEF1A1 was much greater than that of 
EEF1A2. In addition, the  mRNA levels  of EEF1A2 were much greater than those of 
EEF1A1 in skeletal muscle of healthy controls. As evidenced in Table 9.3.1. trauma leads to 
an increase in the EEF1A2 mRNA content of 29 folds in respect to healthy conditions, but 
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also to the appearance of a more marked increase of the EEF1A1 transcript (165 folds). p66 
(ShcA)  mRNA levels were about 3 times greater in patients than in controls.  Mean c-MYC 
mRNA levels tended to be greater in patients, but no statistical significance was achieved.  In 
skeletal muscle of patients, mRNA levels of EEF1A1 and p66 (ShcA) directly correlated with 
the rate of proteolysis (Figure 9.3.1.B), previously evaluated (Biolo et al., 2000a; Biolo et al., 
2000b). Moreover, a direct relationship was found between p66 (ShcA) and EEF1A1 mRNA 
(R=0.89, P<0.01).  
Being non available a commercial antibody able to distinguish between eEF1A1 and 
eEF1A2 proteins, we performed western blotting analysis of total eEF1A content. 
Nonetheless,  the total content of eEF1A proteins resulted informative to gain insight on the 
protein level changes between healthy and trauma samples. As illustrated in Figure 9.3.1.C. 
(A: western blots; B-C: data quantification) cytoplasm total eEF1A proteins content tend to 
increase in trauma patients compared to healthy controls. Furthermore, to gain more insights 
about the possible connection between EEF1A and other potentially correlated genes involved 
in muscle catabolism, the PARP cleavage status, a known marker of apoptosis, as well as the 
levels of actin and tubulin, both markers of cytoskeleton and sarcomeric disorganization was 
evaluated. In trauma patients a decrease in total actin (p=0.008) and tubulin (p= 0.046) 
content, (Heling et al., 2000; Korb et al., 2004; Percipalle, 2007), was observed. The 
eEF1A/actin ratio was four times greater (P=0.02) in trauma patients (3.9±1.2) than in the 
controls (0.8±0.2).  An increased PARP cleavage, (Tolosa et al., 2005), was also observed in 
patients. 
We previously found a thigh relation between ubiquitin UBB and proteolysis (Figure 
9.3.1.D), in these patients (Biolo et al., 2000b). Notably, the ubiquitin UBB data  correlated 
with EEF1A1 mRNA levels (R=0.829; p<0.05), suggesting a molecular mechanism for the 
execution of apoptotic programs in acute muscle atrophy involving eEF1A1. It could be 
hypothesised that eEF1A1 contributes to ubiquitin-mediated protein degradation by 
transferring nascent proteins to the proteasome after their release from the ribosome. 
 Our previous observations pointed out that the lysosomal cathepsin B may be involved 
in muscle catabolic response in trauma patients (Bosutti et al., 1999; Bosutti et al., 2002). In 
fact, as we reported, mRNA levels of this protease were significantly increased in muscle 
biopsies from hypercatabolic trauma subjects (Bosutti et al., 2002). Cathepsin B enzyme 
activity resulted also greater in acute condition (Bosutti et al., 2002). These observations, 
prompt us to evaluate the relation between the here studied parameters and both cathepsin B 
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mRNAs and enzyme activity. We did not evidence significant relationships connected with 
cathepsin B (unpublished data). 
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Table 9.3.1: The fold increases in mRNA expression were calculated as ratio between  the mean of mRNA levels 
in skeletal muscle of individual patients and that of healthy controls. Data are expressed as means ± SEM. **, 
P<0.01 patients versus controls; *, P<0.05 patients versus controls. Ns: not statistical significance. 
  
CONTROLS 
 
TRAUMATIZED 
PATIENTS 
 
FOLD INCREASE 
 IN mRNA LEVELS 
 
(Traumatized patients/healthy 
controls) 
  
EEF1A1 
 
0.6±0.4 
 
81.4±35.0** 
 
165±87 
 
EEF1A2 
 
 
7·104±4·104 
 
215·104±63·104** 
 
29±15 
 
P66(ShcA) 
 
72±20 
 
 
211±53* 
 
2.9±2.6 
 
C-MYC 
 
313±166 
 
985±437 
 
 
3.1±2.6ns 
Muscle mRNA levels of EEF1A1, EEF1A2, p66 (ShcA) and  c-MYC  
in trauma patients and healthy controls (Bosutti et al., 2007c). 
Figure 9.3.1.A: Rates of protein synthesis and degradation and rate of net catabolism,  
In leg skeletal muscle of trauma patients 
(Bosutti et al.,2007c) 
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Figure 9.3.1.B:. Relationships between EEF1A1 or p66 (ShcA) mRNA levels  
and the rate of muscle proteolysis  
 
(Bosutti et al., 2007c) 
 
 
R=0.826; p<0.05 
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Figure 9.3.1.C: Protein contents of eEF1A, cleaved PARP and actin in skeletal muscle of patients and healthy 
controls. A) In lane 1 a representative control (with an average band intensity for each protein probed) is 
reported; in lanes 2-7 trauma patients samples are shown. B-C) is reported  the data quantification of eEF1A, 
actin and tubulin protein contents expressed as ratio to GAPDH protein levels.  
Data are reported as means ± SEM (Bosutti et al.,2007c).
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R=0.753; p<0.05 
Relationships between Ubiquitin UBB mRNA levels 
and the rate of muscle proteolysis  
Ubiquitin mRNA levels  were quantified by quantitative-competitive PCR  and expressed as fraction of 
GAPDH mRNA contents. 
 
(Biolo  et al.,  2000a) 
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10. DISCUSSION 
 
10.1 Skeletal muscle atrophy in healthy conditions. Interaction between energy restriction 
and muscle unloading in the regulation of lean body mass, protein kinetics or inflammatory 
response in healthy subjects 
10.1.1 Calorie restriction accelerates the catabolism of lean body mass during 2 wk of 
bed rest (Biolo  et al., 2007). 
 
Muscle inactivity is commonly associated with spontaneous or enforced reduction in the 
nutrient intake in persons with acute or chronic diseases, in astronauts during space flight, and 
during aging (Ritz and Elia, 1999b). Decreased energy intake is the major cause of negative 
energy balance in patients, because the frequent disease-mediated elevation in the resting 
metabolic rate is overridden by inactivity (Ritz and Elia, 1999b).  
We have hypothesized that a hypocaloric diet would be more catabolic in the bed rest 
state than in the ambulatory condition. The combination of reduced physical activity and 
negative energy balance would accelerate the loss of LBM in healthy subjects through 
changes in whole body  protein kinetics, as assessed by using stable isotopes of amino acids. 
Subjects were studied 4 times at the end of 14-d periods of any combination of normal 
physical activity or strict bed rest with adequate energy intake or hypocaloric nutrition (see 
table 8.1). Energy intake was individually tailored to account for the decrease in energy 
requirement during bed rest and then decreased by ~20% during the hypocaloric periods. This 
investigation was conducted within the frame of the Short-Term Bed Rest Study of Integrated 
Physiology (STBR-IP) set up by the German Aerospace Institute (DLR) and the European 
Space Agency. Results relative to the bed rest period in eucaloric conditions were previously 
reported (Biolo et al., 2004).  At the beginning of each examination period, resting energy 
expenditure (REE) was calculated for each individual according to the FAO/WHO equations 
(Muller et al., 2004). 
In the four study phases, energy intake was carefully tailored to the REE of individual 
subjects and to their level of physical activity. During bed rest in eucaloric conditions, energy 
intake was ≈21±1% lower than that during the ambulatory period in eucaloric conditions. 
Achievement of an energy balance throughout the 2 eucaloric experimental periods was 
shown by the fact that the body weight and fat mass of subjects did not change significantly 
during either the bed rest or the ambulatory condition. During the 2 hypocaloric periods, 
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energy intake was 18±2% and 15±2% lower than that during the corresponding eucaloric 
periods in the bed rest and ambulatory conditions. The periods of bed rest in the hypocaloric 
condition led to the greatest decrease in energy intake (i.e., 34 ± 1% lower than that in the 
ambulatory eucaloric period). The negative energy balance of subjects was clearly shown by 
the fact that their fat mass significantly decreased by ≈8% in both the bed rest and ambulatory 
conditions. Energy balance did not differ significantly during the hypocaloric period between 
the ambulatory and the bed rest conditions. In fact, with an assumption of an energy density 
for fat and lean mass of 8192 and 800 kcal/kg, respectively, changes in body composition 
accounted for a negative energy balance of 8603 ± 2489/14 d and 9037 ± 1993 kcal/14 d (P= 
0.87) during the hypocaloric period in the ambulatory and bed rest conditions, respectively. In 
addition, during the hypocaloric period in bed rest, the subjects lost ≈2% of their LBM.  
DXA analysis shown that bed rest with hypocaloric nutrition led to the greatest wasting 
of LBM (Table 9.1.1.A). Our results indicate that physical inactivity in conditions of negative 
energy balance may lead to a rapid loss of LBM and that such catabolic effects can be 
prevented, at least in the short term, by a moderate level of physical activity. Previously, 
Biolo et al., demonstrated that a blunted amino acid–induced stimulation of protein synthesis 
is the main catabolic mechanism associated with short-term inactivity in eucaloric conditions 
(Biolo et al., 2004). This observation suggested that, during physical inactivity, a greater 
protein intake may counteract the postprandial defect in amino acid utilization (Biolo et al., 
2004). In here analysed data, whole-body kinetics of the stable isotope of leucine indicated 
that the mechanisms of such accelerated protein loss involved an increased net protein 
catabolism in the post absorptive state combined with an impaired amino acid–mediated 
stimulation of protein synthesis in the fed state. Moreover, such negative changes in lean body 
mass during the combination of hyponutrition and bed rest were significantly greater than 
those observed during hyponutrition in ambulatory conditions or during bed rest in eucaloric 
conditions (Table 9.1.1.A).  
Such a hypothesis was confirmed in a study showing that supplementation with 
essential amino acids maintained muscle protein synthetic capacity and ameliorated muscle 
loss during 28 d of bed rest (Paddon-Jones et al., 2004). Nonetheless, that study had a dietary 
caloric content that was sufficient to contribute to an increase in whole-body fat mass during 
bed rest, which suggests a positive energy balance throughout the experimental period. It 
remains to be shown whether such anticatabolic effects of increased amino acid availability in 
hypercaloric conditions during bed rest are also observed in eucaloric conditions or even 
during a hypocaloric diet. In such controlled conditions, we have shown that bed rest–
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mediated impairment of protein anabolism in the fed state is quantitatively not different in the 
eucaloric and hypocaloric conditions. Despite the fact that energy intake varied during the 4 
experimental periods, daily protein intake remained constant at 1 g protein/kg body wt.  
During the 2 hypocaloric periods, energy restriction was achieved through decreases in 
carbohydrate and lipid intake.  As expected, energy restriction in ambulatory conditions did 
not lead to significant alterations in whole-body protein kinetics. In contrast, we found that 
the combination of bed rest and calorie restriction led to a greater rate of leucine oxidation, as 
a marker of net protein catabolism, and to less nonoxidative Rd, as a marker of protein 
synthesis, in the post absorptive state (Table 9.1.1.B). Decreased energy intake is the major 
cause of negative energy balance in these subjects. On the other hand, hypocaloric dieting is 
also widely prescribed to overweight subjects to treat the metabolic syndrome and to prevent 
complications of obesity.  In these persons, loss of body fat is usually accompanied by a 
decrease in lean mass (Gallagher et al., 2000). In contrast, exercise training during calorie 
restriction may preserve lean mass while further reducing fat mass (Ross et al., 1995).  
Notably,  stress mediators, such as cortisol and adipocytokines (leptin), may further 
amplify the catabolic response of LBM to inactivity and hyponutrition, as well as undermine 
vascular function (Ferrando et al., 1999; Paddon-Jones et al., 2004). Given that  energy 
restriction can reduced inflammatory burden, we hypothesised that moderate energy 
restriction may prevent activation of inflammatory markers induced by inactivity, and may 
decreased the cardiovascular risk. We also hypothesised that the long pentraxin PTX3 (a 
novel potential marker of vascular dysfunction and atherosclerosis) and the leptin  may  
trigger this response. To test this hypothesis we evaluated  the interaction between energy 
restriction, muscle unloading and the gene expression of some markers and mediators of 
inflammation, including the long pentraxin PTX3 and plasma levels of leptin, in the previous 
(Biolo et al., 2007) described bed rest study. 
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10.1.2 Calorie restriction prevents inactivity-induced systemic inflammatory response: 
evidence for inverse regulation of CRP and PTX3 by energy balance (Bosutti et al.,  2007 
JCEM submitted) 
 
The effects of the interaction between prolonged muscle inactivity and reduced energy 
intake on some markers and mediators of the systemic inflammatory response were 
investigated. We found that hypocaloric diet was the only factor rescuing the inflammatory 
state produced by bed rest, plausibly by reducing body fat mass.  
Several studies have shown that calorie restriction and loss of fat mass are associated 
with anti-inflammatory effects at different levels of the inflammatory cascade (Chung et al., 
2001a). First, calorie restriction and loss of fat have additive affects in suppressing leptin 
production at the level of adipose tissue (Trujillo and Scherer, 2006). Second, there is a 
decrease in pro-inflammatory cytokine production in adipose tissue mainly from stromal and 
vascular components (Trujillo and Scherer, 2006). Finally, changes in adipose tissue may 
directly or indirectly modify systemic inflammatory response which includes hepatic 
production of CRP (Trujillo and Scherer, 2006). These events could explain the close direct 
correlation observed between leptin and CRP concentrations in this and in other study 
(Somech et al., 2007). 
In addition to the regulatory action of fat mass and energy intake, leptin secretion is 
influenced also by physical activity. Its plasma concentrations are reduced by exercise 
training (Kraemer et al., 2002a). Recent evidence shows direct stimulatory effect of bed rest 
on leptin production (Blanc et al., 2000). In the present study, multiple regression analysis 
indicate that fat mass and energy intake independently explained 86% of leptin concentration 
variance among subjects in the different study phases. In order to determine the effect of bed 
rest, values of plasma concentrations of this hormone were normalized by units of fat mass and 
of energy intake (Figure 9.1.2.B). Results indicated that bed rest in eucaloric conditions 
significantly increased normalized leptin concentration values whereas such effect was not 
observed in hypocaloric conditions (Figure 9.1.2.B). Such bed rest mediated effect on leptin 
concentration was paralleled by changes in CRP concentrations (Table 9.1.2.B). We may 
speculate, therefore, that, at any given level of body fat mass, changes in leptin secretion 
secondary to changes in energy intake or physical activity could have contributed to up- or 
down-regulation of systemic inflammation. Moreover, leptin variability throughout the four 
experimental phases (in response to changes in activity, fat mass, energy intake and balance) 
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independently predicted individual CRP levels, supporting the concept that this adipose tissue 
hormone is a link between energy metabolism and inflammation This view is also supported 
by the direct relationships between nutritional indexes (fat mass, changes in fat mass, energy 
intake and insulin concentrations) and leptin concentrations observed in the present study 
(Table 9.1.2.B).  
Leptin, is a critical fat-derived cytokine-like hormone, which provides an important 
signal of energy status that contributes directly to the regulation of food intake and energy 
expenditure. By multiple regression analysis, we found that at any given level of body fat 
mass, changes in leptin secretion secondary to changes in energy intake or physical activity 
could have contributed to up- or down-regulation of systemic inflammation (Table 9.1.2.B). 
Otherwise, changes in pro-inflammatory cytokine expression may also induce leptin synthesis 
and release, i.e. in adipose tissue (Grunfeld et al., 1996). On the other hand, exercise training 
with weight loss may  reduced concentrations of pro-inflammatory cytokines in adipose 
tissue, while could increased them in skeletal muscle. We suppose also that muscle unloading  
may increase inflammation in adipose tissue, by reducing the mobilization of immune cells 
producing inflammatory mediators in skeletal muscle (Gomez-Merino et al., 2007).  
In this study,  we evidenced also  some discrepancies concerning changes in levels but 
not in mRNA of some cytokines (is seen for IL-6, and the opposite pattern, changes in mRNA 
but not levels observed for IL-10). It is known,  the mRNA transcripts reflected cytokine 
expression potential in blood cells, while different tissues simultaneously contributed to 
plasma cytokines concentrations (blood cells, endothelium, fat tissue, gut, muscle, etc.). 
Therefore, we can speculate that some  discrepancies may stem from differential regulation of 
cytokine expression in various tissues. Here, we studied a selected population of healthy, 
young, male volunteers. The gender, age or  disease state, but also genetic or environmental 
factors, such as cytokine polymorphisms, could either enhanced or down-regulated such bed 
rest effects on inflammatory response (Biolo et al., 2006a; El Yousfi et al., 2005; van Eijk et 
al., 2007). To clearify this intringuing point, we calculated the ratio between IL-6 and IL-10 
mRNA or cytokines levels. We found that the IL-6 to IL-10 ratios in plasma and cell mRNA 
transcripts increased to similar extent following bed rest (Table 9.1.2.A), suggesting that the 
unbalanced expression of pro- and anti-inflammatory cytokines may involve blodd cells and 
other tissues.     
We also provided evidence that, bed rest increased PTX3 plasma concentration. 
Moreover, IL-10 plasma level appeared to be an independent determinant in PTX3 variability 
(Table 9.1.2.C). PTX3 is an acute phase reactant structurally related but distinct from CRP 
 134 
 
 
(Kraemer et al., 2002a). PTX3 over-expression associated with increased systemic 
inflammation or involved in termination of an acute inflammatory response (Introna et al., 
1996; Latini et al., 2004). PTX3 is produced either from endothelial cell, skeletal muscle, 
macrophages, but also from adipocytes in response to TNF-alpha (Abderrahim-Ferkoune et 
al., 2003). TNF-alpha expression in adipose tissue increases during long-term positive energy 
balance and correlates with fat cell size (Chung et al., 2001a). Nonetheless, experimental 
evidence also suggests that TNF-alpha may serve as a short-term physiologic regulator of 
certain metabolic processes in adipose tissue acting with autocrine and paracrine mechanisms 
(Chung et al., 2001a). In vivo evidence in humans indicates that acute changes of adipose 
tissue lipolysis induced by fasting and meal ingestion as well as by adrenergic stimulation are 
closely and directly associated with local TNF-alpha production (Orban et al., 1999).  
 Furthermore, individual values of PTX3 inversely correlated with changes in fat 
mass and leptin levels. Intriguingly, nutrient intake and decreases in body fat affected in 
opposite directions both CRP and PTX3 plasma levels. While a direct association between 
CRP and body fat changes was expected, the inverse relationship between PTX3 and body fat 
decreases represents a novel finding. Possibly, in addition to inactivity, nutritional factors and 
body composition may play a role in regulation of this acute phase reactant. We may  
speculate that the direct relationship between changes in fat mass and PTX3, might be 
mediated by a paracrine mechanisms, by changes in lipolysis and TNF-alpha secretion from 
adipose tissue (Orban et al., 1999; Trujillo and Scherer, 2006). Moreover, the association 
between negative energy balance and increases in PTX3 levels could be mediated by 
increases in expression of anti-inflammatory cytokines, like IL-10, in circulating cells or in 
adipose tissue (Skurk et al., 2007). 
In conclusion, this preliminary study suggests that calorie restriction can prevent bed 
rest-mediated activation of IL-6 and CRP inflammatory mediators, possibly by reducing body 
fat mass contents. Moreover, the direct association between muscle unloading and the 
synthesis of the long pentraxin PTX3,  prompted us to speculate about a  novel mechanistic 
explanation of the effects of  prolonged muscle inactivity on cardiovascular function, at least 
in part, mediated by PTX3 gene expression.  In spite, our study suggests that energy 
restriction may improve cardiovascular function, by reducing inflammatory milieu, an 
inadequate energy intake may also accelerate the loss of lean body mass in bedridden persons 
and this alteration may rapidly lead to severe malnutrition. Thus, our study emphasizes the 
necessity of combating a sedentary lifestyle and of combining the prescription of exercise 
training with calorie restriction for instance in the treatment of obesity or other chronic 
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pathological conditions. In which, the nutrition of patients should be optimized by matching 
energy requirements with nutrient intake via either enteral or parenteral routes.  
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10.2 Low grade-muscle atrophy: the chronic catabolic conditions.  
10.2.1 Relationships between cardiovascular risk and inflammatory response at whole body 
and adipose tissue levels in cardiovascular–patients  
 
Relation between the plasma levels of LDL-cholesterol and the expression of the early marker 
of inflammation long pentraxin PTX3 and the stress response gene p66 (ShcA) in pacemaker 
implanted patients. (Bosutti et al., 2007b) 
 
 The relevance of the lipid profile with regard to the up-regulation of genes involved in 
inflammation and oxidative stress responses, has long been recognized (Metzler et al., 2000; 
Napoli et al., 2001). Our goal was to explore the possible relation between the expression of 
p66(ShcA) and PTX3, two emerging regulators of stress response and inflammation processes, 
respectively,  and a marker of cardiovascular risk, the circulating levels of LDL-cholesterol,  
in a well recornized inflammation and oxidative-stress associated diseases such as 
cardiovascular disease. This investigation prompted us to speculate about a novel link 
between some bed-rest effect on vasculature or cardiovascular risk, at least in part involving 
the long pentraxin PTX3. 
The p66 (ShcA)  and PTX3 mRNA contents were determined locally, in subcutaneous 
adipose specimens of non diabetic pacemaker implanted patients, and systemically, in the 
circulating white blood cells (WBC), obtained from the same patients. The mean of the 
circulating LDL levels (125 mg/dl) was chosen as a threshold to identify two groups here 
considered to have high (> 125 mg/dl) and low (<125 mg/dl) LDL plasma levels. 
The PTX3 and p66 (ShcA) mRNA levels were significantly more elevated in WBCs and in 
adipose tissue samples of patients with high levels of  LDL. Additionally, a multiple 
regression analysis indicates that among LDL, TG, HDL, total cholesterol, CRP, creatinine 
and glucose levels, the only variable significantly affecting p66(ShcA) and PTX3 mRNA 
expressions either in adipose tissue or in WBCs was represented by the circulating amount of 
LDL.  
PTX3 has been proposed to be a local marker of vascular inflammation and plaque formation 
(Introna et al., 1996; Rolph et al., 2002) and its strong prognostic significance of 3 months 
mortality has been recognized (Latini et al., 2004).  In vitro studies  suggested that PTX3 may 
be implicated in the pro-inflammatory effect induced by atherogenic LDL lipoproteins. In 
particular, it has been shown that human vascular smooth muscle cells cultivated in the 
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presence of atherogenic LDL display a dose dependent increase in the expression of PTX3 
(Klouche et al., 2004). We now observe in vivo that patients with high (>125 mg/dl) levels of 
LDL, display significantly higher PTX3 mRNA levels in WBC cells (p=0.01, figure 9.2.1.A). 
Additionally, we further extend this observation to the adipose tissue where we show a 
significant increase in PTX3 mRNA levels in patients with high LDL plasma levels (p=0.01, 
figure 9.2.1.A). Additionally, the reported relation between LDL and PTX3 expression in 
WBCs and in adipose tissue indicates a novel link through which LDL may be connected to 
inflammation mediators (Table 9.2.1.). The understanding of the mechanisms ruling this 
biological phenomenon, i.e. whether in vivo there is a cause effect relation, deserves further 
investigation. A previous study indicated that the gene expression level of p66 (ShcA) increases 
in PMBCs of subject affected by type 2 diabetes, the most common oxidative stress-related 
disease (Pagnin et al., 2005). As these patients typically have high LDL plasma levels, we 
decided to verify whether p66 (ShcA) increased expression only attains to the diabetic disease or 
other isolated variable such as LDL plasma levels could contribute to this phenomenon. Our 
data, obtained in non-diabetic patients, indicate that p66 (ShcA) gene expression in WBCs is 
related to the LDL levels (Figure 9.2.1.B) and that this relation holds true also in the adipose 
tissue (Figure 9.2.1.B). This observation suggests a connection between LDL and the 
expression of p66 (ShcA) which, together with the diabetic status may concur to the 
maintenance of oxidative stress (Table 9.2.1). As mentioned for PTX3, the understanding of 
the mechanisms ruling this biological phenomenon, deserves further investigation. It is known 
that oxidative and inflammatory mediators can interact (Abderrahim-Ferkoune et al., 2003) 
through mechanisms which are only in part understood. Here we strength this concept, 
providing in vivo evidence of a possible common connection for the marker of inflammation 
PTX3 and for the oxidative stress response gene p66(ShcA) to the circulating levels of LDL. 
Additionally, the observed correlation between the mRNA levels of PTX3 and p66(ShcA) in the 
adipose tissue and in WBC, further points towards a possible combined action of these two 
genes (Figure 9.2.1.C). Moreover, the fact that the relation among PTX3/ p66(ShcA)  mRNA 
contents and the circulating levels of LDL holds true both in WBCs and in adipose tissue, is in 
favour of a systemic (WBCs) and local effect (adipose tissue) of LDL plasma levels on 
inflammation and oxidative cascade of events.   
 The medical treatments followed by the patients enrolled were not stopped before 
WBCs and adipose tissue harvesting. Thus, in principle, this variable, together with the  
underlying cardiovascular pathology, the levels of TG, HDL, total cholesterol, CRP, 
creatinine and glucose, could have affected the presented results. However, the only 
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statistically significant correlation (Table 9.2.1) was observed between LDL serum levels and 
the expression levels of PTX3 and p66(ShcA).  Whereas we cannot exclude that an additional 
unknown variable might  contribute to the control of PTX3 and  p66(ShcA)  expression levels, 
our data strongly point towards a relevant role of LDL serum levels in the induction of  these 
genes. 
In conclusion, here we propose the relation between LDL and the expression of the 
local inflammatory mediator PTX3 and the stress-response gene p66 (ShcA). Our data suggest 
that increased plasma levels of LDL may favour the expression of PTX3 and p66(ShcA) both 
locally (adipose tissue) and systemically (WBCs), suggesting a possible novel link between 
two mediators of inflammation/oxidative stress and the lipid profile. We believe that this 
observation can contribute to further understand of the pathogenesis of oxidative-stress and 
inflammation related diseases such as atherosclerosis.  
 
 
10.2.  Low grade-muscle atrophy: the chronic catabolic conditions.  
 
10.2.2 Contribution of cytokine genotypes on inflammation and cardiovascular risk in chronic 
renal failure 
 
Association of interferon-gamma 1874A polymorphism with reduced long-term inflammatory 
response in haemodialysis patients (Biolo et al.,200 a) 
 
Haemodialysis is associated with a low-grade systemic inflammation that reflects the 
unbalanced expression of pro- and anti-inflammatory cytokines and contributes to the 
progression of atherosclerotic vascular disease and malnutrition. CRP is one of the best 
indicators of the response to inflammation. Elevated CRP levels have been described in a 
significant proportion of chronically uremic patients undergoing haemodialysis and were 
significantly associated with malnutrition, and morbidity and mortality for cardiovascular 
disease.  Cytokine expression and production is, in part, genetically determined, which leads 
to a considerable inter-individual variability in the degree of systemic inflammatory 
activation. To a better understanding of the influence of cytokine genetic variability in the 
degree of systemic inflammation, we evaluated the relative influence of a specific IFN-
gamma polymorphism on the 2-year CRP response in a group of chronic haemodialysis 
patients. We also studied the effects of IFN-gamma polymorphism on gene transcriptions of 
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several pro- and anti inflammatory cytokines including IFN-gamma. Since, cytokine serum 
levels do not accurately reflect rate of expression during haemodialysis, the expression of 
cytokine genes has been evaluated at the level of individual cytokine mRNA content in 
circulating blood cells. 
We found that the presence of the +874 A/A IFN-gamma polymorphism, or the IFN-
gamma ‘low-producer’ genotype, was associated with the greatest preventive effect on CRP 
elevation.  In these  IFN-gamma ‘low-producer’ patients the frequency of abnormally elevated 
CRP over 2 years averaged only 37%, whereas in the ‘high and intermediate-producer’ groups 
this feature was similar to that of the entire haemodialysis population, i.e. 57%. In the IFN-
gamma high-and intermediate-producer genotype patients mean mRNA levels of IFN-gamma 
were 27 and 14 times greater than in the low-producer patients. IFN-gamma is a principal 
mediator of innate as well as adaptive immunity (Rossouw et al., 2003). In addition to the 
pivotal role of IFN-gamma in host defence, its excessive release has been associated with 
chronic inflammation (Rossouw et al., 2003). Among the biological activities of IFN-gamma, 
is of key importance the up-regulation of a variety of pro-inflammatory mediators including 
IL-6 (Striz et al., 2000). In fact, our IFN-gamma ‘low-producer’ patients exhibited parallel 
reductions of mRNA levels of both IFN-gamma and IL-6. This suggests that the effect of the 
IFN-gamma ‘low producer’ genotype on frequency of CRP elevation could have been 
mediated, at least in part, by modulation of IL-6 expression (Striz et al., 2000). 
The rapid kinetics of CRP metabolism appears to be closely parallel to the degree of 
inflammation. Nonetheless, even in periods free of clinical events, microinflammation and 
CRP levels fluctuate in time, in haemodialysis patients (Tsirpanlis et al., 2004). In order to 
reduce longitudinal variability within subjects, we have monitored serum CRP level every 
month in a cohort of clinically stable uremic patients on haemodialysis that underwent 
prospective follow-up for 2 years. The overall level of systemic inflammation was then 
expressed as fraction of altered CRP values over the total number of determinations. The 
percentage of altered CRP individual value exhibited a great interindividual variability and 
the average value of this indicator of overall 2-year inflammatory response was 54% (the 
median was equal to 53%) with a coefficient of variation of 60%. Seven of the 102 patients 
followed in this study always exhibited normal serum CRP concentrations during the 2-year 
observation, whereas serum CRP was always found abnormal in 13 of the patients even in the 
absence of intercurrent infections. 
Evidence indicates that elevated CRP concentrations may be directly involved in the 
initiation and progression of atherosclerosis (Lagrand et al., 1999), particularly in patients 
 140 
 
 
with more frequent elevation of CRP such as those on haemodialysis (Tsirpanlis et al., 2004).  
It remains to be determined whether this marker of inflammation actually has a causal relation 
with cardiovascular disease or simply reflect the underlying disease process.  
Recent studies have identified a synergistic interaction between CRP and IFN-gamma 
on the pathogenesis of coronary atherosclerosis and its acute complications (Nakagomi et al., 
2000). The present study underlines that IFN-gamma gene polymorphism is one determinant 
of CRP levels in haemodialysis patients, and a significant portion of such CRP variability 
may be explained by IFN-gamma polymorphisms. We may predict therefore that IFN-gamma 
gene polymorphism could also influence cardiovascular risk and mortality in these patients. 
The annual mortality rate for the haemodialysis patients was 9.8%. There was no significant 
difference in mortality between patients with different IFN-gamma genotypes. Nonetheless, 
the annual mortality rate tended to be lower in the patients with the ‘low producer’ IFN-
gamma genotype (7.6%) than in the patients with the ‘high-producer’ IFN-gamma genotype 
(13.6%). 
In our study the observation period was too short and the number of patients was 
insufficient to accurately assess the effect of IFN-gamma genotypes on mortality rate. A 
further study with an appropriate experimental design will be needed to test the hypothesis 
that the‘low-producer’ IFN-gamma ±874 A/A genotype is associated with a lower risk of 
cardiovascular and/or all-cause mortality in haemodialysis patients, and to evaluate the 
relationship between IFN-gamma ±874 A/A genotype and muscle architecture in these 
patients. Further studies with  the analysis of the muscle cross-sectional area by MRI axial 
images and the measurement of the muscle thickness by ultrasonography may help us to clear  
the link between cytokine genotypes or CRP  variability on muscle mass loss in this 
inflammatory condition (Pavy-Le Traon et al., 2007).  
Recent issues  have clearly established that IL-10 genotype strongly influences the CRP 
variation range (Perianayagam et al., 2005). By limiting the inflammatory activation in end-
stage renal disease patients, the ‘high-producer’ IL-10 genotype is associated with a lower 
risk of cardiovascular disease and even mortality (Perianayagam et al., 2005). The main 
function of this cytokine is to keep under strict control the inflammation by adjusting the 
intensity of the immune and inflammatory responses, providing the final shut-down of the 
inflammation. IL-10 provides an efficient mechanism for limiting the expression of a broad 
range of pro-inflammatory factors including IL-6, INF-gamma and TNF-alpha. In chronic 
inflammatory conditions, a defective synthesis of IL-10 directly contributes to increase IL-6 
and other pro-inflammatory cytokines and is permissive for frequent elevations of acute phase 
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proteins. In spite, we did not observed significant changes in mRNA levels of this cytokine 
among the three INF-gamma genotype groups, our study suggests that, in addition to the 
‘high-producer’ IL-10 genotype, a ‘low-producer’ IFN-gamma genotype may downregulate 
the inflammatory activation in dialysis patients and, possibly, cardiovascular risk. 
In conclusion, we have shown that the interindividual variability in the degree of 
systemic inflammatory response activation exhibited by haemodialysis patients is in part 
explained by polymorphisms of the IFN-gamma gene, whereas the IFN-gamma ‘low-
producer’ genotype was associated with the greatest preventive effect on CRP elevation. 
These results suggest that patients with IFN-gamma ‘low-producer’ genotype may be 
relatively protected from the risk of developing cachexia and cardiovascular disease 
associated to the uremic syndrome. In addition, we may speculate that the treatment of severe 
inflammation in haemodialysis patients should be also targeted towards down regulation of 
the IFN-gamma gene. 
 
 
10.2.  Low grade-muscle atrophy: the chronic catabolic conditions.  
10.2.3. The inflammatory milieu and organ failure 
 
Decreased IL-10 mRNA expression in patients with advanced renal failure undergoing 
conservative treatment (Bosutti et al.,  2007a) 
 
Chronic renal failure is characterised by persistent systemic inflammatory response and 
malnutrition (muscle atrophy). We tested the hypothesis that the balance between synthetic 
capacity of pro-inflammatory, as TNF-alpha and IL-6, and anti-inflammatory cytokines, as 
IL-10, may become progressively impaired during decline of renal function and this may 
affect body composition in CRF patients on conservative therapy. Patients with far-advanced 
CRF (GFR lower than 15 ml/min per 1.73 m2) were compared to patients with less-advanced 
CRF (GFR greater than 15 ml/min per 1.73 m2). Patients with less-advanced CRF exhibited 
parallel increases of  TNF-alpha,  IL-6 and IL-10 mRNA transcript levels. In contrast, the 
patients with far-advanced impairment of renal function were characterized by further 
increases of TNF-alpha, no changes in IL-6, but decreases in IL-10 transcript expression. 
These results suggest that a down regulation of expression of the anti-inflammatory cytokine 
IL-10 may contribute to the pronounced inflammatory status and cardiovascular risk 
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associated with far-advanced CRF.  No differences in BMI index between the two patient 
groups were evidenced. 
Despite the fact that we showed opposite effects of progression of CRF on TNF-alpha 
and IL-10 mRNA transcript levels, our patients with far-advanced and less-advanced CRF did 
not exhibit significant differences in plasma concentrations of TNF-alpha and IL-10 proteins.  
Concentrations of both cytokines tended to increase in the far-advanced CRF group without 
achieving statistical significance. This was expected on the basis that GFR is a major 
determinant of plasma cytokine concentrations. The kidney is the main site of metabolic 
clearance of most cytokines (Poole et al., 1990). Thus, in CRF patients, cytokine synthetic 
capacity is better represented by mRNA levels than by plasma concentrations of these 
mediators. In addition, plasma concentrations of cytokines do not represent their tissue actions 
which are mostly regulated by paracrine and autocrine mechanisms.  The inflammatory 
reaction triggers simultaneously the synthesis of a number of cytokines with pro-
inflammatory and anti-inflammatory properties. Anti-inflammatory mediators, as IL-10, are 
efficiently secreted to prevent excessive activation of the pro-inflammatory ones, as TNF-
alpha and IL-6. As expected, our patients with less-advanced CRF exhibited a systemic 
inflammatory response that included activation of both pro-inflammatory and anti-
inflammatory cytokines (Stenvinkel et al., 2005a). IL-6 mRNA increased by more than  30 
times, whereas TNF-alpha and IL-10 transcript levels increased in parallel by about 5 times 
with respect to the values observed in a group of age-matched healthy controls. This suggests 
conservation of the feedback control system between TNF-alpha and IL-10 in less advanced 
kidney failure.  In contrast, an imbalance in the expression of TNF-alpha and IL-10 was 
observed in the patients with far-advanced renal failure suggesting a defective feedback 
inhibition of proinflammatory cytokine production. Our results are in perfect agreement with 
a previously reported impaired IL-10 synthesis by monocytes exposed to a uremic 
environment (Perianayagam et al., 2005). In this context, anti-oxidants restored IL-10 
synthetic capacity (Perianayagam et al., 2005), suggesting that oxidative stress and 
mitochondrial dysfunction could be responsible or down-regulation of IL-10 synthesis in 
advanced uraemia.  
Several studies indicate that IL-10 plays a key role in the pathogenesis of cardiovascular 
disease (Girndt and Kohler, 2003). Besides controlling synthesis of proinflammatory 
cytokines, IL-10 down-regulates production of molecules involved in atherosclerotic plaque 
formation, such as metalloproteinases and adhesion molecules (Girndt and Kohler, 2003). An 
anti-atherogenic effect of IL-10 is confirmed by in vivo findings. There are IL-10 gene 
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polymorphisms that are relevant for cytokine production. The G→A base-exchange at 
position –1082 in the promoter of the gene is associated to decreased IL-10 synthesis (Girndt 
et al., 2002). This polymorphism turned out to be highly predictive for cardiovascular events 
in chronically uremic patients on haemodialysis (Girndt et al., 2002). Our data suggest, 
therefore, that the association between advanced CRF and greater frequency of cardiovascular 
events could be explained, at least in part, by decreased IL-10 synthetic capacity. In 
conclusion, our study shows that advanced renal failure is characterized by unbalanced 
synthetic capacity of pro- and anti-inflammatory cytokines.  
A progressive decrease in IL-10 synthetic capacity during the course of chronic renal failure 
could contribute to increasing cardiovascular risk in these patients. 
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10.3. Accelerated grade muscle atrophy: the hypercatabolic conditions.  
10.3.1 Mechanisms of skeletal muscle atrophy induced by acute stress 
 
Overexpression of the Elongation Factor 1A1 relates to muscle proteolysis and pro-apoptotic 
p66(ShcA) gene transcription in hypercatabolic trauma patients (Bosutti et al., 2007c) 
 
Systemic stress response and muscle wasting are common features in severely 
traumatized patients. The rate of muscle proteolysis is greatly accelerated and not balanced by 
the rate of protein synthesis (Biolo et al., 2002). Several studies have indicated that muscle 
catabolism is associated with an increased expression and activity of critical components of 
proteolytic and apoptotic systems (Du et al., 2004) Close relationships between proteolytic 
pathways and apoptotic response in human skeletal muscle have been demonstrated (Mansoor 
et al., 1996; Du et al., 2004). However, the molecular mechanisms underlining these 
processes remain to be elucidated. 
In our study we found that the level of EEF1A1 mRNA was dramatically increased in 
our patients by 165 folds and directly correlated with the rate of proteolysis suggesting a 
production of eEF1A1 as a response to trauma (Borradaile et al., 2006). A more contained 
increase in EEF1A2 levels (29 folds) was also observed. Moreover, in trauma patients the 
eEF1A total proteins content tended to be greater than in healthy controls. Based on the 
mRNA and protein data we hypothesise that the trauma induced the de novo synthesis of 
eEF1A1 to exploit its non-canonical functions such as protein degradation and apoptosis 
triggering (Ruest et al., 2002). In contrast, eEF1A2 level was less affected, probably because 
eEF1A2 is just required as translation factor. The modest increase in EEF1A2 mRNA level in 
critically hypercatabolic patients might be a consequence of the attempt to sustain muscle 
survival maintaining or increasing the protein synthesis rate (Biolo et al., 2002). We observed 
that the trauma induced a decrease in total actin and tubulin level suggesting a cytoskeleton 
and sarcomeric disorganization (Percipalle, 2007). Moreover, since actin may have a critical 
role in ensuring translation fidelity (Kandl et al.,2002), its decrease might further contribute to 
increase the frequency of translation errors in trauma muscle, thus stimulating eEF1A1 
coupled-proteosome degradation of damaged proteins (Attaix et al., 2005; Duttaroy et al., 
1998; Kandl et al., 2002). This observation is consistent with the fact that the ratio 
eEF1A/actin was four times greater in patients than in controls.   It is possible that in muscle 
cells eEF1A1 may contribute to the ubiquitin-mediated protein degradation by transferring 
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damaged nascent proteins to the proteasome after their release from the ribosome. In our 
patients, muscle p66 (ShcA) mRNA levels directly correlated with EEF1A1 expression and 
proteolysis rate. Both genes are involved in apoptotic programs and, accordingly, in trauma 
patients we found an increase of the cleaved form of PARP . This observation supports 
previous evidence linking p66 (ShcA) over-expression with stress-induced apoptosis 
(Migliaccio et al., 2006) and with muscle wasting and atrophy (Jiang X et al., 2003). In 
contrast to p66 (ShcA), c-MYC mRNA levels were not significantly different in patients and 
controls. This finding is in agreement with the fact  that c-MYC was not involved in 
regulation of apoptosis in denervated rat skeletal muscle (Siu and Alway, 2005). Therefore, 
this concept can also be extended to human traumatized muscle.  
In conclusion, our results indicate that an increased muscle expression of the p66 (ShcA) 
and eEF1A1 genes in hypercatabolic trauma patients may be a novel molecular marker for  
tissue injury. The mechanism we described could provide a starting point for further 
molecular investigations on the role of these proteins in the stress response of hypercatabolic 
patients. In particular, studies could be developed with nutritional factors on their expression 
levels in order to plan more effective therapeutic approaches for the recovery of muscle 
wasting and traumatized patients. 
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11. CONCLUSIONS 
 
Till now, the interpretation from prominent studies is that atrophy processes are not 
occurring independently of each other, but in sooth are delicately co-ordinated by a network 
of intricate signalling pathways. Many atrophy factors have been identified to dictate this 
network, but the precise time of activation and their precise plane of action (especially, in 
term of fiber or skeletal muscle types) remain yet to be deciphered. Certainly, muscle 
suffering results from the combined effect of oxidative stress and catabolic/anabolic or 
inflammatory (TNF-alpha)/growth factor (IGFs) unbalances,  but on the other hand, there is 
also the proof of the crucial role played by the mechanical action “per se”. Nonetheless, 
inflammation remains the key player in metabolic and muscular dysfunctions (Stenvinkel P et 
al 2005, Bosutti A et al 2007c). Either because, it impairs insulin action and IGF-I signalling, 
or because it modulates myogenesis, apoptosis and protein turn-over.  Pro-inflammatory 
signals, such as TNF-alpha, pilot also cardiovascular dysfunction and atherosclerotic process. 
Peripheral vascular inflammation and peripheral atherosclerosis contribute to tissue and organ 
wasting, by limiting blood vessel diameter, blood flow, O2 delivery and activating cellular 
stress signalling pathways (Isenberg et al., 2007).  Moreover, recent reports suggest that 
genetic variance in inflammatory markers or mediators could link inflammation to 
cardiovascular risk, organ failure (Bennermo et al., 2004; Biolo et al., 2006a; Menzaghi et al., 
2007; Pisani et al., 2004) and muscle plasticity (Stewart and Rittweger, 2006). Clinical 
evidence indicates also that such a combination of physical inactivity and low energy intake 
may rapidly lead to protein-energy malnutrition, increased incidence of complications, and a 
poor clinical outcome (Ritz and Elia, 1999c). Calorie restriction has been found associated 
with decreased inflammation, whereas energy excess and fat deposition activate the 
inflammatory response (Chung et al., 2001a). Nonetheless, the specific effects of inactivity 
and energy balance on muscle are difficult to be separated from confounding variables that 
arise from disease, aging, or prolonged immobilization.  
 A more comprehensive understanding of the extracellular or intracellular molecular 
relationships underpinning muscle atrophy, inflammation and cardiovascular risk in different 
human clinical models should be helpful to design new therapies to the recovery of muscle in 
diseases or healthy conditions (Dalla Libera et al., 1997). Thus, we focused our investigations 
to highlight the contribution of some effectors of inflammatory/oxidative responses on muscle 
atrophy in chronic or acute catabolic diseases. Moreover, the interaction between energy 
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restriction and muscle unloading in the regulation of lean body mass and inflammatory 
response in healthy subjects, as well as the relationships between inflammation and genetic 
variability, were here investigated. In particular, our attention was reserved to two novel 
mediators of inflammatory/oxidative stress: the long pentraxin PTX3 and the stress response 
protein p66(ShcA); to some representative adipocitokines (TNF-alpha, IL-6, INF-gamma, IL-10 
and TGF-beta1 and the leptin); and finally to the interplay between the p66(ShcA) and the two 
eukaryotic elongation factors EEF1A1 and EEF1A2 in acute muscle atrophy. 
Previously, it was defined that the chronic muscle loss due to disuse rises mainly from 
a decreased rate of protein synthesis rather than degradation (Biolo G et.al. 2007).  In 
particular, the major catabolic mechanism for the effect of muscle unloading on protein 
metabolism is the impaired ability of protein/amino acid feeding to stimulate body protein 
synthesis (Biolo G et al 2005). Here, we tested the hypothesis that the combination of reduced 
physical activity and negative energy balance would accelerate the loss of lean body mass in 
healthy subjects through changes in whole body protein kinetics. Reading our data, it appears 
that the coupling between muscle disuse and nutritional impairment, such as an inadequate 
energy and total food (protein or amino-acids) intakes, is a key determinant in lean body mass 
loss (Biolo et al., 2007). Notably, unloading at neutral energy balance activated pro-
inflammatory cascade, as shown by the unbalanced expression of critical inflammatory 
cytokines (Bosutti et al., 2007 JCEM, submitted). Whilst, a moderate energy restriction 
prevented the activation of inflammatory markers induced by inactivity. The adipose tissue 
appears to play a pivotal role in this response (Bosutti et al., 2007 JCEM, submitted). 
Plausibly, the leptin may be a crucial link between energy metabolism and inflammation in 
this condition. 
Several bed rest studies shown that metabolic adaptation to muscle inactivity involves 
development of resistance to the glucoregulatory action of insulin, decreased energy 
requirements, or  increased insulin and leptin secretion (Pavy-Le Traon A et al 2007). These 
alterations account to the reduced insulin sensitivity and may contribute to reduce protein 
anabolism  but also can activate inflammation (Pavy-Le Traon A et al 2007). In agreement, 
we observed that at any given level of body fat mass, changes in leptin secretion secondary to 
changes in energy intake or physical activity could have contributed to the up- or down-
regulation of systemic inflammation.  
Leptin shows either positive (anabolic) or negative (catabolic) effects on 
musculoskeletal system, likely depending on a bimodal threshold triggered by its serum 
concentration.  In unloading condition, high dose of leptin  decreases the circulating levels of 
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IGF-I, paralleled by bone loss (Martini et al., 2001). On the other hand, decreased leptin 
levels, as encountered in response to energy restriction,  impair the IGF-I pathway, with  the 
further negative effect on muscle  anabolism (Hamrick and Ferrari, 2007). Possibly, the 
observed deleterious effect on bone metabolism induced by high leptin levels, is due in part to 
a leptin-induced energy unbalance with related hormonal changes (Martini et al., 2007); it is 
not excluded a similar effect also into muscle. Recent evidence shows direct stimulatory 
effect of bed rest on leptin production (Blanc et al., 2000), and the preventive effect of 
exercise training (Kraemer et al., 2002a). Reading our data, bed rest in eucaloric conditions 
significantly increased either leptin concentration (normalized by units of energy intake and body 
fat mass content) or muscle loss. Intriguingly, such effect on leptin was not observed in 
hypocaloric conditions. Believable, increased leptin levels (in response to unloading) may 
compromise muscle, via the down-regulation of IGF axis (Hamrick and Ferrari, 2007; Martini 
et al., 2007); alternatively, energy restriction “per se” may down-regulate systemic IGF-I. In 
addition, a reduce muscle exertion might decrease the activation of mechano-signalling 
pathways and the IGF-I system, including muscle MGF synthesis (Goldspink  et al., 2005). It 
should be intriguing clarify the role of leptin in this mechano- sensitive-response.   
As a result, we defined a dualistic role for energy restriction. On one side we found a positive 
effect, since it reduced inflammatory risk, but on the other side, if not balanced, it accelerates 
muscle loss.  Genetic or environmental factors, such as cytokine polymorphisms, gender, age, 
metabolic disorders or disease states might either enhance or down-regulate these bed rest 
effects (Biolo et al., 2006; El Yousfi et al., 2005; van Eijk et al., 2007). 
Bed rest is a well recornized cardiovascular risk factor (Convertino, 1994). Recent 
investigations on vascular deconditioning due to bed rest, highlighted that vascular adaptation 
to deconditioning might impaired energy expenditure and endothelial homeostasis (Tyml and 
Mathieu-Costello, 2001; Bleeker WP et al 2005; Hesse et al., 2005), representing in such a 
way an independent risk factor for atherosclerosis. Moreover, prolonged immobilization can 
affect lipid profile, such as total cholesterol level (Hesse et al., 2005). In our study, prolonged 
immobilization increased significantly the circulating levels of the pentraxin PTX3, but 
without significant activity-by-diet interaction. Currently, it is not yet clear whether this 
protein is protective or harmful (Latini et al., 2004;Napoleone et al., 2002; Salio et al., 2008; 
Norata et.al., 2008). Notwithstanding, PTX3 is involved in atherosclerosis and vasculites 
(Rolph et al.,  2002). Its gene expression significantly relates to the prognosis of patients with 
acute myocardial infarction and to advanced atherosclerotic plaques formation (Latini et al., 
2004).  Thus, our enquiry was to understand whether PTX3 was a key of reading of some 
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bed-rest effect on cardiascular system. To clarify this point, we explored the possible relation 
between this protein and a critical cardiovascular risk factor, namely, the circulating level of 
LDL-cholesterol, in adipose tissue and WBCs in a group of well defined heart failure patients. 
Given that the interplay between inflammation and oxidative stress in cardiovascular 
dysfunction, we defined also the relation of PTX3 and LDL with the stress response gene 
p66(ShcA)  (Bosutti et al.,2007). Our data suggested that increased plasma levels of LDL may 
favour the expression of PTX3 and p66(ShcA) both locally (adipose tissue) and systemically 
(WBCs), indicating a possible novel link between these two mediators of 
inflammation/oxidative stress and the lipid profile (Bosutti et al., 2007). These results, 
prompted us to  speculate about a novel mechanistic effect of prolonged muscle inactivity on 
vascular deconditioning, at least in part, mediated by PTX3 gene expression (Bosutti et al. 
2007, JCEM submitted).  
Remarkable, genetic studies shown a synergistic interaction between cardiovascular 
risk, organ failure and cytokine genotypes.  The direct relationships among cytokine genetic 
variants and the magnitude of cardiovascular risk (such as circulating levels of LDL-
cholesterol), emphasized the relevance of genotypes in cardiovascular diseases (Biolo G et al., 
2006; Bannermo et al., 2004;  Pisani et al., 2004; Menzaghi et al., 2007). Polymorphic 
variants of cytokine genes may be functionally relevant to determine not only an increased 
cytokine expression but also the degree of inflammatory process or organ failure  
(Balakrishnan et al., 2004). Notably, in physiological condition, the kidney plays a pivotal 
role in the control of cytokine catabolism and excretion. But, during chronic renal failure, the 
progressive decrease in glomerular filtration rate, increases the degree of inflammation and 
the frequency of its clinical consequences, including muscle atrophy (Bosutti A et al 2007c). 
Nevertheless, cytokine plasma concentrations not always reflect accurately the kidney 
function or cardiovascular risk, because their renal clearence is compromised (Girndt et al., 
2002). It was in this point of view, that we investigated  the influence of cytokine genotypes 
and renal function in the degree of systemic inflammation and cardiovascular risk (Biolo et 
al., 2006a; Bosutti A et al 2007c). We used as models of study two groups of CRF patients on 
haemodialysis and conservative treatments, respectively. We have shown that the degree of 
inflammatory response is straight coupled with cytokine genotypes. Especially, IFN-gamma 
‘low-producer’ polymorphism associates with the greatest preventive effect on CRP elevation 
in haemodialysis patients. We suggest that this preventive effect, could be mediated, at least 
in part, by the downregulation  of IL-6 expression (Striz et al., 2000). This may imply that 
CRF patients with IFN-gamma ‘low-producer’ genotype may be relatively protected from the 
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risk of developing cachexia, muscle atrophy and cardiovascular disease. However, appropriate 
experimental design will be needed to test this hypothesis. Also, further studies based on MRI 
axial images and ultrasonography (Pavy-Le Traon et al., 2007), may help us to clear the link 
between cytokine genotypes, inflammation and the impairement of muscle architecture in 
these subjects. In particular, these investigations associated with muscle biopsy analysis, may 
clarify novel molecular aspect of muscle atrophy in support to inflammation. Recent 
evidences shown a direct link between some “myokines” genotypes with the training-induced 
muscle “quality”, as well as with the inflammatory state of striated muscle, in particular after 
the acute resistance exercise (Stewart and Rittweger, 2006; Dennis et al., 2004). 
 Furthermore, the oxidative stress has emerged as a constant feature of CRF, which 
presence is commonly evidenced by an overabundance of lipid, carbohydrate, and protein 
oxidation products in  plasma and tissues. Studies on muscle biopsies, documented a direct 
association between muscle loss and the deregulation of some muscle oxidative or anti-
oxidative enzymes. Oxidative stress and mitochondria dysfunction could be responsible of 
down-regulation of IL-10 synthesis (Perianayagam MC et al 2005) and can amplify 
inflammatory cascade, leading, as the final consequence, to a massive loss of muscle (Bosutti 
et al., 2007c).  As we relieved (Bosutti et al., 2007c), a progressive decrease in anti-
inflammatory IL-10 synthetic capacity during the course of chronic renal failure and its 
association with the degree of glomerular filtration rate could increased not always, the 
cardiovascular risk in these persons, but also muscle suffering (Bosutti A et al 2007c).  All 
these findings provide new insights on some molecular mechanisms that may increase or 
reduce the inflammatory effects induced by muscle unloading. 
Finally, as discussed in our introduction, the cross-interaction between translational 
machinery,  proteolysis pathways and apoptosis may be  crucial trigger of skeletal muscle 
loss.  Even so, the molecular mechanisms underpinning this process remain to be elucidated. 
In particular, we hypothesised that muscle atrophy induced by acute stress, may be 
orchestrated by the interplay between the eukaryotic elongation factor EEF1A1 and the stress 
response protein p66(ShcA). Our results described an increased muscle expression of both genes 
in hypercatabolic condition, which relates with increased apoptosis and cytoskeletal-
sarcomeric derangements and with the rate of muscle  proteolysis (Bosutti et al., 2007a).  
An abnormal cell shape, growth, and differentiation in L6 skeletal muscle cells  over-
expressing the p66 (ShcA) was already described (Natalicchio et al.,  2004). Likely, caused by 
the inhibitory effect of p66 (ShcA)  on MEK/Erk pathway.  Also, an up-regulation of p66 (ShcA)  
was found in skeletal muscles and spinal cord of aged rats with sensorimotor impairment 
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(Jiang X et al., 2003). More recently, Zaccagnini, remarked the crucial role of p66 (ShcA)  in 
regenerative skeletal muscle pathways in response to acute ischemia. The authors investigated 
whether tissue regeneration following acute hindlimb ischemia was altered in p66Shc-ko 
mice. Upon femoral artery dissection, the muscle regeneration in p66Shc-ko mice started 
earlier  and was completed faster than in wt control and associated to low oxidative stress 
level.  Also, myogenic conversion induced by MyoD overexpression was more efficient in 
p66 (ShcA)  ko fibroblast compared to wt (Zaccagnini et al., 2007).  
All together these data prompt us to speculate that p66 (ShcA) may be a novel molecular 
marker for tissue injury (Bosutti A et al 2007a).  
At this point of the discussion emerges a simple element, apparently catabolic diseases 
show a common picture of atrophy pathomechanisms linking inflammatory/atherosclerosis 
processes to muscle withering. Clearly, the knowledge of the exact timing of activation of 
these events is yet restricted, but crucial appears their interplay. The reduce mechanical action 
amplifies the process. Plausibly, the magnitude of decreased O2 delivery to tissues may 
represent the pathophysiological starting point to muscle decline (Chowdhuri et al., 2007; 
Cummins et al., 2007), whereas genotypes may represent the key modulators of 
intraindividual variability and vulnerability to the process. A more controlled nutrient intake 
combined with various exercise regimes might protect from the effects of unloading and may 
be a reasonable approach to maintain muscle mass in health but also in disease conditions.  
In conclusion, a wealth scenario of molecular triggers, effectors and targets of skeletal 
muscle atrophy has been reached us. The complete comprehension of when these molecular 
activations occur may be the basic line to design new therapeutic interventions. In this view, 
bed rest studies may increase our knowledge about the clinical implications of muscle 
function and "the mean by which the movement is the “essence” to human health. 
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